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Antimicrobial resistance is a problem of longstanding, serious concern in both human and 
veterinary medicine.  Physicians and scientists described emerging resistance to major 
classes of antibiotics including sulphonamides1, penicillin2,3 and streptomycin4 within a 
few years of their discoveries in the 1930’s and 1940’s.  Veterinary researchers observed 
in vitro resistance to penicillin in organisms isolated from cases of bovine mastitis around 
that same time.5  The problem intensified throughout the latter half of the twentieth 
century.  Methicillin-resistant Staphylococcus aureus (MRSA) was isolated in 
hospitalized human patients barely a year after that drug’s first use in 1960.6  Reports of 
MRSA in the veterinary literature appear in the early 1970’s, again in association with 
bovine mastitis.7  
 
Additional nuances arose going into the twenty-first century, including the appearance of 
genetically unique strains of bacteria in cases of community acquired MRSA,6  increased 
resistance in anaerobic isolates such as Bacteroides fragilis,8 emergence of vancomycin 
resistant strains of Staphylococcus aureus,9 Enterococcus species 10 and others, and 
resistant gram negatives such as Klebsiella species and Acinetobacter baumannii.11  
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The veterinary literature again mirrored these concerns, with increased investigation into 
MRSA infections in horses and companion animals,12,13 vancomycin-resistant 
Enterococcus species, 14 and resistance patterns of gram negative pathogens. 15,16 
 
 
Strategies to minimize antimicrobial resistance in the interest of public health and animal 
well-being have been promoted by governments, medical and veterinary organizations,17 
researchers and clinicians since the problem was first recognized.  Early efforts included 
Great Britain’s Penicillin Act of 1947 and subsequent Aureomycin and Chloramphemicol 
Regulation of 1951 that eliminated free access to antibiotics by the general public, 
theoretically reducing the risk of selective pressure from unnecessary use or inappropriate 
dosing.18  As the microbiological complexities of antibiotic resistance became clearer, 
myriad other proposed strategies focused on reduced use of antimicrobials,19  
implementation of more appropriate dosing regimens,20 development of new 
antimicrobial drugs and vaccines,6 susceptibility testing of anaerobic isolates,8 increased 
attention to the effect of antibiotic residues in the environment and the role of 
commensals as reservoirs of resistance,11 isolation of patients harboring resistant 
bacteria,21 and uniform preparation of annual antibiograms to track resistance and 
improve therapy.22 
 
While antibiotic resistance in clinical veterinary medicine has traditionally paralleled 
discoveries in human clinical medicine, the two have been inextricably linked by the 
issue of antibiotic use in food animals.23,24  A similar point of debate has been the 
significance of working in close proximity to animals on human acquisition of  multi-
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drug resistant zoonoses.  Veterinary personnel historically have been the target of such 
research, with variable conclusions drawn over time. 25-27  Attention is increasingly being 
focused on the transmission of resistant pathogens between companion animals, horses 
and their owners, particularly as concerns methicillin-resistant Staphylococcus aureus. 28-
30  Furthermore, organisms such as Streptococcus equi zooepidemicus that are typically 
associated with equine disease occasionally are reported to cause serious disease in 
humans that live or work in proximity to horses. 31-33  Rhodococcus equi emerged as a 
pathogen of human concern following reports of increased incidence in patients with 
Human Immunodeficiency Virus (HIV) infection.34   Both veterinary and human 
literature demonstrate a rise in concern for public health in venues such as petting zoos, 
35,36 a  topic gaining importance in human medicine due to the prevalence of animal 
assisted therapies for the ill, disabled, elderly and immunocompromised. 37,38   
 
In light of this, an in-depth understanding of the institutional, local and regional microbial 
population is a prerequisite for effective and responsible antimicrobial use by veterinary 
hospital clinicians and field practitioners.   Consideration of the potential impact of 
biosecurity and antibiotic protocols on the health of patients, staff, clients, and the general 
public is of paramount importance.  To that end, the current project was undertaken with 
the goal of providing a baseline analysis of bacterial isolates from equine specimens 
submitted to the Oklahoma Animal Disease and Diagnostic Laboratory (OADDL) from 
the Boren Veterinary Medical Teaching Hospital (BVMTH), the Oklahoma State 
University College of Veterinary Health Sciences Ranch (CVHSR) and the regional 
veterinary community (RVC).  The objectives of this retrospective study were as follows:  
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1. To describe the general characteristics of equine submissions to OADDL, 
including demographics, sample sources, bacteria isolated, and antimicrobial 
sensitivities. 
2. To describe major differences in these characteristics between samples submitted 
from the BVMTH and CVHSR, and samples submitted from the RVC. 
3. To describe major differences in these characteristics over time. 
4. To discuss the status of antimicrobial isolation and resistance patterns at the 
BVMTH, CVHSR and in the RVC in the context of current veterinary literature. 
5. To perform a detailed analysis of possible nosocomial infections in BVMTH 
cases, including oxacillin-resistant Staphylococcus aureus, multi-drug resistant 
Enterococcus faecalis, and others. 
6. To generate current antibiograms for major equine pathogens for the BVMTH and 
for the RVC. 
7. To generate meaningful discussion regarding current antibiotic use and 
biosecurity practices by CVHS facilities and regional practitioners. 





REVIEW OF LITERATURE 
 
Overview of Equine Microbiology 
Current literature in equine medicine encompasses a broad range of  topics in both 
clinical and research microbiology, including nosocomial infections,39,40 zoonotic 
transmission of disease41,42 and multi-drug resistance.43  Efforts to describe the 
microbiological environment encountered in equine practice range from broad 
retrospective surveys of multiple pathogens 44,45 to detailed molecular characterization of 
individual isolates.46,47   Salient characteristics including disease presentations, reported 
trends in antimicrobial resistance and zoonotic concerns are summarized below for the 
principal bacterial organisms encountered in equine clinical practice.  Brief literature 
reviews are provided regarding the pertinent microbiology of major organ system 
diseases and the one common device-associated infection in equine veterinary medicine, 




Escherichia coli is a commensal organism in the gastrointestinal tracts of most mammals, 
but also may be associated with disease.48  Some studies have shown that horses have 
greater diversity in commensal E.coli strains than other species,49 although the medical 
significance of this has not been investigated.  Clinical disease caused by E.coli in horses 
includes neonatal sepsis,50,51 and the organism has been reported in association with 
fertility problems in mares. 52 
 
E. coli is an organism of significance in the etiogenesis of antimicrobial resistance, being 
well-documented as a reservoir for transmissible drug resistance plasmids.23,53,54  In vitro, 
conjugal transfer of resistance genes from equine clinical E. coli isolates to clinical, 
multi-drug resistant Salmonella isolates has been demonstrated.16   
 
Reports of antimicrobial resistance in equine E. coli isolates are widespread 
geographically and over time.  E.coli isolated from large animals in a Pennsylvania 
veterinary teaching hospital from 1985 to 1990 showed overall better susceptibility to 
amikacin (98.91%)  than gentamicin (80.29%), but susceptibility to amikacin showed a 
decreasing trend over the five years of the study. 55  Multi-drug resistant E. coli isolated 
from septicemic foals in a California veterinary teaching hospital in the early 1990’s 
showed resistance patterns to ampicillin, cephalothin, chloramphenicol, gentamicin, 
kanamycin, streptomycin, triple sulfonamides, tetracycline and trimethoprim 
sulfonamides.53  Antimicrobial resistance was found in E. coli isolates from 107 of 143 
(74.8%) horses in an abbatoir study in Australia in 1993.  All isolates showed 
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streptomycin resistance, with variable resistance to gentamicin, tetracycline, 
chloramphenicol, sulphafurazole, ampicillin, trimethoprim, and furazolidone. 56  
Susceptibilities of E. coli isolates from equine clinic and field service cases at a western 
Canadian veterinary teaching hospital between 1998 and 2003 included amikacin 
(100%), ceftiofur (94%), enrofloxacin (91%), amoxicillin/CA (84%), spectinomycin 
(81%), gentamicin (80%), tetracycline (65%), ampicillin (62%), trimethoprim 
sulfamethoxazole (62%) neomycin (61%) cephalothin (50%), erythromycin (6%), and 
penicillin (0%).45  
 
In a population of horses in Colorado examined in 2002 through 2005, E.coli from the 
feces of hospitalized horses receiving and not receiving antimicrobial therapy showed 
increased resistance to antibiotics relative to control horses in the community.  Resistance 
to trimethoprim sulfamethoxazole was most common, followed by gentamicin and 
tetracycline, and multi-drug resistance was frequently observed. 57   Extended-spectrum 
cephalosporin resistant E.coli was isolated from purulent debris, stomach, synovial tissue 
and uterine fluid of horses in the Netherlands studied in 2003 through 2005.  Multi-drug 
resistance to ampicillin, amoxicillin/CA, cephalexin, ceftiofur, ceftazidime, cefotaxime, 
streptomycin, gentamicin, kanamycin, chloramphenicol, tetracycline, norfloxacin, 




The most common streptococcal pathogens in equine disease include the Lancefield 
Group C beta-hemolytic streptococci, Streptococcus equi zooepidemicus, Streptococcus 
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equi equi, and Streptococcus dysgalactiae equisimilis. 58  Streptococcus equi 
zooepidemicus is a commensal of the equine upper respiratory tract, and is also one of the 
most frequently isolated organisms in equine clinical disease.45,59  This organism is 
associated with a broad range of pathological conditions, including respiratory, 
reproductive, 59-61 and ophthalmologic disease.62   Streptococcus dysgalactiae equisimilis 
is a commensal of the skin and mucosa, and has been associated with lymphadenitis and 
placentitis 59 as well as upper respiratory disease. 59,60  Streptococcus equi equi is the 
causative organism of upper respiratory infection and lymphadenopathy. 59  α-Hemolytic 
streptococci have been reported in association with equine respiratory, reproductive, 
urinary tract and ocular disease, as well as neonatal septicemia45 and mastitis.63   
 
Streptococcal species traditionally have shown less of a predilection for the development 
of significant resistance than other species of bacteria. 64  Streptococcus equi 
zooepidemicus isolates are reported to be consistently susceptible to beta-lactam and 
potentiated sulfonamide antibiotics. 65  Documentation of significant resistance trends 
was not apparent in current literature, though concern was transiently expressed about the 
possibility of resistance to trimethoprim sulfamethoxazole.65  A recent large-scale 
evaluation of equine isolates submitted to a university diagnostic lab showed 
susceptibility of Streptococcus equi zooepidemicus to ceftiofur (100%), cephalothin 
(99%), penicillin (95%),  ampicillin (92%), enrofloxacin (91%), erythromycin (91%), 
amoxicillin/CA (87%), spectinomycin (87%), gentamicin (85%), tetracycline (59%), 
trimethoprim sulfamethoxazole (55%), neomycin (20%) and amikacin (5%).45 
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Antibiotic susceptibility of Streptococcus equi equi isolates in a recent retrospective of 
specimens submitted to a university diagnostic laboratory showed good susceptibility to 
most antimicrobials tested, including ceftiofur (100%), cephalothin (100%), penicillin 
(100%),  ampicillin (100%), erythromycin (100%), amoxicillin/CA (100%), 
spectinomycin (100%), enrofloxacin (95%), gentamicin (95%), tetracycline (92%), 
trimethoprim sulfamethoxazole (79%), neomycin (0%) and amikacin (0%).45 
 
Resistance to α-hemolytic Streptococcus species was reported in 1988 to sulphonamide, 
nalidixic acid, gentamicin, kanamycin, neomycin and fucidin in strains isolated from milk 
of a mastitic mare and her septic foal; sensitivity was noted to ampicillin.63  Sensitivity to 
α-hemolytic Streptococcus species reported recently by a university veterinary diagnostic 
laboratory included ceftiofur (100%), cephalothin (100%), spectinomycin (100%), 
tetracycline (93%), penicillin (89%),  ampicillin (89%), erythromycin (89%), gentamicin 
(89%), enrofloxacin (86%), amoxicillin/CA (83%), trimethoprim sulfamethoxazole 




Equine Salmonellosis is a frequently observed disease with considerable zoonotic 
potential.  Clinical disease due to Salmonella infection in equine patients is most 
commonly colitis, but other manifestations such as neonatal sepsis may occur. 66  
Zoonotic outbreaks of equine origin have been documented in venues where horses and 
humans coexist in close contact, such as veterinary hospitals. 42  
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The epidemiology of equine Salmonellosis varies with report.  In one study of 1,451 
hospitalized horses, 46 (3.2%) cultured positive for Salmonella with less than half of 
these (20) having positive cultures on admission.67  Another study of asymptomatic 
hospitalized horses showed 7 of 250 (2.8%) to be Salmonella positive, while a population 
of 75 mares on a stud farm showed no positive Salmonella cultures. 68  In one abbatoir 
study, samples from ileal swabs of 39 of 143 (27.3%) horses cultured positive for 
Salmonella. 56  A seasonal incidence has been observed in some studies, with cases 
clustered in late summer and early fall. 67  It is not uncommon for Salmonellosis to occur 
in outbreaks. 69-71 
 
The most common serotype causing disease in both horses and humans is S. 
Typhimurium.  S. Anatum is also frequently cultured, but less likely to be associated with 
clinical disease. 56,67,68  One study showed an increasing frequency of Salmonella 
Typhimurium DT104 at a veterinary teaching hospital, in which up to 92% of Salmonella 
isolates were of this type. 72 
 
Because of the high risk of zoonotic transmission, drug resistance in Salmonella species 
is of particular interest.  Concern over plasmid-mediated multi-drug resistance in 
Salmonella species was documented in the literature over three decades ago.  A 1971 
multi-species survey study that included a small number of horses found that 935 of 
1,251 isolates showed resistance to one or more of 11 antimicrobials tested.  The most 
frequent resistance was observed to ampicillin, dihydrostreptomycin, 
sulfamethoxypyridazine, and tetracycline.  S. Typhimurium showed the highest incidence 
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of multi-drug resistance among serotypes tested. 73  A retrospective covering the years 
1973 through 1979 revealed that most equine isolates were resistant to streptomycin and 
sulfonamides, but that only rarely were isolates resistant to more than two 
antimicrobials.74  By the next decade, emerging resistance to chloramphenicol, ampicillin 
and gentamicin was observed in a study including primarily equine and environmental 
samples from a veterinary hospital. 75  Resistance in Salmonella Typhimurium DT104 
has been found to ampicillin, tetracycline, gentamicin, sulfonamides and amikacin in 
Canada between 1997 and 2000. 72  Similar strains isolated in the Netherlands between 
1993 and 2000 showed frequent resistance to ampicillin and tetracycline, though 
susceptibility improved over time.  Resistance was also shown to 
trimethoprim/sulfonamide, kanamycin, gentamicin and enrofloxacin, and strains 
intermediate to ceftiofur were noted. 76  A national survey of multiple species in 1997 and 
1998 including healthy and clinically ill animals showed emerging resistance to 
extended-spectrum cephalosporins most common in turkeys, horses, cats and dogs. 77 In 
2000 an outbreak of multidrug-resistant Salmonella Typhimurium in an equine hospital 
occurred with resistance reported to amoxicillin, ampicillin, cefazolin, cefoxitin, 
ceftiofur, cephalothin, chloramphenicol, gentamicin, ormethoprim, rifampin, tetracycline, 
ticarcillin and trimethoprim/sulfadiazine and intermediate status to cefotaxime. 78 
 
Emerging multi-drug resistance in equine isolates of S. Anatum was found to ampicillin, 
tetracylines, chloramphenicol, carbenicillin, ticarcillin, gentamicin, tobramycin, 
trimethoprim sulfamethoxazole and cephalothin in a veterinary hospital in Pennsylvania. 
66  Multi-drug resistant S. Anatum was the primary serotype (69.2%) identified in ileal 
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samples from horses in an abbatoir study in Australia, with all isolates resistant to 
streptomycin, and variable resistance to sulphafurazole and tetracycline.56   
 
Emergent multi-drug resistant S. Agona was reported in a population of horses in 
Kentucky in 1986, showing very low susceptibility to most antimicrobials tested 
including erythromycin (0%), penicillin (0%), tetracycline (1.2%), triple sulfonamide 
(2.4%), ampicillin (3.6%), carbenicillin (3.6%), kanamycin (3.6%), cephalothin (4.8%), 
chloramphenicol (4.8%), gentamicin (4.8%), streptomycin (9.6%), neomycin (16.9%), 
trimethoprim sulfamethoxazole (84.3%), nitrofurantoin (100%), polymyxin B (100% ) 
and amikacin (100%).79  
 
An outbreak of multi-drug resistant Salmonella Heidelberg in a veterinary hospital 
showed concurrent resistance to ampicillin, streptomycin, tetracycline, chloramphenicol, 
sulphathiazole, trimethoprim, kanamycin, spectinomycin, and gentamicin. 43 
 
Multi-drug resistant Salmonella Infantis, in which 80.3% of isolates were resistant to at 
least one antimicrobial, and 67.8% were resistant to five or more antimicrobials, persisted 
in a veterinary teaching hospital environment for nine years.80 
 
Staphylococcus aureus  
Staphylococcus aureus (S. aureus) is found in the upper respiratory and gastrointestinal 
tracts of clinically normal horses, and is reported commonly in incision and wound 
 13
infections, intravenous catheter infections and bacteremia as well as pneumonia, implant 
infections, septic arthritis, umbilical infections, abscesses and osteomyelitis. 27,81 
 
Multi-drug resistant strains of S. aureus are an increasingly important cause of 
nosocomial infections in both human and veterinary medicine. 82  Concern regarding 
evolving resistance of S. aureus in equine patients has been reported since the 1970’s, 
with one early report indicating nearly 84% of equine isolates were resistant to one or 
more antibiotics. 83 Another report in 1991 showed 59.2% of S. aureus strains tested were 
resistant to at least one antibiotic. 81 Tetracycline and spectinomycin resistant S. aureus 
was reported in reproductive tract isolates from horses in 1998. 84  Recently reported 
susceptibilities for all S. aureus isolates from a veterinary teaching hospital diagnostic 
laboratory included amikacin (100%), gentamicin (100%), trimethoprim 
sulfamethoxazole (100%), cephalothin (100%), enrofloxacin (97%), ceftiofur (97%), 
tetracycline (97%), amoxicillin/CA (94%), erythromycin (84%), neomycin (83%), 
ampicillin (55%), penicillin (55%) and spectinomycin (29%).45  Methicillin resistant S. 
aureus (MRSA) was reported in a wound in a horse in 1997. 85  
 
Epidemiology of MRSA in horses and humans that work with horses varies across 
reports.  One prevalence study conducted with specimens from Ontario, Canada and New 
York State in 2003 showed MRSA in 4.7% of horses tested, and in 13% of humans tested 
at the same locations. 86  A multi-species, multi-center study conducted in 2001 and 2002, 
and involving veterinary teaching hospitals across the country showed that in 22% of 
equine patients with a S. aureus infection, methicillin resistance was present. 12  A 
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surveillance study conducted in 2002 and 2003 in a tertiary care veterinary teaching 
hospital in Canada showed that over half of MRSA positive horses in the study period 
had MRSA at the time of admission, while 44% acquired nosocomial infections. 87  A 
study in 2005 showed no MRSA in a community-based population of 300 horses in 
Slovenia, although 42% were colonized with methicillin resistant coagulase negative 
staphylococci.13  Similar results were found in 50% of a population of 100 horses, both 
hospitalized and in the community, in 2005 in Denmark,88 and in a group of 200 
clinically healthy horses in 2004 in the Netherlands, of which 22.5% harbored a 
methicillin resistant coagulase negative staphylococci identified as Staphlyococcus sciuri. 
89   Prevalence of MRSA in a population of equine veterinarians attending an 
international conference in 2006 was 10.1%.90  It is of interest that while MRSA is a 
significant problem in one tertiary care teaching hospital in Canada, another Canadian 
veterinary teaching hospital with a 75% first opinion caseload reported minimal 
resistance in their S. aureus isolates.45 
 
Susceptibility studies of MRSA to other antibiotics indicate that multi-drug resistance is 
often present in these strains.  Reported susceptibilities of equine MRSA in one report 
included clindamycin (100%), imipenem (100%), amikacin (95%), chloramphenicol 
(95%), erythromycin (75%), rifampin (70%), enrofloxacin (36%), gentamicin (14%), 
oxacillin (0%), trimethoprim sulfamethoxazole (0%) and tetracycline (0%).86 Another 
study of equine and human MRSA showed susceptibilities of doxycycline (100%), 
minocycline (100%), rifampin (29%), trimethoprim sulfamethoxazole (21%), 
erythromycin (14%), gentamicin (12%) and tetracycline (4%).27 
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Intensifying the concern over MRSA in horses is mounting evidence of zoonotic 
transmission.  Strains of MRSA isolated from equine patients and the humans treating 
them have been found to be identical, 91 though other comparisons of equine and human 
types of methicillin resistant S. aureus show them to be unrelated in origin. 47  Recent 
studies suggest that transmission occurs between horses and humans in both directions. 
27,41  Intra-hospital spread of a single MRSA strain has been reported. 92  In a cross 
species study, strain variability within individual institutions suggested a predominance 
of community acquired rather than hospital acquired MRSA. 12  Environmental 
contamination has also been proposed as a factor in institutional spread of MRSA. 46 
 
Variable risk factors have been identified for the acquisition of MRSA by horses.  One 
study showed the only risk factor significantly associated with MRSA colonization in a 
horse population to be living on a farm with greater than 20 horses,86 while another 
described previous identification of MRSA in the horse, colonized horses on the same 
farm, antimicrobial administration within 30 days, admission to the NICU, and admission 
to a hospital on a non-surgical service as significant. 93  Risk factors associated with 
nosocomial MRSA include administration of ceftiofur or aminoglycosides during 
hospitalization.  Horses with MRSA on admission were more likely to develop clinically 
apparent MRSA infections. 87  Horses with nosocomial MRSA have significantly longer 
hospitalization than horses without MRSA or horses with community acquired MRSA, 87 
although specific associated costs have not been reported. 
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Numerous strategies for treatment and elimination of MRSA have been described.  
MRSA has been eliminated from one large farm with the implementation of management 
and screening practices, and minimal antimicrobial therapy. 94  Vancomycin has been 
used in some cases for the treatment of MRSA and resistant enterococcus infections. 95  
Simple handwashing has been shown to be protective for the presence of MRSA in 
veterinary personnel. 90 
 
Pseudomonas aeruginosa 
Although relatively little has been written specifically pertaining to non-ophthalmologic 
antimicrobial resistance in equine Pseudomonas isolates, multi-drug resistant 
Pseudomonas  aeruginosa  (P. aeruginosa) isolates have been identified in canine 96 and 
human 97 critical care environments. 
 
Equine isolates of P. aeruginosa have been shown to have greater susceptibility to 
amikacin than gentamicin, 89.66% versus 73.10% in one study in 1997. 55  Recently 
reported data on P. aeruginosa isolates from equine clinical cases at a veterinary teaching 
hospital showed limited susceptibility to most antimicrobials tested, including  amikacin 
(92%), gentamicin (56%), enrofloxacin (30%), amoxicillin/CA (13%), neomycin (13%), 
spectinomycin (7%), ceftiofur (0%), tetracycline (0%), ampicillin (0%), trimethoprim 






Klebsiella pneumoniae (K. pneumoniae) may be part of normal flora in nasal passages, 
feces and the mare’s caudal reproductive tract and has been isolated from the semen of 
healthy stallions,98 but may also be associated with pathology including respiratory 
disease,  endometritis,98 infertility,15,99 and neonatal septicemia. 50  This organism is 
rarely reported in association with abortion and meningitis. 99 
 
Extended spectrum cephalosporin resistance due to extended spectrum ß-lactamases has 
been reported in K. pneumoniae clinical isolates from purulent material and feces of a 
geriatric horse and two foals.  These isolates showed concurrent resistance to ampicillin, 
cephalexin, ceftiofur, ceftazidime, cefotaxime, streptomycin, gentamicin, kanamycin, 
chloramphenicol, tetracycline, trimethoprim and sulfamethozole. 16  A recent survey of 
Klebsiella species isolates from uterine infections in mares showed 100% susceptibility 
to amoxicillin/CA, cephalexin, and gentamicin, with good susceptibility shown to 
chloramphenicol (97%), cefazolin (89%), tetracycline (89%) and 
trimethoprim/sulfamethoxazole (89%). Clear patterns of multi-drug resistance were not 
noted in this study.15  Equine isolates of K. pneumoniae may be more susceptible to 
amikacin (96.80%) than gentamicin (63.20%). 55  Susceptibility to spectinomycin was 
greater for uterine isolates of K. pneumoniae than for isolates from other tissues in an 
Oklahoma study encompassing the years 1983 to 1987. 100 A recent multi-species study 
of clinical Klebsiella isolates identified three of 17 K. pneumoniae isolates as being 
multi-drug resistant; these isolates were obtained from horses with endometritis, cystitis 
and a liver abscess.101 
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Staphylococcus xylosus and other Staphylococcus species 
Staphylococci other than S. aureus are also frequently isolated from the skin of clinically 
normal animals.  In one horse population, 89.5% cultured Staphylococci.  The most 
frequent isolate was S. sciuri in 76.5% of horses, with S. xylosus found in 23.5%.  Other 
species isolated included S. hominis, S. capitis, S. saprophyticus and S. epidermidis along 
with four unidentified species.  Two to three different Staphylococcus species were found 
in 41.2% of colonized horses.102  Staphylococcus sciuri and S. xylosus are more 
frequently isolated from normal skin relative to skin lesions, which more frequently 
culture S. aureus, S. intermedius and S. hyicus. 103 
 
Methicillin resistant coagulase negative Staphylococcus species have been isolated from 
the nasal passages in up to 50% of horses, including S. epidermidis, S. sciuri, S. vitulinus 
and S. haemolyticus, and were often multi-drug resistant.88  Coagulase negative 
staphylococci possessing the gene for methicillin resistance, including Staphylococcus 
sciuri and Staphylococcus lentus, have been isolated from non-reproductive specimens in 
a group of healthy broodmares.104  This is of particular concern as there is some evidence 
for transferability of the methicillin resistance gene (mecA) from coagulase negative 
Staphylococcus to S. aureus.105    
 
Other research has shown increases in the percentage of multi-drug resistance in 
Staphylococci isolated from the skin of horses following hospitalization, 105 and 
resistance to tetracycline concurrent with at least five other antimicrobials including 
ampicillin, chloramphenicol, neomycin, streptomycin, erythromycin, or trimethoprim 
 19
sulfamethoxazole has been documented in S. epidermidis, S. haemolyticus, S. 
intermedius, S. sciuri and S. xylosus.84  A chloramphenicol resistance plasmid was 
identified in S. sciuri isolated from the prepuce of a clinically normal stallion.106 
 
Enterococcus species 
Enterococci are gram positive bacteria formerly categorized as Streptococcus group D, 
and show intrinsic resistance to some antimicrobials including aminoglycosides, 
lincosamides and trimethoprim.   Enterococci have shown an increased likelihood to 
develop resistance relative to other Streptococci, 64 although Enterococcus isolates 
reported recently from equine clinical cases at a veterinary teaching hospital showed 
some susceptibility to all antimicrobials tested, including  amoxicillin/CA (100%), 
ampicillin (96%), penicillin (86%), gentamicin (75%), trimethoprim sulfamethoxazole 
(68%), spectinomycin (67%), tetracycline (64%), erythromycin (50%), enrofloxacin 
(46%), cephalothin (36%), neomycin (33%), ceftiofur (29%) and amikacin (25%). 45 
Vancomycin-resistant Enterococci including E. faecalis and E. faecium are the species of 
greatest concern as they tend to be concurrently resistant to most other antibiotics as well.  
Emergence of vancomycin resistance is theorized to be due in part to the past use of the 
glycopeptide feed additive avoparcin in cattle in Europe, though the problem is not 
limited to this geographic area.64  Vancomycin resistant Enterococcus species have been 
isolated in horses in Europe.10,14  Relative to swine and human isolates, the equine 





Actinobacillus species are commensals of the mucous membranes, oral cavity and 
respiratory tract of healthy animals, and are also agents of equine disease.107  
Actinobacillus equuli (A. equuli) has been reported in conjunction with peritonitis,108 
endocarditis,109 pulmonary hemorrhage,110 and soft tissue infections.111   Actinobacillus 
suis (A. suis) has been associated with respiratory, reproductive and soft tissue 
infections,112 as well as neonatal septicemia.113  Untyped Actinobacillus (Actinobacillus 
sp.) infections have occurred in postoperative infections114 and neonatal bacteremia.115 
 
Concerns about antimicrobial resistance in Actinobacillus species are reported rarely.  A 
case series of horses with A. equuli peritonitis revealed that 79% of isolates for which 
sensitivities were performed were susceptible to all antibiotics tested, with sporadic 
resistance to penicillin and trimethoprim sulphadimidine in the others.108  A. equuli 
isolated from cellulitis in a foal in Italy in 2008 was susceptible to amikacin, amoxicillin-
CA, ceftiofur, cefazolin and trimethoprim sulfonamide.111  Susceptibility data for A. 
equuli from a veterinary teaching hospital in Canada showed good susceptibility to most 
antimicrobials tested, including  amoxicillin/CA (100%), cephalothin (100%), 
enrofloxacin (100%), ceftiofur (98%), tetracycline (93%), trimethoprim sulfamethoxazole 
(93%), ampicillin (91%), gentamicin (79%), penicillin (67%), neomycin (47%), amikacin 
(46%), spectinomycin (40%), erythromycin (39%). 45 
 
Nine clinical isolates of A. suis from horses in New Zealand between 1978 and 1980 were 
susceptible to all antibiotics tested, including benzyl penicillin, ampicillin, streptomycin, 
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tetracycline, neomycin and kanamycin.112 A report of A. suis from two foals in Wisconsin 
in 1996 showed one susceptible to all antimicrobials tested, while the other was resistant 
to amikacin and penicillin, and intermediate to ceftiofur, gentamicin, tetracycline and 
tobramycin.113   
 
Multi-drug resistance was a concern in one report of Actinobacillus sp. isolated obtained 
between 1995 and 2000 from postsurgical cases in Pennsylvania.  While all isolates were 
susceptible to amikacin, ceftiofur, cephalothin, chloramphenicol, enrofloxacin, 
gentamicin, polymixin B and rifampin, all were resistant to penicillin, bacitracin and 
vancomycin with variable resistance to ampicillin, oxacillin and ticarcillin.114  In a 
Swedish veterinary hospital in 1999, an antimicrobial susceptibility analysis was 
suggestive of acquired resistance to penicillin, ampicillin, streptomycin and 
trimethoprim-sulfa in some isolates of Actinobacillus.107  Actinobacillus sp  isolates from 
a Canadian veterinary teaching hospital showed good susceptibility to most 
antimicrobials tested, including enrofloxacin (100%), ampicillin (95%), ceftiofur (95%), 
cephalothin (95%), trimethoprim sulfamethoxazole (95%) amoxicillin/CA (91%), 
tetracycline (91%), gentamicin (73%), penicillin (68%), amikacin (33%), neomycin 
(25%), spectinomycin (18%), and erythromycin (14%). 45 
 
Rhodococcus equi 
Rhodococcus equi is most commonly associated with pyogranulomatous pneumonia in 
foals, as well as diarrhea, uveitis, polysynovitis and abscesses.  Rhodococcus equi 
infections have historically been treated with a combination of erythromycin and 
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rifampin, though resistance to rifampin has been reported. 116,117  Fluoroquinolone 
resistance has also been reported.118 Clarithromycin119 and doxycycline120 have been 
recommended as possible alternative treatments. 
 
Other Bacterial Infections of Horses 
Other less frequently isolated bacteria still play a role in equine disease, particularly in 
critical care settings.  Emergent multi-drug resistance has been reported in the human 
medical literature for bacteria such as Acinetobacter baumannii121 and Serratia 
marscens122 that also have been known to cause infection in hospitalized horses.  
Nosocomial outbreaks of multi-drug resistant strains of both bacteria have also been 
reported in companion animal medicine.123,124 
 
Acinetobacter baumannii has been reported as a cause of intravenous catheter infections 
in horses with consistent resistance to amoxicillin, amoxicillin/CA, ceftiofur, tetracycline 
and potentiated sulfonamides and variable resistance to gentamicin, flumequine and 
enrofloxacin.125  A strain of Acinetobacter baumannii isolated from a skin lesion of a 
horse during an outbreak in a veterinary teaching hospital in Switzerland in 2001 was  
resistant  to amoxicillin, cefoperazone, ticarcillin, gentamicin, sulfonamides, 
sulfonamide-trimethoprim, tetracycline, and chloramphenicol, and was susceptible to 
caftazidime, imipenem, and ciprofloxacin.39  A DNA fragment from an equine isolate of 
Acinetobacter baumannii was found to be similar to a resistance plasmid previously 
identified in Klebsiella pneumoniae, Serratia marcescens and Escherichia coli.126 
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Nosocomial infection was suspected in a subset of horses with Serratia species infection 
in one report.  The most common isolate, Serratia marcescens, showed consistent 
resistance to penicillin and variable resistance to chloramphenicol and gentamicin. 127 An 
isolated report of Serratia marcescens sensitive to trimethoprim sulfadiazine was the 
cause of fatal endocarditis in a horse. 128  Serratia marcescens associated with abortion in 
a mare was susceptible only to ceftiofur out of fifteen antibiotics tested. 129  A strain of 
Serratia marcescens causing septicemia in two horses receiving intravenous infusions 
from a common source was susceptible to amikacin, gentamicin, chloramphenicol and 
trimethoprim sulphamethoxazole.130 
 
Microbiology of Equine Pathogens by Body System 
Reproductive 
Mare reproductive tract samples are among the most common equine specimens 
submitted to veterinary diagnostic laboratories.45  Streptococcus equi zooepidemicus and 
E. coli are frequently reported as the most common isolates from uterine cultures. A 1979 
study of 498 positive uterine culture results produced ß-hemolytic Streptococci (39%), E. 
coli (27%) and Klebsiella pneumoniae (7%).131  In a recent study from a university 
teaching hospital diagnostic laboratory, uterine culture isolates included Streptococcus 
equi zooepidemicus (35.6%) followed by E. coli (13.8%).45  A recent (2008) retrospective 
of antimicrobial susceptibility of isolates from mares with fertility problems showed the 
most frequent isolates to be Streptococcus group C (31.7%) and E. coli (18.4%).52 
Streptococci in the 1979 study showed 100% susceptibility to ampicillin, penicillin, 
cephaloridine and chloramphenicol, while E. coli showed 100% susceptibility to 
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chloramphenicol and gentamicin.  In the university study cited above, the Streptococcus 
species showed most uniform susceptibility to amoxicillin/CA (82.7%) with significant 
resistance to kanamycin, gentamicin and enrofloxacin.  The E.coli isolates showed good 
susceptibility to multiple antibiotics including amoxicillin/CA (78.1%), enrofloxacin 
(75.3%), gentamicin (73.5%), trimethoprim sulphamethoxazole (71.9%), and kanamycin 
(67.2%). 52 
 
Another study reported slightly different results with E. coli (43.5%) being the most 
frequent, and ß-hemolytic streptococci (12.9%) the second most common isolate.  
Sensitivity of the ß-hemolytic streptococci included decreased susceptibility to 
clindamycin (90%), trimethoprim sulphamethoxazole (90%), oxytetracycline (29%), 
gentamicin (19%) and neomycin (13%), though all isolates were susceptible to penicillin, 
ampicillin, cephalothin and chloramphenicol. For the E. coli isolates, no resistance was 
noted to enrofloxacin, though 3% were intermediate.  Reported susceptibilities included 
nitrofurantoin (99%), gentamicin (96%), chloramphenicol (94%), neomycin (93%), 
ampicillin (86%), trimethoprim sulphamethoxazole (85%),  oxytetracycline (81%), 
streptomycin (51%) and cephalothin (18%).132 
 
Streptococcocus equi zooepidemicus was the sole focus of another study of uterine 
isolates from mares with endometritis; susceptibility was high to ampicillin (100%), 
cephalexin (100%) and gentamicin (98.5%) and enrofloxacin and trimethoprim 
sulphamethoxazole were considered acceptable. The susceptibility to gentamicin was 
reported to be considerably higher than in other studies. 133 
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Respiratory 
Frequently cultured specimens from the equine respiratory tract include transtracheal 
washes, nasal swabs and guttural pouch washes.  Common respiratory isolates in one 
large scale study included  Streptococcus equi zooepidemicus (40.5%),  Actinobacillus 
suis (22.6%) and Actinobacillus equuli (15.4%); significant problems with resistance 
were not noted. 45 
 
Gastrointestinal 
The mammalian gastrointestinal tract is a rich source of microbial life.  As pertains to the 
more focused issue of antimicrobial resistance, commensal organisms of the 
gastrointestinal tract may serve as reservoirs for transmission of resistance plasmids to 
more pathogenic bacteria.  E. coli has demonstrated this characteristic, transferring 
resistance genes to clinical isolates of multi-drug resistant Salmonella.16   Enterococcus 
species demonstrate the ability to acquire significant multi-drug resistance, potentially 
causing untreatable infections.64  Vancomycin resistant Enterococcus faecium was 
identified in fecal samples from 8% of clinically normal horses tested. 14  Another study 
found similar results, with 6.7% of equine samples containing vancomycin resistant 
Enterococcus casseliflavus or Enterococcus faecium. 10 
 
Blood Cultures 
Blood cultures from septic foals historically produce gram negative bacteria including E. 
coli, Actinobacillus spp, and K. pneumoniae; recent results from a university hospital 
retrospective were consistent with this. 45  Mixed infections with gram positive or 
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anaerobic bacteria in addition to gram negative bacteria occurred in approximately half of 
the septic foals in one report.50 A more recent study showed that while E. coli was still 
the most common isolate, 33.8% of foal blood cultures returned only a gram positive 
organism.   E. coli isolates in this study showed 80% susceptibility to amikacin, and 80% 
susceptibility to gentamicin. 51  
 
Ocular 
Streptococcus equi zooepidemicus is frequently reported as the most common isolate in 
surveys of equine bacterial keratitis.45  A recent retrospective found 33.3% of isolates to 
be Streptococcus equi zooepidemicus; all were susceptible to ciprofloxacin, cephalothin 
and chloramphenicol, with decreased susceptibility to gentamicin (82.4%), bacitracin 
(64.3%), polymyxin B (21.4%) and neomycin (6%).  Pseudomonas aeruginosa and 
Staphylococcus spp. each accounted for 11.8% of the isolates in this study.  All 
Pseudomonas isolates were susceptible to ciprofloxacin, gentamicin, neomycin, 
polymyxin B and tobramycin. 134  Another study found Pseudomonas aeruginosa (22%) 
and Streptococcus equi zooepidemicus (20%) to be the most common isolates, although 
in this report the Streptococcus isolates showed increasing resistance to gentamicin over 
the ten year retrospective period while the Pseudomonas isolates showed increasing 
resistance to both gentamicin and tobramycin. 135 A retrospective examining 
susceptibilities of ß-hemolytic streptococci isolated from equine ulcerative keratitis 
showed 100% susceptibility to bacitracin, carbenicillin, cephalothin, and 
chloramphenicol with 100% resistance to kanamycin and neomycin.  Susceptibility to 
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other antibiotics included trimethoprim sulfa (90.9%), ampicillin (54.5%),  gentamicin 
(45.5%), polymyxin B (18.2%), enrofloxacin (18.2%) and tobramycin (9.1%).62 
 
Intravenous Catheters 
Scattered reports exist in the literature pertaining to intravenous catheter infections in 
horses.  Commonly isolated organisms include coagulase negative Staphylococci, 
Corynebacterium species, Enterobacter species and Streptococci.136  Acinetobacter 
baumannii was isolated in catheter tips from seven horses.  All strains showed resistance 
to amoxicillin with or without clavulanic acid, ceftiofur, tetracycline and potentiated 
sulfonamides, and two were resistant to fluoroquinolones.  All were intermediate or 
resistant to gentamicin and susceptible to neomycin.  Clinical indication of catheter 
infection was evident in only three horses with positive cultures. 125  In one study of long 
term catheterization in colic cases, Enterobacter and Staphylococcus aureus were 







Data describing equine specimens submitted to OADDL is stored across multiple 
automated databases including the University Veterinary Information System (UVIS), its 
now defunct predecessor the Veterinary Laboratory Information Management System 
(VetLIMS), and the Sensititre microbiology system.  Additional demographic data 
regarding equine patients hospitalized at the Boren Veterinary Teaching Hospital 
(BVTH) is stored in the Medical Information Management System (MIMS), and detailed 
case management data is stored in paper records in the Medical Records Department. 
 
To create the most comprehensive single research database file possible, bacterial isolate 
and sensitivity data for the years 2005 through 2007 were exported from Sensititre to a 
Microsoft Excela spreadsheet.  Patient and client demographic data for the same years 
were extracted from UVIS and exported to another Excel spreadsheet.  Records were 
matched manually to determine specimens that were submitted to OADDL by the 
BVMTH, and those samples that were submitted by the RVC.  Individual case data were 
obtained from MIMS or paper records as required.    
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Data wer analyzed using both Excel and Microsoft Accessb.  Analysis included 
description of isolates by organism, by body system of origin, and by location of origin 
(BVMTH and CVHSR versus RVC).  For the most frequently isolated pathogens, 
phenotypic susceptibility typing was performed.  Although this method is less definitive 
as molecular typing for describing the epidemiology of infectious diseases, it nonetheless 
provides valuable initial information on the microbial environment. 82  Antibiograms 
were developed for each of these pathogens for both the BVMTH/CVHSR and the RVC.  
Duplicate isolates from a single patient were removed prior to susceptibility analysis.  
Research in humans suggests that removal of duplicate isolates results in significantly 
different antibiogram patterns than when repeat isolates from chronically, critically ill 
patients are included in the analysis.138  All antibiograms were compiled using only those 
specimens of known origin.  Samples from 2005 classified as “Unknown” due to the lack 
of available data for VetLIMS to identify the origin were excluded from susceptibility 







During the three year period studied 1,885 bacterial isolates from equine specimens were 
cultured and had sensitivities performed at OADDL.  Of this total, 1,610 were first 
isolates.  Complete data was unavailable to classify 427 first isolates as coming from 
BVMTH facilities versus the RVC.  Regional veterinary community specimens totaled 






  2005 2006  2007 Total
Regional Veterinary Community (RVC) 61 320  258 639
Boren Veterinary Medical Teaching Hospital (BVMTH) 47 221  229 497
Unknown  417 9  1 427
College of Veterinary Health Sciences Ranch (CVHSR) 5 19  23 47
Total  530 569  511 1610
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County  2005 2006 2007 Total % Total 
Payne  60 303 345 708 37.6% 
Unspecified  496 30 10 536 28.4% 
Le Flore  20 83 126 229 12.1% 
Logan  12 107 13 132 7.0% 
Oklahoma  2 21 23 46 2.4% 
McClain  7 19 26 1.4% 
Creek  3 14 6 23 1.2% 
Carter  1 8 11 20 1.1% 
Mayes  13 4 17 0.9% 
Canadian  10 5 15 0.8% 
Garvin  1 4 7 12 0.6% 
Other (41 Counties) 17 55 49 121 6.4% 
Total  612 655 618 1885 100.0% 
 
Escherichia coli (15.7%), Streptococcus equi zooepidemicus (13.7%) and all Salmonella 
species (11.9%) were the most common bacteria isolated overall.  First isolates showed 
the same distribution of organisms with E. coli (14.3%), Streptococcus equi 
zooepidemicus (12.7%) and all Salmonella species (10.9%).  Tables A-1 and A-2 provide 
detail on all bacteria isolated.  The frequency of isolation of individual bacteria varied 
with location.  E. coli and Streptococcus equi zooepidemicus were the most common 
isolates from the BVMTH and RVC, but this was reversed for CVHSR specimens.  The 
third most common isolate at the BVMTH remained Salmonella species, while it was 
Pseudomonas aeruginosa for the RVC and Klebsiella pneumoniae at the CVHSR.  
Tables A-3, A-4 and A-5 detail isolate frequencies for each location. 
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Reproductive system specimens were the most common of all submissions to OADDL at 
35.1%, with 16.3% gastrointestinal specimens and 16.2% respiratory tract samples.  
Table A-6 details these findings.  The most common specimen submitted from the 
BVMTH was feces (17.9%) followed by lower respiratory tract samples (16.5%), blood 
cultures (8.0%), intravenous catheters (6.8%) and eye swabs (5.0%)  Nearly half (48.8%) 
of all RVC specimens were uterine samples, followed by lower respiratory tract samples 
(9.5%).  Specimen sources from the CVHSR included uterus (51.1%) and feces (19%).  
Tables A-7, A-8 and A-9 detail specimen samples by location of origin. 
 
Findings by Organism 
Escherichia  coli 
Escherichia coli (E. coli) and E. coli beta together equaled 310 (16.4%) total isolates and 
245 (15.2%) first isolates. Fourteen of these isolates were E. coli beta; all were first 
isolates.  The most common sources of E. coli were the mare reproductive tract and the 
gastrointestinal system.  E. coli was isolated from numerous other sources as shown in 












Source  2005 2006 2007  Total
Uterus/Vagina/Cervix  45 57 37  139
Feces/GI Tract  19 24 23  66
Wound/Incision/Skin Lesion 7 7 4  18
Blood Culture  7 8 2  17
TTW/Lung  5 3 6  14
Urine/Urolith  6 3 2  11
Umbilicus  6 2 8
Abscess  1 3 2  6
Other  3 1 2  6
Liver  3 2  5










Total  104 116 90  310
 
Ninety four E. coli susceptibility phenotypes were identified; these are detailed in Table 
A-10.  A single antimicrobial susceptibility phenotype designated Phenotype 1 accounted 
for 26.5% of all E. coli isolates, and showed resistance only to rifampin.  This phenotype 
was present in all years and from all locations of origin.  The next seven most frequent 
phenotypes, including 5 to 13 isolates, showed resistance not only to rifampin, but to 
varying combinations of erythromycin, oxacillin, penicillin, spectinomycin, tetracycline 
and trimethoprim sulfamethoxazole.   The remaining isolates showed numerous patterns 
of multi-drug resistance.  There were no antimicrobials tested for which all isolates were 
susceptible.  Twenty phenotypes (28 isolates) showed resistance to enrofloxacin, while a 
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further seven single-isolate phenotypes were intermediate.  One isolate was intermediate 
to imipenem, and one was susceptible only to imipenem.  Nearly one-third (31%) of 
isolates were resistant to one antibiotic, 68% were resistant to two or more, and 50% 
were resistant to five or more. 
 
A trend toward decreasing susceptibility to cephalosporins was present in both BVMTH/ 
CVHSR and RVC isolates over the three year period.  Tables A-11 and A-12 show 
susceptibility percentages for isolates for each location. 
 
Streptococcus equi zooepidemicus 
Streptococcus equi zooepidemicus was the second most frequently isolated organism 
overall (258; 13.7%) and for first isolates (205; 12.7%).  The mare reproductive tract (98; 
37.9%) and the lower respiratory tract (54; 20.9%) were the most frequent sources of 
Streptococcus equi zooepidemicus.  Table 4 below summarizes the sources of all 













Source  2005 2006 2007  Total 
Uterus/Vagina/Cervix 47 36 15  98 
Lung/TTW  13 22 19  54 
Wound/Incision/Skin Lesion 6 8 5  19 
Nasal/Sinus/Guttural Pouch 7 5 7  19 
Other  4 8 5  17 
Abscess  6 5 5  16 
Thorax/Pleura  2 7  9 
Sheath/Penis/Urethra 1 3 1  5 
Bone/Tendon/Joint  3 1  4 
Abdominal  2 1 3 
Eye/Conjunctiva  3 3 
Umbilicus  2 1  3 
Catheter  2  2 





Total  95 94 69  258 
 
Of all 205 first isolate Streptococcus equi zooepidemicus specimens 47% (97) were 
submitted by the RVC, 23% (48) by the BVMTH and 5% (11) by the CVHSR.  Nearly 
one-quarter (24%) of the samples did not have a location of origin specified.    
 
Ninety-five individual sensitivity patterns were identified from Streptococcus equi 
zooepidemicus first isolates.  Phenotype 1 was the most common, accounting for 15.6% 
(32) of all Streptococcus equi zooepidemicus isolates and occurring in all years and all 
locations.  Regional veterinary community submissions accounted for 62.5% (20) of 
Phenotype 1 isolates.   
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Phenotype 1 was susceptible to all antibiotics tested with the exception of being 
intermediate to erythromycin.  Phenotypes 2 and 3 accounted for 5.4% (11) and 4.8% 
(10) of Streptococcus equi zooepidemicus isolates respectively, and were identical to 
Phenotype 1 with the exception that Phenotype 2 was resistant to tetracycline and 
Phenotype 3 was intermediate to enrofloxacin.  Individual isolates showed more frequent 
intermediate and resistant status to cephalosporins, imipenem, chloramphenicol and 
tetracycline.  Only one isolate, a 2006 RVC sample, showed resistance to 
trimethoprim/sulphamethoxazole.  Sixty-nine phenotypes were single isolates.  Thirty-
two percent (31) of RVC isolates had unique sensitivity patterns, compared with 40% 
(19) of BVMTH isolates and 45% (5) of CVHSR isolates.   
 
No phenotype was susceptible to all antimicrobials tested, though 42% of isolates showed 
intermediate status to at least one antimicrobial, but no resistance.  Only 7% of isolates 
were resistant to five or more antibiotics.  All phenotypes with resistance to greater than 
three antimicrobials were single isolates.   Table A-13 provides detailed data on all 
susceptibility phenotypes for Streptococcus equi zooepidemicus isolates. 
 
Different susceptibility trends were observed in BVMTH and CVHSR versus RVC 
isolates over the three year retrospective period.  Improved susceptibility to amikacin, 
ampicillin and gentamicin was noted in BVMTH and CVHSR samples, while 
susceptibility to amoxicillin/CA, cephalosporins, chloramphenicol, erythromycin, 
oxacillin, penicillin and rifampin decreased.  Specimens from the RVC showed decreased 
susceptibility to amikacin and tetracycline, with transient resistance noted in 2006 to 
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imipenem and trimethoprim sulfamethoxazole.   Complete antibiograms are shown in 
Tables A-14 and A-15. 
 
Salmonella 
Salmonella was the third most frequently isolated bacteria in this study.  A total of 224 
(11.9%) Salmonella isolates were received, with 175 (10.9%) of these being first isolates.  
Approximately two-thirds of the specimens were submitted by the BVMTH and the 
remainder by the RVC.  Samples submitted by the RVC came from 16 of Oklahoma’s 77 






The most frequent Salmonella isolate overall for the study period was Group B (24%), 
though this varied by year.  In 2005, 38% of isolates were Group C2 while 30% were 
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Group B.  In 2006, Group C2 made up just 8% of the year’s total, while Salmonella 
Group B remained consistent at 27%.  In that period, unidentified Salmonella isolates 
increased from 8% to 52% of the annual total.  In 2007 64% of isolates were unidentified, 
15% were Salmonella Group C1 and 13% were Group B.  Table A-16 provides a detailed 
breakdown of Salmonella first isolates. 
 
Of 224 total Salmonella isolates, 210 (93.7%) came from the gastrointestinal tract.  Table 




Source  2005 2006 2007 Total 
Gastrointestinal 70 80 60 210 
Joint  1 1 3 5 
TTW/Lung  2 2 






Total  75 82 67 224 
 
Fourteen susceptibility phenotypes were identified for Group B isolates.  Phenotype 1 
accounted for 54.7% (23) of Group B first isolates, and occurred with similar frequency 
in both BVMTH and RVC specimens.  This phenotype was resistant to clindamycin, 
erythromycin, oxacillin, penicillin, rifampin and spectinomycin, and was susceptible to 
all other antibiotics tested.  Phenotype 2 was limited to 5 isolates identified in February 
and March, 2005.  Resistance was present to all antibiotics except amikacin, enrofloxacin 
and imipenem. Four Phenotype 2 samples were from feces and one was from a catheter 
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tip; although specimen origin data was unavailable the catheter tip makes it likely that 
these were BVMTH samples.  Phenotype 3 included three specimens submitted in 2006, 
one from the RVC and two from the BVMTH.  This differed from Phenotype 2 in being 
sensitive to gentamicin, marbofloxacin and trimethoprim/sulfamethoxazole and 
intermediate to ticarcillin and ticarcillin/CA.  The remaining eleven phenotypes were 
single isolates.  Five were from the BVMTH, three were from unknown origin, two were 
from the RVC and one was from the VMR.  All Group B isolates were resistant to five or 
more antimicrobials tested.  Details of Group B susceptibility phenotypes are presented in 
Table A-17. 
 
Group C1 included seven susceptibility phenotypes.  Phenotype 1 accounted for 63.6% of 
Group C1 isolates, and identified in BVMTH and RVC specimens across all years.  This 
phenotype was sensitive to all antibiotics tested except clindamycin, erythromycin, 
oxacillin, penicillin and rifampin.  Phenotype 2 was identified in 2 samples in 2005, 
while Phenotype 3 was identified in one specimen each in 2005 and 2006.  The remaining 
phenotypes were single isolates. Ninety-five percent of isolates were resistant to five or 
more antibiotics.  Details of Group C1 susceptibility phenotypes are presented in Table 
A-18. 
 
Group C2 included fifteen susceptibility phenotypes.  Phenotype 1 made up 30% of 
Group C2 isolates, and was resistant only to clindamycin, erythromycin, oxacillin, 
penicillin and rifampin.  This phenotype was present in all years, and in both BVMTH 
and RVC specimens.  Phenotype 2 made up 20% of Group C2 isolates and was present in 
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2005 only.  Resistance in this phenotype included amoxicillin/CA, ampicillin, cefazolin, 
cefoxitin, cefpodoxime, ceftiofur, cephalothin, chloramphenicol, erythromycin, oxacillin, 
penicillin, rifampin, sulphadimethoxine, spectinomycin, tetracycline, ticarcillin, and 
ticarcillin/CA.  Phenotypes 3 and 4 both were present in 2005 only, and showed 
susceptibility patterns identical to Phenotype 2 except that Phenotype 3 was intermediate 
to ticarcillin/CA and Phenotype 4 was intermediate to ticarcillin.  Phenotypes 5 through 
14 were found in single isolates in 2005, and Phenotype 15 in a single isolate in 2006. 
Ninety-three percent of Group C2 isolates were resistant to five or more antimicrobials.  
Details of Group C2 susceptibility patterns are shown in Table A-19. 
 
A single Group D isolate was identified in a RVC fecal specimen in 2006.  The isolate 
was sensitive to amikacin, gentamicin, enrofloxacin, marbofloxacin, imipenem, and 
trimethoprim/sulfamethoxazole, intermediate to ticarcillin and ticarcillin/CA, but 
resistant to all other antibiotics tested.  
 
The seven Group E isolates were identified in an eight month period from June 25, 2005 
to February 22, 2006.  The last three were BVMTH isolates; location of origin of the first 
four was unknown due to unavailable automated data for that time period.  The first five 
isolates showed an identical susceptibility pattern, resistant only to rifampin.  The sixth 
isolate occurred after a change in testing protocol, and showed resistance to clindamycin 
in addition to rifampin; the previous five isolates were not tested for clindamycin.  The 
final isolate showed resistance to rifampin, clindamycin and tetracycline.        
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Untyped Salmonella species included 20 susceptibility phenotypes.  Phenotype 1 
included 63.3% of all untyped isolates, and was present in all years and from BVMTH 
and RVC specimens.  Phenotype 1 was resistant to clindamycin, erythromycin, oxacillin, 
penicillin, rifampin and spectinomycin.  Phenotype 2 was isolated from four RVC 
specimens (three different veterinary hospitals and one breeding farm) in 2006 and 2007.  
This phenotype was resistant or intermediate to all antibiotics tested except amikacin, 
gentamicin, imipenem and marbofloxacin.  Phenotype 3 was found in one RVC specimen 
and 2 BVMTH specimens in 2006 and 2007; it was identical to Phenotype 1 except for 
resistance to tetracycline.  Phenotypes 4 and 5 included two specimens each, and the 
remainders were single isolates.  Phenotype 12 was a unique susceptibility pattern 
identified in a foal at the CVHSR in 2007.  Ninety-nine percent of isolates were resistant 
to five or more antimicrobials.  Detailed susceptibility patterns of all untyped Salmonella 
isolates are shown in Table A-20. 
 
Tables A-21 and A-22 show annual antibiograms for all Salmonella isolates for the 
BVMTH and RVC respectively.  Emerging resistance to fluoroquinolones was noted for 
both locations.  Improved susceptibility to tetracycline was also noted in both groups.  
 
Staphylococcus aureus 
Staphylococcus aureus (S. aureus) was the fourth most common isolate, making up 4.2% 
(80) overall and 3.5% (57) first isolates.  Soft tissue sources provided 23.7% (19) of all S. 






Source  2005 2006 2007  Total 
Wound/Incision/Skin Lesion 3 7 9  19 
Abscess  3 5 6  14 
Transtracheal Wash  1 9  10 
Other  2 3 4  9 
Uterus  1 3 2  6 
Thorax/Pleura  5  5 
Urine  2 2 4 
Bone/Tendon/Joint  2 1  3 
Eye  1 2  3 





Total  16 22 42  80 
 
The BVMTH and the RVC each provided 42% (24) of all S. aureus first isolates.  The 
remaining 16% (9) were unidentified.  Regional veterinary community S. aureus was 






Twenty-four susceptibility phenotypes were identified.  Phenotypes 1 and 2 each 
accounted for 19.2% (11) isolates.  Phenotype 1 was identified in 2 specimens from 2005, 
2 from 2006 and 7 from 2007.  The two 2005 samples were unidentified as to location, 
and the remaining 9 came from the BVMTH.  This was a multi-drug resistant strain, with 
resistance to oxacillin and all other antibiotics tested except chloramphenicol, 
enrofloxacin, rifampin and tetracycline.  Phenotype 2 was identified in 2006 and 2007 in 
both RVC and BVMTH samples, and was susceptible to all antibiotics tested.  While 
28% of all S. aureus isolates showed no resistance, 40% were resistant to five or more 
antimicrobials tested. 
 
Seven phenotypes (1, 4, 10, 11, 14, 18 and 20) including 20 isolates showed oxacillin 
resistance, strongly suggestive of methicillin resistant Staphylococcus aureus (MRSA). 
Phenotype 1 included 11 isolates, Phenotype 4 included 4 isolates and the others were 
single isolates.  Three of the isolates (1 of the Phenotype 4, and Phenotypes 11 and 20) 
came from the RVC, and the rest from the BVMTH.   Detailed susceptibility patterns for 
all phenotypes are provided in Table A-23.  The epidemiology of the BVMTH isolates is 
detailed in the Case Studies section below.  Tables A-24 and A-25 provide annual 









Pseudomonas aeruginosa (P. aeruginosa) made up 3.8% (72) of all isolates, and 3.2% 
(53) of first isolates.  Uterine specimens accounted for 38.8% (28) of all P. aeruginosa 




Source  2005 2006 2007  Total 
Uterus  6 11 11  28 
Semen  1 3 4  8 
Thorax  8  8 
Miscellaneous Swabs/Fluid 3 2 1  6 
Sinus/Nasal Passages 3 1 1  5 
Trachea/Lung  1 2 1  4 
Urine  1 2  3 






Grand Total  19 23 30  72 
 
Fifty-three percent (28) of P. aeruginosa isolates came from the RVC, while 21% (11) 
came from the BVMTH, 2% (1) came from the CVHSR and 25% (13) were unknown. 
Twenty susceptibility phenotypes were identified.  Phenotype 1 accounted for 20.8% (11) 
of first isolates and was resistant to amoxicillin/CA, ampicillin, all cephalosporins, 
rifampin, tetracycline and trimethoprim sulphamethoxazole.  Phenotype 2 was identical 
to Phenotype 1 except for being susceptible to trimethoprim sulfamethoxazole.  There 
was no antimicrobial to which 100% susceptibility was observed; amikacin was the 
closest with one isolate showing an intermediate status.  Virtually all isolates showed 
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resistance to five or more antimicrobials.  The susceptibility patterns of all phenotypes 
are detailed in Table A-26. 
 
Antibiograms were constructed using very small sample sizes and are shown in Tables A-
27 and A-28.  CVHS facility isolates showed increasing resistance to amikacin, 
enrofloxacin and trimethoprim sulfamethoxazole.  Community isolates showed 




Klebsiella pneumoniae (K. pneumoniae) was the sixth most common isolate overall, 
accounting for 3.1% (58) total isolates and 3.2% (50) of first isolates.  The greatest 
proportion of K. pneumoniae isolates came from uterine specimens at 27.6% (16), with 














Source  2005 2006 2007 Total 
Uterus  1 6 9 16 
Transtracheal Wash 1 7 2 10 
Semen  6 2 8 
Incision  4 4 
Placenta  1 3 4 











Other  1 1 2 
Total  14 24 20 58 
 
Forty-four percent of K. pneumoniae isolates came from RVC specimens, with 34.0% 
from the BVMTH, 6.0% from the CVHSR and 16.0% unidentified.  Twenty-two 
resistance phenotypes were identified, with Phenotype 1 accounting for 50% of the 
isolates.  This phenotype was present across all years and from all locations.  Resistance 
was common among K. pneumoniae isolates, with 98% being resistant to five or more 







Untyped ß-Streptococcus accounted for 2.6% (49) of all isolates, and 3.0% (48) of first 
isolates. Over half (51.0%) came from uterine cultures; sources of the remaining isolates 




Source  2005 2006 2007  Total 
Uterus  9 7 9  25 
Transtracheal Wash  1 4 1  6 
Miscellaneous Swabs/Fluid 3 2 5 
Abscess  2 2 
Guttural Pouch  2 2 
Umbilicus  1 1 2 






Total  20 17 12  49 
 
Forty-six percent of ß-Streptococcus isolates came from the RVC, with 19% from the 
BVMTH, 2% from the CVHSR and 33% from unknown locations. 
 
Thirty-seven resistance phenotypes were identified.  The most common phenotype 
included five isolates and was susceptible to all antibiotics tested.  No drug resistance 
was seen in 27% of isolates, with only 8% showing resistance to five or more 
antimicrobials.  Resistance was most common to tetracycline and sulphadimethoxine.  
Table A-32 details susceptibility of all ß-Streptococcus isolates.  Annual antibiograms are 
provided in Tables A-33 and A-34, although the sample size for this organism was small. 
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Streptococcus equi equi 
Streptococcus equi equi (S. equi equi) accounted for 2.2% (41) of all isolates, and 2.3% 




Source  2005 2006 2007 Total 
Abscess  9 3 4 16 
Nasal Swab  3 3 1 7 
Guttural Pouch  3 2 5 
Lymph Node  1 1 1 3 
Transtracheal Wash 1 2 3 





Total  18 8 15 41 
 
Specimens from the RVC accounted for 47.4% of S. equi equi first isolates.  The 
BVMTH made up 21.1% of the isolates and 31.6% of isolates were unidentified.    Of the 
38 total first isolates, 37 susceptibility phenotypes were defined; these are detailed in 
Table A-35.  Resistance was absent in 16% of isolates, while 39% showed resistance to 
five or more antibiotics.   
 
Due to a single BMVTH S. equi equi isolate in 2005 and none in 2006, one cumulative 
antibiogram was constructed, show in Table A-36.  The most notable trends in the RVC 
annual antibiograms was a decrease in susceptibility to chloramphenicol and complete 
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resistance to tetracycline in 2007.  Table A-37 shows the details of the RVC annual 
antibiograms. 
 
Streptococcus dysgalactiae equisimilis 
Streptococcus dysgalactiae equisimilis made up 2.1% (39) of all isolates, and 2.3% (37) 
of first isolates.  Uterine cultures provided 53.8% of the isolates; Table 11 below shows 
the sources of all isolates.  The RVC provided most of the specimens producing 
Streptococcus dysgalactiae equisimilis at 45.9%, with 16.2% coming from the BVMTH 




Source  2005 2006 2007 Total 
Uterus  13 6 2 21 
Abscess  2 2 4 
Wounds, Skin Lesions 1 3 1 5 
Eye Swab  2 2 






Total  16 14 9 39 
 
About one-third (35%) of isolates showed no resistance, while one-quarter (24%) were 
resistant to five or more antibiotics.  Table A-38 provides detail of susceptibility 





Staphylococcus xylosus (S. xylosus) made up 1.9% (36) of all isolates and 1.9% (31) of 
first isolates.  Uterine cultures provided the majority of isolates, 55.5%.  S. xylosus 
isolates came primarily from the RVC (54.5%) with 21.2% from BVMTH specimens.  





Source  2005 2006 2007 Total 
Uterus  5 5 10 20 
Blood Culture  1 3 3 7 






Total  9 8 19 36 
 
Table A-41 details the antimicrobial susceptibility phenotypes of all S. xylosus 
phenotypes.  Multi-drug resistance was common, with 47% of isolates resistant to two to 
four antimicrobials, and 34% resistant to five or more.  Four isolates were resistant to 
oxacillin; all were multi-drug resistant, and one was resistant to all antimicrobials tested.  
Tables A-42 and A-43 show annual antibiograms for the BVMTH and the RVC. 
 
Staphylococcus species 
Untyped Staphylococcus species made up 1.6% (31) of all isolates, and 1.9% (31) of first 
isolates.  Uterine cultures accounted for 54.8% of Staphylococcus species.  Table 13 
 51
details the sources of all isolates.  Most isolates came from RVC (48.4%) specimens, 




Source  2005 2006 2007 Total 
Uterus  5 4 8 17 
Eye  3 1 4 
Blood Culture  1 2 3 
Catheter  1 1 
Wounds, Skin Lesions 2 2 
Other  1 1 2 
Lymph Node  1 1 
Urine  1 1 
Total  10 8 13 31 
 
Table A-44 summarizes the susceptibility phenotypes of all Staphylococcus species.  
Thirteen percent of isolates showed no resistance, 23% were resistant to one 
antimicrobial, and the remaining isolates were resistant to two or more antimicrobials.  
Two isolates were oxacillin resistant, one of which was resistant to all antimicrobials 
tested.  Tables A-45 and A-46 show annual antibiograms for the BVMTH and RVC. 
 
Enterococcus species 
Enterococcus species made up 1.8% (34) of all isolates, and 1.7% (27) of first isolates.  
Uterine cultures made up 35.2%, while incisional infections and urine cultures accounted 
for 14.7% each.  Enterococcus species were isolated primarily from BVMTH specimens 
(48.1%), with 25.9% coming from the RVC, 7.4% from the CVHSR and 18.5% from 






Source  2005 2006 2007 Total 
Uterus  3 4 5 12 
Incision Line  1 4 5 
Urine  1 4 5 






Total  7 8 19 34 
 
Twenty-seven susceptibility phenotypes were identified for Enterococcus isolates.  Multi-
drug resistance was common as seen in Table A-47, with 81% of isolates showing 
resistance to five or more antimicrobials.  Only 7% of isolates showed no resistance.  
Tables A-48 and A-49 show annual antibiograms for the BVMTH and RVC. 
 
Actinobacillus equuli 
Actinobacillus equuli (A. equuli) made up 1.0% (19) of all isolates, and 1.1% (18) of first 
isolates.  Lower respiratory specimens produced 57.8% of A. equuli isolates.  Table 15 
shows the remainder of the specimen sources.  Fifty percent of the A. equuli isolates 
came from the BVMTH, 17% from the RVC and 6% from the CVHSR.  The origin was 









Source  2005 2006 2007 Total 







Total  10 4 5 19 
 
Resistance was relatively uncommon, with 50% of isolates showing no resistance at all, 
and the remaining isolates showing resistance to one (28%) or two (22%) antibiotics.  
Table A-50 details resistance phenotypes for A. equuli isolates.  Annual antibiograms are 
presented in Tables A-51 and A-52 for BVMTH and RVC isolates. 
 
Actinobacillus suis 
Actinobacillus suis (A. suis) made up 1.1% (20) of all isolates, and 1.2% (20) of first 
isolates.  Lower respiratory tract specimens accounted for 35% of all isolates.  Table 16 
details specimen sources of A. suis.  Forty percent of isolates came form each the 











Source  2005 2006 2007 Total 
Transtracheal Wash 1 5 1 7 
Nasal Swab  1 2 3 
Uterus  1 1 2 
Blood Culture  1 1 2 





Total  6 11 3 20 
 
Resistance was relatively uncommon, with 60% of isolates showing no resistance.  
Twenty percent were resistant to one antimicrobial, and 20% were resistant to two to four 
antimicrobials.  Susceptibility patterns of all A. suis phenotypes are detailed in Table A-
53, while Tables A-54 and A-55 present annual antibiograms. 
 
Actinobacillus species 
Untyped Actinobacillus species made up 1.0% (18) of all isolates and 1.1% (18) of first 
isolates.  Lower respiratory tract samples accounted for one-third of the specimen 
sources.  The RVC provided 38.8% of the samples, with 33.3% from the BVMTH and 










  2005 2006 2007 Total 
TTW/Lung  2 4 6 
Uterus  1 1 1 3 








Total  3 6 9 18 
 
Twenty-eight percent of isolates showed no resistance, while 44% were resistant to only 
one antimicrobial.  Table A-56 details all susceptibility phenotypes for untyped 
Actinobacillus species, and annual antibiograms are presented in Tables A-57 and A-58. 
 
Rhodococcus equi 
Fifteen Rhodococcus equi isolates had sensitivities performed on them during the study 
period; over one-half of these were respiratory specimens.   Table 18 summarizes all 




Source 2005 2006 2007 Total
TTW/Lung 5 2 1 8
Abdominal Fluid 1 1
Abscess 1 1 2
Lymph Node 1 1 2
Nasal Swab 1 1
Feces 1 1
Total  8 4 3 15
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The majority of Rhodococcus equi (57.1) isolates did not have a location of origin 
specified.  The RVC provided 35.7% and the BVMTH 7.1%.  Table A-59 details the 
antimicrobial sensitivities for Rhodococcus equi isolates.  One isolate was susceptible to 
all antimicrobials tested, while seven were resistant to two to four antimicrobials and six 
were resistant to five or more.  Two of the fourteen isolates (14.2%) were resistant to 
rifampin, and two (14.2%) were resistant to erythromycin.  One isolate was resistant to 
both erythromycin and rifampin.  Table A-60 provided a cumulative antibiogram for 
Rhodococcus equi first isolates.  All isolates are considered together due to the small 
sample size. 
 
Findings by Body System 
Reproductive Tract 
Reproductive tract specimens were the most common sample in the study overall, and for 
the CVHSR and RVC whereas less than 5% of BVMTH specimens fell into this 
category.  Tables 19, 20 and 21 below detail isolates from uterine cultures submitted from 
each of these three locations.   Noticeable differences exist in organisms isolated from 
mares in each location.  Streptococcus equi zooepidemicus and E. coli were the most 
common isolates from the CVHSR.  In the small sample size from the BVMTH, E.coli 
accounted for 42.9% of isolates, with a complete absence of Streptococcus equi 
zooepidemicus.  E. coli (21.8%) and Streptococcus equi zooepidemicus (11.9%) were the 
most common isolates from the RVC.  The RVC sample was characterized by a much 






Organism 2005 2006 2007 Total  % Total
Streptococcus equi ss zooepidemicus 1 6 3 10  41.7%
E. coli  2 1 3  12.5%
Actinobacillus species  1 1 2  8.3%
Streptococcus dysgalactiae ss equisimilis 1 1 2  8.3%
Actinobacillus equuli ss equuli 1 1  4.2%
Enterococcus faecalis  1 1  4.2%
Enterococcus species  1 1  4.2%
Pasteurella pneumotropica 1 1  4.2%
Pseudomonas aeruginosa 1 1  4.2%
Pseudomonas fluorescens 1 1  4.2%
Streptococcus beta  1 1  4.2%







Organism  2005 2006 2007 Total  % Total
E. coli  3 3 6  42.9%
Actinobacillus suis  1 1  7.1%
Enterococcus faecalis  1 1  7.1%
Enterococcus species  1 1  7.1%
Escherichia hermannii  1 1  7.1%
Klebsiella pneumoniae ss pneumoniae 1 1  7.1%
Pseudomonas aeruginosa 1 1  7.1%
Staphylococcus aureus ss aureus 1 1  7.1%
Streptococcus beta  1 1  7.1%
















Organism  2005 2006 2007 Total  % 
E. coli  5 40 23 68  21.8%
Streptococcus equi ss zooepidemicus 2 24 11 37  11.9%
Pseudomonas aeruginosa 5 9 14  4.5%
Staphylococcus xylosus 5 9 14  4.5%
Streptococcus beta  1 5 8 14  4.5%
Klebsiella pneumoniae ss pneumoniae 4 9 13  4.2%
Staphylococcus species 4 8 12  3.8%
Citrobacter koseri  4 6 10  3.2%
Staphylococcus beta haemolytic 3 5 8  2.6%
Streptococcus dysgalactiae ss equisimilis 2 5 1 8  2.6%
Enterococcus species  3 4 7  2.2%
Gram negative non fermenter 3 4 7  2.2%
Enterobacter aerogenes 4 2 6  1.9%
Enterobacter cloacae  2 3 5  1.6%
Enterobacter species  2 3 5  1.6%
Streptococcus species  1 1 3 5  1.6%
Corynebacterium species 2 2 4  1.3%
E. coli beta  1 1 2 4  1.3%
Streptococcus alpha haemolytic 3 1 4  1.3%
Acinetobacter lwoffi  3 3  1.0%
Bacillus species  3 3  1.0%
Enterobacter amnigenus 1 2 3  1.0%
Enterococcus faecalis  1 2 3  1.0%
Gram negative rod  1 2 3  1.0%
Pseudomonas species  2 1 3  1.0%
Staphylococcus aureus ss aureus 1 2 3  1.0%
Citrobacter freundii  2 2  0.6%
Comamonas testosterone 2 2  0.6%
Escherichia hermannii  2 2  0.6%
Gram negative organism 1 1 2  0.6%
Klebsiella oxytoca  2 2  0.6%
Pasturella species  2 2  0.6%
Pseudomonas fluorescens 1 1 2  0.6%
Ralstonia pickettii  1 1 2  0.6%
Serratia marcescens  1 1 2  0.6%
Staphylococcus epidermidis 1 1 2  0.6%
Staphylococcus intermedius 2 2  0.6%
Stenotrophomonas maltophilia 1 1 2  0.6%
Streptococcus equi ss equi 2 2  0.6%
Other (single isolates)  1 10 9 20  6.4%





Table A-61 shows comparative cumulative antibiograms for the combined CVHSR and 
BVMTH, and RVC E. coli and Streptococcus equi zooepidemicus isolates.  Though 
numbers are small, some differences are apparent.  E.coli susceptibility to trimethoprim 
sulphamethoxazole for RVC isolates was much lower at 72% than for CVHSR/BVMTH 
isolates at 100%.   Streptococcus equi zooepidemicus isolates from the CVHSR/BVMTH 
appeared less susceptible than RVC isolates to amikacin (40% versus 59%), cefpodoxime 
(40% versus 78%), enrofloxacin (40% versus 76%) and gentamicin (60% versus 89%). 
 
Respiratory Tract 
While Streptococcus equi zooepidemicus was the most common transtracheal wash 
isolate for both BVMTH and RVC submissions, as a percent of total isolates it was twice 
as frequently cultured in RVC specimens (31.9%) as in BVMTH specimens (16.0%).  E. 
coli was considerably less common in RVC samples (2.3%) than in BVMTH samples 














Organism  2005 2006 2007 Total  % Total
Streptococcus equi ss zooepidemicus 7 6 13  16.0%
Actinobacillus equuli ss equuli 2 2 3 7  8.6%
E. coli  1 2 4 7  8.6%
Klebsiella pneumoniae ss pneumonia 5 2 7  8.6%
Actinobacillus suis  3 1 4  4.9%
Streptococcus alpha haemolytic 2 2 4  4.9%
Actinobacillus species  1 2 3  3.7%
Actinobacillus ureae  3 3  3.7%
Pasteurella aerogenes atypical 3 3  3.7%
Pasturella species  3 3  3.7%
Bordetella bronchiseptica  1 1 2  2.5%
Enterobacter cloacae  1 1 2  2.5%
Staphylococcus aureus ss aureus 1 1 2  2.5%
Streptococcus beta  1 1 2  2.5%
Streptococcus equi ss equi  2 2  2.5%
Streptococcus mitis  1 1 2  2.5%
Actinobacillus lignieresii  1 1  1.2%
Chryseobacterium indologenes 1 1  1.2%
Citrobacter species  1 1  1.2%
Corynebacterium species  1 1  1.2%
Escherichia hermannii  1 1  1.2%
Flavobacterium species  1 1  1.2%
Gram negative non fermenter 1 1  1.2%
Pasteurella pneumotropica 1 1  1.2%
Pseudomonas aeruginosa  1 1  1.2%
Salmonella subgenus 1  1 1  1.2%
Sphingobacterium multivorum 1 1  1.2%
Sphingomonas paucimobilis 1 1  1.2%
Staphylococcus haemolyticus 1 1  1.2%
Streptococcus dysgalactiae ss equisimilis 1 1  1.2%
Streptococcus suis  1 1  1.2%












Organism  2005 2006 2007 Total  % Total 
Streptococcus equi ss zooepidemicus 2 9 3 14  31.8% 
Actinobacillus ureae  5 5  11.4% 
Streptococcus beta  1 3 4  9.1% 
Actinobacillus species  1 1 2  4.5% 
Actinobacillus suis  2 2  4.5% 
Klebsiella pneumoniae ss pneumoniae 2 2  4.5% 
Pseudomonas aeruginosa 1 1 2  4.5% 
Rhodococcus equi  2 2  4.5% 
Actinobacillus equuli ss equuli 1 1  2.3% 
Actinobacillus lignieresii 1 1  2.3% 
Bordetella bronchiseptica 1 1  2.3% 
E. coli  1 1  2.3% 
Enterobacter aerogenes 1 1  2.3% 
Enterobacter cloacae  1 1  2.3% 
Pasteurella aerogenes atypical 1 1  2.3% 
Pasteurella pneumotropica 1 1  2.3% 
Pasturella species  1 1  2.3% 
Pseudomonas aeruginosa/putida 1 1  2.3% 
Ralstonia pickettii  1 1  2.3% 
Total  6 32 6 44  100.0% 
 
Gastrointestinal Tract 
Cultures from gastrointestinal tract specimens included 18.4% foals less than one month 




Age  2005 2006 2007 Total  % Total 
Less than 1 month  1 21 19 41  18.4% 
1 to 6 months  1 6 12 19  8.5% 
7 months to 1 year  0 3 6 9  4.0% 
Greater than 1 year  1 40 28 69  30.9% 
Unknown  72 12 1 85  38.1% 








Organism  2005 2006 2007 Total  % Total
Salmonella  55 60 46 161  72.9%
E. coli  15 20 15 50  22.6%
Klebsiella pneumoniae ss pneumonia 1 2 3  1.4%
Escherichia fergusonii  1 1 2  0.9%
Citrobacter freundii  1 1  0.5%
Enterobacter aerogenes  1 1  0.5%
Enterobacter cloacae  1 1  0.5%
Gram negative non fermenter 1 1  0.5%
Rhodococcus equi  1 1  0.5%
Total  74 82 65 221  100.0%
 
The most common gastrointestinal tract isolate was Salmonella at 72.9%.  All E. coli 
isolates from patients for whom ages were known came from foals less than one month of 
age, except for one yearling and one three-month-old. 
 
Blood Cultures 
Of 51 isolates from the blood cultures of 43 neonatal patients, E. coli was the most 
frequently cultured organism.  Across the three year study period, E. coli fell from 50.0% 
of all isolates in 2005 to 10.5% of all isolates in 2007.  Staphylococcus xylosus and 
Staphylococcus species increased from 7.1% each in 2005 to 15.8% and 10.5% 
respectively in 2007.  The remainder of the isolates are detailed below in Table 26.    
Susceptibilities of neonatal blood culture isolates of E. coli were equal or better for all 







Organism  2005 %2005 2006 %2006 2007 %2007  Total % Total
E. coli  7 50.0% 6 33.3% 2 10.5%  15 29.4%
Staphylococcus xylosus  1 7.1% 1 5.6% 3 15.8%  5 9.8%
Corynebacterium species        4 22.2%       4 7.8%
Staphylococcus species  1 7.1%     2 10.5%  3 5.9%
Streptococcus α hemolytic  1 7.1% 1 5.6% 1 5.3%  3 5.9%
Acinetobacter baumannii          2 10.5%  2 3.9%
Acinetobacter lwoffi              2 10.5%  2 3.9%
Enterococcus species          2 10.5%  2 3.9%
Gram negative diplococcus              2 10.5%  2 3.9%
Micrococcus species      2 11.1%     2 3.9%
Actinobacillus equuli ss equuli  1 7.1%             1 2.0%
Actinobacillus species  1 7.1%         1 2.0%
Citrobacter species  1 7.1%             1 2.0%
E. coli beta      1 5.6%     1 2.0%
Enterobacter cloacae              1 5.3%  1 2.0%
Gram negative non fermenter      1 5.6%     1 2.0%
Klebsiella pneumoniae ss        1 5.6%       1 2.0%
Kluyvera ascorbata          1 5.3%  1 2.0%
Lactobacillus species        1 5.6%       1 2.0%
Pseudomonas aeruginosa          1 5.3%  1 2.0%
Salmonella sp. group C2  1 7.1%             1 2.0%
Total  14 100.0% 18 100.0% 19 100.0%  51 100.0%
 










Three adult equine blood cultures produced Actinobacillus suis, Streptococcus species 




Thirty-five isolates were cultured from twelve catheter tips of eleven VTH patients 
during the three year study period.  The most common single isolate at 9% was 
Acinetobacter baumannii.  All three horses culturing A. baumannii from their catheters 
were critically ill patients with lengthy hospitalizations.  Two were foals, one with 
neonatal hypoxic ischemic encephalopathy and another with suspected alloimmune 
thrombocytopenia.  The third was an adult with pleuropneumonia secondary to a 
penetrating chest wound.  All Enterococcus species together accounted for 17%, 
including two isolates each of Enterococcus faecalis, Enterococcus faecium and 
unspeciated Enterococcus.  Pantoea agglomerans, Serratia marcescens and unspeciated 
















Organism  2005 2006 2007 Total  % Total
Acinetobacter baumannii 3 3  9%
Enterobacter species  2 2  6%
Enterococcus faecalis  1 1 2  6%
Enterococcus faecium  1 1 2  6%
Enterococcus species  2 2  6%
Gram negative non fermenter 2 2  6%
Pantoea agglomerans  2 2  6%
Serratia marcescens  2 2  6%
Acinetobacter lwoffi  1 1  3%
Chryseobacterium meningosepticum 1 1  3%
Citrobacter species  1 1  3%
Corynebacterium species 1 1  3%
Enterobacter cloacae  1 1  3%
Flavimonas oryzihabitans 1 1  3%
Klebsiella oxytoca  1 1  3%
Klebsiella pneumoniae ss pneumonia 1 1  3%
Micrococcus luteus  1 1  3%
Providencia rettgeri  1 1  3%
Salmonella group – B  1 1  3%
Staphylococcus aureus ss aureus 1 1  3%
Staphylococcus beta haemolytic 1 1  3%
Staphylococcus epidermidis 1 1  3%
Staphylococcus haemolyticus 1 1  3%
Staphylococcus species  1 1  3%
Stenotrophomonas maltophilia 1 1  3%
Streptococcus equi ss zooepidemicus 1 1  3%










Twenty-five isolates from 15 patients included 12.0% Staphylococcus species and 8.0% 
Pseudomonas aeruginosa, Streptococcus dysgalactiae equisimilis and Streptococcus equi 
zooepidemicus.  Three patients had two isolates, two had three isolates and one had four 




Organism  2005 2006 2007 Total  % Total
Staphylococcus species  2 1 3  12.0%
Pseudomonas aeruginosa  2 2  8.0%
Streptococcus dysgalactiae ss equisimilis 2 2  8.0%
Streptococcus equi ss zooepidemicus 2 2  8.0%
Achromobacter xylo ss xylosoxidans 1 1  4.0%
Aerococcus viridians  1 1  4.0%
Bacillus species  1 1  4.0%
Cedecea lapagei  1 1  4.0%
Enterobacter aerogenes  1 1  4.0%
Enterococcus durans  1 1  4.0%
Escherichia hermannii  1 1  4.0%
Kocuria rosea  1 1  4.0%
Micrococcus luteus  1 1  4.0%
Micrococcus species  1 1  4.0%
Pseudomonas putida  1 1  4.0%
Pseudomonas species  1 1  4.0%
Staphylococcus aureus ss aureus 1 1  4.0%
Staphylococcus xylosus  1 1  4.0%
Streptococcus beta  1 1  4.0%
Streptococcus beta haemolytic 1 1  4.0%
Total  7 14 4 25  100.0%
 
Three ocular cultures submitted by RVC practitioners produced Actinobacillus suis, 




Possible Hospital Acquired Bacterial Infections 
Clusters of multi-drug resistant bacterial isolates known to be involved in nosocomial 
infections in human and veterinary medicine occurred during the study period.  These 
included methicillin resistant Staphylococcus aureus, Enterococcus faecalis, 
Acinetobacter baumanni and Serratia marcescens.  Table A-62 summarizes patient data 
for cases involved. 
 
Oxacillin Resistant Staphylococcus aureus 
From all S. aureus isolates identified, 37 were oxacillin-resistant.  Four of these came 
from an unknown source in 2005, and are excluded from further analysis.  Sources of 
these isolates were an incision infection (February), an abscess (April), unspecified fluid 
(April), and a fracture (June).  Four isolates came from the RVC.  These included two 
specimens from the same mare on a large breeding farm in 2006, and two specimens 
from soft tissue sources from horses at other locarions, one in 2005 and one in 2007.  The 
antibiograms of the two isolates from the broodmare were slightly different, with one 
being susceptible to trimethoprim sulfamethoxazole and one being resistant.  The 
antibiograms of the two soft tissue samples differed from each other, and from the uterine 
sample. 
 
The remaining 29 isolates came from fourteen patients at the BVMTH.  The isolates were 
identified between April of 2006 and December of 2007.  The last new case was in June 
of 2007, with the isolates from July to December of that year being repeat cultures.  Nine 
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patients had one isolate, four patients had two isolates and one patient had twelve 
isolates.  Five different susceptibility phenotypes were identified among the 29 isolates.  
Phenotypes 1, 2 and 5 occurred once each in April of 2006, November of 2006 and 
December of 2007.  Phenotype 4 occurred three times, in November of 2006, May of 
2007 and June of 2007.  The remaining 23 isolates (79.3%) were of Phenotype 3.  Table 
A-63 and A-64 present the details of these cases ordered by patient and by date of 
occurrence. 
 
In Horse 3, who had two isolates, these were identified from the same specimen and 
differed only in susceptibility to tetracycline.  In Horse 11 with twelve isolates, the 
eleventh and twelfth isolates came from the same transtracheal wash and differed in that 
one was identical to the previous ten isolates, including showing resistance to 
clindamycin and erythromycin, and the other differed only in being susceptible to these 
two drugs.  Horse 9 cultured a trimethoprim sulfamethoxazole resistant isolate in April, 
2007 and an isolate susceptible to this drug one month later.  These were the only two 
cultures from that horse. 
 
Enterococcus faecalis 
Twenty-four total isolates of Enterococcus faecalis were identified.  Six of these were 
unidentified specimens from 2005, and are excluded from further analysis.  Six additional 
specimens came from the RVC.  Three of these were from three different horses at the 
same large equine clinic during a two month period in 2007; all three strains showed 
different susceptibility patterns.  The remaining three were from different veterinary 
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clinics, and all showed different susceptibility patterns.  Two isolates came from the 
CVHSR; one of these was from the uterus of a mare that spent time in the BVMTH with 
her foal during the time the isolates were cultured from patients there.   
 
The remaining ten isolates came from seven BVMTH patients between February, 2006 
and July, 2007.  Two horses had catheter infections, three horses had incisional 
infections, one had a uterine infection and one an umbilical infection.  Multi-drug 
resistance was characteristic of all isolates.  One patient had a catheter isolate that was 
intermediate to amoxicillin/CA and chloramphenicol, and resistant to everything else.   
Another patient had a catheter infection with two isolates of E. faecalis that had different 
susceptibilities.  This patient also had two different phenotypes of oxacillin-resistant S. 
aureus.  Three other patients with the E. faecalis also had oxacillin-resistant S. aureus. 
Susceptibility phenotypes of E. faecalis isolates are presented in Table A-65. 
 
Acinetobacter baumannii 
A total of ten A. baumanni isolates were cultured in the three year study period.  Two A. 
baumannii isolates cultured from a uterus and an unspecified tissue specimen, were 
submitted by RVC practitioners. 
 
The remaining eight A. baumannii specimens came from BVMTH patients, one in 
October, 2006 and the remainder clustered between April and July 2007.  The 2006 
isolate was an ophthalmology patient, and the others included three catheter infections, 
two blood cultures and a thoracic cavity infection.  All isolates were susceptible to 
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amikacin and imipenem, with resistance to most other antimicrobials tested.  
Susceptibility phenotypes of A. baumannii isolates are shown in Table A-66. 
 
Serratia marcescens 
Eight S. marcescens isolates were cultured, including three from two uterine cultures and 
a draining tract were submitted by RVC practitioners.  The remaining five isolates came 
from four BVMTH patients between April and August, 2007.  One patient had two 
isolates with different susceptibility phenotypes cultured from an intravenous catheter. 
All isolates were susceptible to imipenem and fluoroquinolones, with resistance to most 
other antimicrobials tested.  Phenotypes are detailed in Table A-67. 
 
Cumulative Antibiograms 
Tables A-68 and A-69 provide summary antibiograms for the twelve most common 
equine pathogens for the CVHS locations and the RVC for the 2007 calendar year.  Table 
A-70 represents an effort to define the degree of multi-drug resistance present in isolates 







Bacterial isolates from equine specimens submitted to OADDL by the BVMTH, the 
CVHSR and the RVC over a three year period provide significant insight to the 
institutional and regional microbiological environment.  The major weakness of this 
study was the very small sample sizes for some of the pathogens examined, so that 
comparisons across years, and between the BVMTH, RVC and CVHSR should be made 
in consideration of that fact. 
 
From a broad perspective, the types of submission, organisms, susceptibilities and trends 
in equine clinical microbiology are consistent with what is reported in current literature, 
with a few notable differences. 
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The overall character of the submissions likely reflects the nature of veterinary practice in 
each location.  The high percentage of reproductive specimens in the RVC submissions is 
likely representative of the high level of breeding activity in this region.  The greater 
variety of BVMTH specimens including blood cultures, intravenous catheters, fecal 
cultures, and ocular samples reflects the added focus of the BVMTH on critical care and 
specialty practice.  Respiratory specimens were common from both the BVMTH and the 
RVC, consistent with the prevalence of infectious respiratory disease in equine practice. 
 
The preponderance of E. coli and Streptococcus equi zooepidemicus as the two most 
common organisms isolated from equine specimens is not surprising.  This finding is 
consistent with other large-scale retrospective studies using data from veterinary teaching 
hospital diagnostic laboratories, although some variations in reporting exists.45,139  
Salmonella was the third most common isolate from BVMTH specimens and the fourth 
most common from the RVC behind Pseudomonas aeruginosa.  In two similar studies, 
Salmonella was not listed in the top ten139 or fourteen45 isolates.  This may represent a 
greater than average prevalence of Salmonella in horses in Oklahoma relative to other 
parts of North America, and a possible area of further study.  Actinobacillus species were 
less commonly isolated in the present study relative to some other reports.  First isolates 
at OADDL included A. suis (1.2%), A. equuli (1.1%) and Actinobacillus species (1.1%) 




Actinobacillus species also were less prevalent in foal blood cultures than in other 
reports, making up only 4% of the total, and occurring only in the first year.  In other 
studies, Actinobacillus species accounted for 20%, 107 25% 140 and 30% 115 of neonatal 
blood cultures.  The prevalence of E. coli in neonatal blood cultures is consistent with 
other reports, as is the increase in gram-positives over time. 51,140 
 
Assessing the level of antimicrobial resistance of OADDL isolates in comparison to what 
is reported in the literature is somewhat difficult due to the differences in susceptibility 
testing, antimicrobial panels and reporting methods.  The label “multi-drug resistant” 
lacks a uniform definition throughout the literature, for example in some studies this is 
defined as resistance to a specific number of antimicrobials,101 whereas in other it is 
resistance to chosen set of specific drugs.97  General trends and conclusions may 
nonetheless be identified and targeted for further study. 
 
As indicated in Table A-70, multi-drug resistance in the general sense was evident in 
numerous bacterial organisms analyzed in this study, and this tended to occur in 
organisms that are documented in the literature to have a known or emergent trend 
toward multi-drug resistance.  
 
While the most frequent E. coli isolates showed good susceptibility to antimicrobials 
tested, individual isolates showed resistance to penicillins, cephalosporins, macrolides, 
aminoglycosides, lincosamides, potentiated sulfonamides and fluroquinolones.  Similar 
multi-drug resistance has been reported in equine isolates within the past year. 16  This is 
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of concern due to the demonstrated ability of E. coli to transfer some types of resistance 
to other potential, zoonotic pathogens, including Salmonella.16,54   
 
In spite of differing approaches to testing and describing antimicrobial resistance patterns 
across the literature, it appears that the level of resistance present in OADDL E.coli 
isolates may be greater than in other survey reports.  One recent hospital-based study 
reported 73% of hospitalized horses receiving antibiotics and 50% of those not receiving 
antibiotics cultured E.coli resistant to one or more antimicrobial,57 whereas 100% of 
OADDL isolates were resistant to at least one antimicrobial.  In that same study, 23% of 
hospitalized horses receiving antimicrobials and 5% of those not receiving antimicrobials 
showed resistance to six or more antimicrobials, whereas in the OADDL population this 
number was 45.3%.  Unlike the present study, these were all fecal cultures and the 
antimicrobial history of each patient was known. 
 
One non-hospital based survey conducted in 1993 showed 15.9% of isolates resistant to 
one or more antimicrobial and 6.5% resistant to at least three,56 whereas this was 100% 
and 68.2%  respectively for all OADDL first isolates.  Overall susceptibility of 2007 
BVMTH E. coli isolates to most antimicrobials except cephalothin was slightly less than 
for a recent retrospective at a teaching hospital in western Canada where the caseload is 




Overall multi-drug resistance was relatively low for Streptococcus equi zooepidemicus 
with 42% of isolates susceptible to all antimicrobials tested.  This is consistent with what 
is reported in the literature.64  The overall susceptibility of OADDL isolates was much 
greater for amikacin and trimethoprim sulfamethoxazole than those recently reported by 
another veterinary teaching hospital.45   What is not clearly shown by the susceptibility or 
resistance analysis is the predominance of intermediate strains; this is similar to what is 
currently reported with  “resistant” S. pneumoniae infections humans.64  Ongoing study 
tracking intermediate strains as well as minor fluctuations in MIC would provide a more 
sensitive indicator of resistance patterns. 
 
Multi-drug resistance was the rule rather than the exception for Salmonella isolates in all 
populations in this study.  While the most common isolates of each Salmonella species 
showed relatively good susceptibility to major drug classes including cephalosporins and 
fluoroquinolones, each species had many isolates that were resistant to these 
antimicrobials.  As made evident in the above literature review on Salmonella 
susceptibility patterns, increasing resistance has been seen across time, in a wide 
geographic area, and to all major classes of antibiotics.  Given the apparently greater 
frequency with which Salmonella is isolated in horses under veterinary care in 
Oklahoma, this may be an area for further study of this organism and its susceptibilities 
in a large number of both hospitalized horses and those in the general population. 
 
Multi-drug resistance in commensal organisms known to be reservoirs for resistance was 
also found in the OADDL isolates.  Methicillin resistance has been documented in 
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coagulase negative Staphylococcus and while many of these organisms are opportunistic, 
the risk of resistance transfer to pathogenic species such as S. aureus is real.105  Four 
isolates of S. xylosus in this study showed oxacillin resistance; it is of interest that the 
two for which a location of origin was available were community rather than hospital 
isolates.  Enterococcus isolates were also highly resistant.  The primary concerns with 
this organism are its ability to acquire resistance readily, in particular to glycopeptides 
antimicrobials such as vancomycin.  Though this was not evaluated for these isolates, the 
predominance of multi-drug resistant Enterococcus isolates would make such an 
investigation an interesting area of further research. 
 
Numerous strains of oxacillin resistant S. aureus were isolated, suggestive of the presence 
of MRSA.  Overall, resistance of S. aureus to tetracycline diminished.  Similar to a study 
reported by eight veterinary diagnostic laboratories, suspected MRSA strains were multi-
drug resistant.12 
 
One of the most interesting and clinically relevant observations coming out of the 
analysis of this data is the pattern of occurrence for hospital infections including most 
notably Staphylococcus aureus and Salmonella that are suggestive of nosocomial spread.  
The observation of these types of patterns retrospectively is not unexpected, as one report 
suggests that nosocomial infection in equine patients is not uncommon, with 21.9% of 
horses receiving cultures in a 6-month period having acquired gram-negative aerobic 
infections.40    
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At the BVMTH, the oxacillin-resistant Staphylococcus aureus occurred in 14 patients 
providing 29 samples, of which 23 showed the same susceptibility phenotype.  On an 
ongoing basis, confirmation of newly isolated strains as methicillin resistant 
Staphylococcus aureus (MRSA) would be ideal.  The establishment of possible 
epidemiological relationships inclusive of both equine patients and hospital personnel 
through molecular typing techniques would enhance the health and safety of both patients 
and personnel, while developing a database to contribute to the knowledge of the 
epidemiologic and pathogenic role of this organism in equine medicine.  
 
During the same time period as the suspected Staphylococcus aureus outbreak, and in 
many of the same patients, other organisms commonly associated with hospital-acquired 
infections were isolated.  These included Acinetobacter baumannii, Serratia marcescens 
and Enterococcus faecalis.  The occurrence of these infections in common patients is 
detailed in Table A-62.  While susceptibility patterns of many of these isolates were not 
identical, molecular typing techniques would help to establish if these infections were 
hospital acquired, or merely coincidental in the large caseload of critically ill patients 
being cared for in the BVMTH at that time.  This knowledge in turn could help identify 
areas for improvement in BVMTH biosecurity, and in existing techniques for procedures 
such as the placement of intravenous catheters.  The current study provides a foundation 
for enhancing the quality of care in the BVMTH, as well as veterinary knowledge in the 
area of equine critical care clinical microbiology.  Current literature supports this 
approach, with one report of molecular analysis following clinical observation of multi-
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drug resistant phenotypes revealing patterns of nosocomial infection for both 
Acinetobacter baumannii and Enterococcus faecium. 39 
 
Salmonella isolates were characterized by a cluster of Group E isolates in an eight month 
period in 2005 and 2006.  Limited data was available on the 2005 isolates and the 2006 
isolates came from a single BVMTH patient, so the significance of this cluster of may be 
questionable.  While extreme drug resistance was not identified, the identification of 
Group E isolates began and ended abruptly.  This is again the type of retrospective 
observation that may provide useful information as to emergent pathogens or current 
biosecurity practices. 
 
This report included the analysis of voluminous amounts of equine clinical microbiology 
data in the hopes of enhancing clinical practice in the BVMTH, providing useful 
information to the regional practitioners that submit specimens to OADDL, and 
enhancing the body of veterinary knowledge pertaining to antimicrobial resistance in 
common equine pathogens.  Ongoing tracking of these pathogens, the creation of annual 
antibiograms and the incorporation of molecular typing techniques where appropriate will 
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Organism 2005 2006 2007 Total % Total
E. coli 98 112 86 296 15.7%
Streptococcus equi ss zooepidemicus 95 94 69 258 13.7%
Salmonella species 6 41 44 91 4.8%
Staphylococcus aureus ss aureus 16 22 42 80 4.2%
Pseudomonas aeruginosa 19 23 30 72 3.8%
Klebsiella pneumoniae ss pneumoniae 14 24 20 58 3.1%
Salmonella group ‐ B 19 25 9 53 2.8%
Streptococcus beta 20 17 12 49 2.6%
Streptococcus equi ss equi 18 8 15 41 2.2%
Salmonella sp. group C2 32 5 2 39 2.1%
Streptococcus dysgalactiae ss equisimilis 16 14 9 39 2.1%
Staphylococcus xylosus 9 8 19 36 1.9%
Enterococcus species 7 8 19 34 1.8%
Streptococcus alpha haemolytic 13 13 6 32 1.7%
Staphylococcus species 10 8 13 31 1.6%
Salmonella species group C1 12 8 10 30 1.6%
Enterobacter aerogenes 8 12 6 26 1.4%
Enterobacter cloacae 10 7 9 26 1.4%
Gram negative non fermenter 7 12 7 26 1.4%
Enterococcus faecalis 6 11 7 24 1.3%
Actinobacillus suis 6 11 3 20 1.1%
Actinobacillus equuli ss equuli 10 4 5 19 1.0%
Corynebacterium species 5 11 3 19 1.0%
Pseudomonas species 11 3 5 19 1.0%
Actinobacillus species 3 6 9 18 1.0%
Staphylococcus beta haemolytic 5 3 9 17 0.9%
Citrobacter koseri 4 6 6 16 0.8%
Acinetobacter lwoffi 4 5 6 15 0.8%
Enterobacter species 7 5 3 15 0.8%
Pasturella species 3 4 8 15 0.8%
Rhodococcus equi 8 4 3 15 0.8%
Streptococcus species 4 4 7 15 0.8%
E. coli beta 6 4 4 14 0.7%
Stenotrophomonas maltophilia 4 5 4 13 0.7%
Proteus mirabilis 4 4 4 12 0.6%
Citrobacter freundii 3 6 2 11 0.6%
Acinetobacter baumannii 2 8 10 0.5%
Bacillus species 5 2 3 10 0.5%
Escherichia hermannii 4 3 3 10 0.5%
Staphylococcus intermedius 4 3 3 10 0.5%
Actinobacillus ureae 6 3 9 0.5%
Enterobacter amnigenus 5 4 9 0.5%
Enterococcus faecium 3 4 2 9 0.5%
Pseudomonas fluorescens 5 2 2 9 0.5%
Morganella morgani ss morganii 1 4 3 8 0.4%
Pantoea agglomerans 3 3 2 8 0.4%
Salmonella group ‐ E 6 2 8 0.4%
Serratia marcescens 1 1 6 8 0.4%
Staphylococcus epidermidis 3 2 3 8 0.4%
Staphylococcus haemolyticus 3 1 4 8 0.4%





Organism 2005 2006 2007 Total % Total
Klebsiella oxytoca 3 4 7 0.4%
Bordetella bronchiseptica 1 2 3 6 0.3%
Flavimonas oryzihabitans 1 1 4 6 0.3%
Pasteurella aerogenes atypical 2 4 6 0.3%
Gram negative diplococcus 5 5 0.3%
Ralstonia pickettii 3 2 5 0.3%
Actinobacillus lignieresii 1 3 4 0.2%
Gram negative rod 1 3 4 0.2%
Micrococcus luteus 2 2 4 0.2%
Micrococcus species 2 2 4 0.2%
Pasteurella pneumotropica 1 2 1 4 0.2%
Staphylococcus hyicus 1 3 4 0.2%
Staphylococcus warneri 1 3 4 0.2%
Aero. hydrophilia ss hydrophilia 1 1 1 3 0.2%
Aeromonas caviae 2 1 3 0.2%
Corynebacterium pseudotuberculosis 1 2 3 0.2%
Escherichia fergusonii 1 1 1 3 0.2%
Kocuria rosea 2 1 3 0.2%
Lactobacillus species 1 2 3 0.2%
Leclercia adecarboxylata 2 1 3 0.2%
Proteus penneri 2 1 3 0.2%
Providencia rettgeri 2 1 3 0.2%
Streptococcus beta haemolytic 1 2 3 0.2%
Achromobacter xylo ss dentrificans 1 1 2 0.1%
Achromobacter xylo ss xylosoxidans 2 2 0.1%
Chryseobacterium indologenes 2 2 0.1%
Chryseobacterium meningosepticum 1 1 2 0.1%
Comamonas testosteroni 2 2 0.1%
Enterobacter gergoviae 2 2 0.1%
Flavobacterium species 1 1 2 0.1%
Gram negative organism 1 1 2 0.1%
Kluyvera ascorbata 1 1 2 0.1%
Ochrobactrum anthropi 1 1 2 0.1%
P. pseudo. ss pseudoalcaligenes 2 2 0.1%
Proteus vulgaris 1 1 2 0.1%
Providencia stuartii 1 1 2 0.1%
Pseudomonas mendocina 2 2 0.1%
Raoultella planticola 2 2 0.1%
Streptococcus beta group ‐ C 2 2 0.1%
Streptococcus bovis 1 1 2 0.1%
Streptococcus mitis 1 1 2 0.1%
Streptococcus suis 1 1 2 0.1%
Streptococcus uberis 1 1 2 0.1%
Aerococcus viridans 1 1 0.1%
Alcaligenes faecalis ss faecalis 1 1 0.1%
Cedecea lapagei 1 1 0.1%
Citrobacter amalonaticus 1 1 0.1%
Citrobacter diversus 1 1 0.1%
Delftia acidovorans 1 1 0.1%
Enterobacter sakazakii 1 1 0.1%





Organism 2005 2006 2007 Total % Total
Gram positive rod 1 1 0.1%
Pasteurella aerogenes 1 1 0.1%
Pasturella multocida ss multocida 1 1 0.1%
Pseudomonas aeruginosa/putida 1 1 0.1%
Pseudomonas alcaligenes 1 1 0.1%
Pseudomonas putida 1 1 0.1%
Psychrobacter phenylpyruvicus 1 1 0.1%
Rhodococcus species 1 1 0.1%
Salmonella choleraesuis ss arizonae 1 1 0.1%
Salmonella group D 1 1 0.1%
Salmonella subgenus 1 1 1 0.1%
Serratia plymuthica 1 1 0.1%
Serratia rubidaea 1 1 0.1%
Sphingobacterium multivorum 1 1 0.1%
Sphingomonas paucimobilis 1 1 0.1%
Staphylococcus hominis ss hominis 1 1 0.1%
Staphylococcus saprophyticus ss saprophyticus 1 1 0.1%
Staphylococcus simulans 1 1 0.1%
Streptococcus mutans 1 1 0.1%





Organism 2005 % 2005 2006 % 2006 2007 %2007 Total % Total
E. coli 78 15% 90 16% 63 12% 231 14.3%
Streptococcus equi ss zooepidemicus 70 13% 81 14% 54 11% 205 12.7%
Salmonella species 5 1% 32 6% 34 7% 71 4.4%
Staphylococcus aureus ss aureus 16 3% 17 3% 24 5% 57 3.5%
Pseudomonas aeruginosa 16 3% 17 3% 20 4% 53 3.3%
Klebsiella pneumoniae ss pneumoniae 10 2% 20 4% 20 4% 50 3.1%
Streptococcus beta 19 4% 17 3% 12 2% 48 3.0%
Salmonella group ‐ B 18 3% 17 3% 7 1% 42 2.6%
Streptococcus equi ss equi 17 3% 8 1% 13 3% 38 2.4%
Streptococcus dysgalactiae ss equisimilis 15 3% 14 2% 8 2% 37 2.3%
Staphylococcus xylosus 8 2% 7 1% 18 4% 33 2.0%
Staphylococcus species 10 2% 8 1% 13 3% 31 1.9%
Salmonella sp. group C2 23 4% 5 1% 2 0% 30 1.9%
Enterococcus species 7 1% 6 1% 14 3% 27 1.7%
Enterobacter aerogenes 8 2% 12 2% 6 1% 26 1.6%
Streptococcus alpha haemolytic 12 2% 10 2% 4 1% 26 1.6%
Enterobacter cloacae 10 2% 6 1% 7 1% 23 1.4%
Gram negative non fermenter 6 1% 11 2% 6 1% 23 1.4%
Salmonella species group C1 9 2% 5 1% 8 2% 22 1.4%
Actinobacillus suis 6 1% 11 2% 3 1% 20 1.2%
Enterococcus faecalis 5 1% 9 2% 6 1% 20 1.2%
Corynebacterium species 5 1% 11 2% 3 1% 19 1.2%
Actinobacillus equuli ss equuli 9 2% 4 1% 5 1% 18 1.1%
Actinobacillus species 3 1% 6 1% 9 2% 18 1.1%
Pseudomonas species 10 2% 3 1% 4 1% 17 1.1%
Staphylococcus beta haemolytic 5 1% 3 1% 9 2% 17 1.1%
Citrobacter koseri 3 1% 6 1% 6 1% 15 0.9%
Pasturella species 3 1% 4 1% 8 2% 15 0.9%
Streptococcus species 4 1% 4 1% 7 1% 15 0.9%
Acinetobacter lwoffi 4 1% 5 1% 5 1% 14 0.9%
E. coli beta 6 1% 4 1% 4 1% 14 0.9%
Enterobacter species 6 1% 5 1% 3 1% 14 0.9%
Rhodococcus equi 8 2% 3 1% 3 1% 14 0.9%
Citrobacter freundii 3 1% 6 1% 2 0% 11 0.7%
Proteus mirabilis 4 1% 4 1% 3 1% 11 0.7%
Stenotrophomonas maltophilia 3 1% 4 1% 4 1% 11 0.7%
Bacillus species 5 1% 2 0% 3 1% 10 0.6%
Staphylococcus intermedius 4 1% 3 1% 3 1% 10 0.6%
Acinetobacter baumannii 0% 2 0% 7 1% 9 0.6%
Actinobacillus ureae 0% 6 1% 3 1% 9 0.6%
Escherichia hermannii 4 1% 3 1% 2 0% 9 0.6%
Enterobacter amnigenus 4 1% 4 1% 0% 8 0.5%
Pantoea agglomerans 3 1% 3 1% 2 0% 8 0.5%
Pseudomonas fluorescens 4 1% 2 0% 2 0% 8 0.5%
Serratia marcescens 1 0% 1 0% 6 1% 8 0.5%
Citrobacter species 5 1% 0% 2 0% 7 0.4%
Enterococcus faecium 2 0% 4 1% 1 0% 7 0.4%
Klebsiella oxytoca 3 1% 0% 4 1% 7 0.4%
Salmonella group ‐ E 5 1% 2 0% 0% 7 0.4%
Staphylococcus epidermidis 3 1% 1 0% 3 1% 7 0.4%
Staphylococcus haemolyticus 3 1% 1 0% 3 1% 7 0.4%





Organism 2005 % 2005 2006 % 2006 2007 %2007 Total % Total
Morganella morgani ss morganii 1 0% 3 1% 2 0% 6 0.4%
Pasteurella aerogenes atypical 2 0% 4 1% 0% 6 0.4%
Flavimonas oryzihabitans 1 0% 1 0% 3 1% 5 0.3%
Ralstonia pickettii 0% 3 1% 2 0% 5 0.3%
Actinobacillus lignieresii 0% 1 0% 3 1% 4 0.2%
Gram negative rod 0% 1 0% 3 1% 4 0.2%
Micrococcus luteus 0% 2 0% 2 0% 4 0.2%
Micrococcus species 2 0% 2 0% 0% 4 0.2%
Pasteurella pneumotropica 1 0% 2 0% 1 0% 4 0.2%
Staphylococcus warneri 1 0% 0% 3 1% 4 0.2%
Aero. hydrophilia ss hydrophilia 1 0% 1 0% 1 0% 3 0.2%
Aeromonas caviae 2 0% 1 0% 0% 3 0.2%
Corynebacterium pseudotuberculosis 0% 1 0% 2 0% 3 0.2%
Escherichia fergusonii 1 0% 1 0% 1 0% 3 0.2%
Gram negative diplococcus 0% 0% 3 1% 3 0.2%
Kocuria rosea 2 0% 1 0% 0% 3 0.2%
Lactobacillus species 1 0% 2 0% 0% 3 0.2%
Leclercia adecarboxylata 2 0% 1 0% 0% 3 0.2%
Proteus penneri 2 0% 0% 1 0% 3 0.2%
Providencia rettgeri 0% 2 0% 1 0% 3 0.2%
Staphylococcus hyicus 1 0% 0% 2 0% 3 0.2%
Streptococcus beta haemolytic 0% 1 0% 2 0% 3 0.2%
Achromobacter xylo ss dentrificans 1 0% 1 0% 0% 2 0.1%
Achromobacter xylo ss xylosoxidans 2 0% 0% 0% 2 0.1%
Chryseobacterium indologenes 0% 2 0% 0% 2 0.1%
Chryseobacterium meningosepticum 0% 1 0% 1 0% 2 0.1%
Comamonas testosteroni 0% 0% 2 0% 2 0.1%
Enterobacter gergoviae 0% 2 0% 0% 2 0.1%
Flavobacterium species 0% 1 0% 1 0% 2 0.1%
Gram negative organism 0% 1 0% 1 0% 2 0.1%
Kluyvera ascorbata 1 0% 0% 1 0% 2 0.1%
Ochrobactrum anthropi 1 0% 1 0% 0% 2 0.1%
P. pseudo. ss pseudoalcaligenes 0% 0% 2 0% 2 0.1%
Proteus vulgaris 1 0% 0% 1 0% 2 0.1%
Pseudomonas mendocina 0% 0% 2 0% 2 0.1%
Raoultella planticola 0% 2 0% 0% 2 0.1%
Streptococcus bovis 1 0% 1 0% 0% 2 0.1%
Streptococcus mitis 1 0% 1 0% 0% 2 0.1%
Streptococcus suis 1 0% 1 0% 0% 2 0.1%
Streptococcus uberis 1 0% 1 0% 0% 2 0.1%
Aerococcus viridans 0% 1 0% 0% 1 0.1%
Alcaligenes faecalis ss faecalis 1 0% 0% 0% 1 0.1%
Cedecea lapagei 1 0% 0% 0% 1 0.1%
Citrobacter amalonaticus 0% 1 0% 0% 1 0.1%
Citrobacter diversus 1 0% 0% 0% 1 0.1%
Delftia acidovorans 0% 0% 1 0% 1 0.1%
Enterobacter sakazakii 1 0% 0% 0% 1 0.1%
Enterococcus durans 0% 1 0% 0% 1 0.1%
Gram positive rod 0% 0% 1 0% 1 0.1%
Pasteurella aerogenes 0% 0% 1 0% 1 0.1%





Organism 2005 % 2005 2006 % 2006 2007 %2007 Total % Total
Providencia stuartii 0% 0% 1 0% 1 0.1%
Providencia stuartiiT 1 0% 0% 0% 1 0.1%
Pseudomonas aeruginosa/putida 0% 1 0% 0% 1 0.1%
Pseudomonas putida 0% 1 0% 0% 1 0.1%
Psychrobacter phenylpyruvicus 0% 0% 1 0% 1 0.1%
Rhodococcus species 1 0% 0% 0% 1 0.1%
Salmonella choleraesuis ss arizonae 0% 0% 1 0% 1 0.1%
Salmonella group D 0% 1 0% 0% 1 0.1%
Salmonella subgenus 1 0% 0% 1 0% 1 0.1%
Serratia plymuthica 0% 1 0% 0% 1 0.1%
Serratia rubidaea 1 0% 0% 0% 1 0.1%
Sphingobacterium multivorum 0% 1 0% 0% 1 0.1%
Sphingomonas paucimobilis 0% 1 0% 0% 1 0.1%
Staphylococcus hominis ss hominis 0% 1 0% 0% 1 0.1%
Staphylococcus saprophyticus ss saprophyticus 0% 1 0% 0% 1 0.1%
Staphylococcus simulans 1 0% 0% 0% 1 0.1%
Streptococcus beta group ‐ C 0% 1 0% 0% 1 0.1%
Streptococcus mutans 1 0% 0% 0% 1 0.1%





Organism 2005 2006 2007 Total % Total
E. coli 6 26 24 56 11.3%
Streptococcus equi ss zooepidemicus 5 22 22 49 9.9%
Salmonella species 19 22 41 8.2%
Staphylococcus aureus ss aureus 11 13 24 4.8%
Klebsiella pneumoniae ss pneumoniae 12 5 17 3.4%
Enterococcus species 2 1 10 13 2.6%
Salmonella group ‐ B 1 9 3 13 2.6%
Pseudomonas aeruginosa 5 6 11 2.2%
Salmonella species group C1 1 4 6 11 2.2%
Streptococcus alpha haemolytic 3 5 3 11 2.2%
Actinobacillus equuli ss equuli 3 2 4 9 1.8%
Streptococcus beta 7 2 9 1.8%
Actinobacillus suis 6 2 8 1.6%
Enterobacter cloacae 3 2 3 8 1.6%
Streptococcus equi ss equi 1 7 8 1.6%
Acinetobacter baumannii 1 6 7 1.4%
Actinobacillus species 2 5 7 1.4%
Corynebacterium species 6 1 7 1.4%
Enterococcus faecalis 5 2 7 1.4%
Staphylococcus species 2 1 4 7 1.4%
Staphylococcus xylosus 2 5 7 1.4%
Gram negative non fermenter 5 1 6 1.2%
Pasturella species 2 4 6 1.2%
Salmonella sp. group C2 4 2 6 1.2%
Streptococcus dysgalactiae ss equisimilis 3 3 6 1.2%
Acinetobacter lwoffi 1 1 3 5 1.0%
E. coli beta 3 2 5 1.0%
Morganella morgani ss morganii 3 2 5 1.0%
Pantoea agglomerans 1 2 2 5 1.0%
Proteus mirabilis 3 2 5 1.0%
Serratia marcescens 5 5 1.0%
Actinobacillus ureae 1 3 4 0.8%
Bordetella bronchiseptica 1 3 4 0.8%
Escherichia hermannii 2 2 4 0.8%
Pasteurella aerogenes atypical 1 3 4 0.8%
Staphylococcus epidermidis 2 2 4 0.8%
Streptococcus species 2 2 4 0.8%
Citrobacter species 1 2 3 0.6%
Enterobacter aerogenes 2 1 3 0.6%
Enterobacter species 3 3 0.6%
Enterococcus faecium 2 1 3 0.6%
Flavimonas oryzihabitans 1 2 3 0.6%
Gram negative diplococcus 3 3 0.6%
Micrococcus luteus 2 1 3 0.6%
Micrococcus species 1 2 3 0.6%
Pseudomonas species 1 2 3 0.6%
Salmonella group ‐ E 1 2 3 0.6%
Actinobacillus lignieresii 1 1 2 0.4%
Chryseobacterium meningosepticum 1 1 2 0.4%
Citrobacter freundii 1 1 2 0.4%
Citrobacter koseri 1 1 2 0.4%
Corynebacterium pseudotuberculosis 2 2 0.4%





Organism 2005 2006 2007 Total % Total
Lactobacillus species 2 2 0.4%
Proteus penneri 1 1 2 0.4%
Proteus vulgaris 1 1 2 0.4%
Providencia rettgeri 1 1 2 0.4%
Staphylococcus beta haemolytic 2 2 0.4%
Staphylococcus haemolyticus 2 2 0.4%
Staphylococcus warneri 2 2 0.4%
Stenotrophomonas maltophilia 1 1 2 0.4%
Streptococcus mitis 1 1 2 0.4%
Achromobacter xylo ss xylosoxidans 1 1 0.2%
Aerococcus viridans 1 1 0.2%
Bacillus species 1 1 0.2%
Cedecea lapagei 1 1 0.2%
Chryseobacterium indologenes 1 1 0.2%
Enterobacter amnigenus 1 1 0.2%
Enterococcus durans 1 1 0.2%
Escherichia fergusonii 1 1 0.2%
Flavobacterium species 1 1 0.2%
Gram negative rod 1 1 0.2%
Gram positive rod 1 1 0.2%
Kluyvera ascorbata 1 1 0.2%
Kocuria rosea 1 1 0.2%
Ochrobactrum anthropi 1 1 0.2%
Pasteurella pneumotropica 1 1 0.2%
Pasturella multocida ss multocida 1 1 0.2%
Providencia stuartii 1 1 0.2%
Pseudomonas fluorescens 1 1 0.2%
Pseudomonas putida 1 1 0.2%
Psychrobacter phenylpyruvicus 1 1 0.2%
Ralstonia pickettii 1 1 0.2%
Raoultella planticola 1 1 0.2%
Rhodococcus equi 1 1 0.2%
Salmonella subgenus 1 1 1 0.2%
Sphingobacterium multivorum 1 1 0.2%
Sphingomonas paucimobilis 1 1 0.2%
Staphylococcus hyicus 1 1 0.2%
Streptococcus beta haemolytic 1 1 0.2%
Streptococcus suis 1 1 0.2%





Organism 2005 2006 2007 Total % Total
E. coli 6 61 33 100 15.6%
Streptococcus equi ss zooepidemicus 8 52 29 89 13.9%
Pseudomonas aeruginosa 3 12 13 28 4.4%
Salmonella species 1 13 11 25 3.9%
Staphylococcus aureus ss aureus 7 6 11 24 3.8%
Klebsiella pneumoniae ss pneumoniae 3 7 12 22 3.4%
Streptococcus beta 4 9 9 22 3.4%
Staphylococcus xylosus 5 13 18 2.8%
Streptococcus equi ss equi 4 8 6 18 2.8%
Streptococcus dysgalactiae ss equisimilis 3 10 4 17 2.7%
Staphylococcus species 6 9 15 2.3%
Enterobacter aerogenes 10 4 14 2.2%
Citrobacter koseri 1 5 6 12 1.9%
Salmonella group ‐ B 1 7 3 11 1.7%
Enterobacter cloacae 2 4 4 10 1.6%
Staphylococcus beta haemolytic 3 7 10 1.6%
Gram negative non fermenter 4 5 9 1.4%
Actinobacillus suis 2 5 1 8 1.3%
Actinobacillus species 3 4 7 1.1%
Enterococcus species 3 4 7 1.1%
Stenotrophomonas maltophilia 1 3 3 7 1.1%
Streptococcus species 2 1 4 7 1.1%
Citrobacter freundii 4 2 6 0.9%
Corynebacterium species 4 2 6 0.9%
Enterobacter amnigenus 2 4 6 0.9%
Enterococcus faecalis 3 3 6 0.9%
Pasturella species 2 4 6 0.9%
Pseudomonas species 1 3 2 6 0.9%
Staphylococcus intermedius 3 3 6 0.9%
Acinetobacter lwoffi 4 1 5 0.8%
Actinobacillus ureae 5 5 0.8%
Enterobacter species 2 3 5 0.8%
Rhodococcus equi 2 3 5 0.8%
Streptococcus alpha haemolytic 4 1 5 0.8%
Bacillus species 1 3 4 0.6%
E. coli beta 1 1 2 4 0.6%
Escherichia hermannii 1 1 2 4 0.6%
Ralstonia pickettii 3 1 4 0.6%
Actinobacillus equuli ss equuli 1 1 1 3 0.5%
Gram negative rod 1 2 3 0.5%
Leclercia adecarboxylata 2 1 3 0.5%
Pseudomonas fluorescens 1 2 3 0.5%
Salmonella species group C1 1 2 3 0.5%
Serratia marcescens 1 1 1 3 0.5%
Acinetobacter baumannii 1 1 2 0.3%
Actinobacillus lignieresii 2 2 0.3%
Aero. hydrophilia ss hydrophilia 1 1 2 0.3%
Comamonas testosteroni 2 2 0.3%
Enterobacter gergoviae 2 2 0.3%
Gram negative organism 1 1 2 0.3%





Organism 2005 2006 2007 Total % Total
Pasteurella pneumotropica 1 1 2 0.3%
Proteus mirabilis 1 1 2 0.3%
Pseudomonas mendocina 2 2 0.3%
Staphylococcus epidermidis 1 1 2 0.3%
Staphylococcus haemolyticus 1 1 2 0.3%
Staphylococcus hyicus 1 1 2 0.3%
Streptococcus beta haemolytic 1 1 2 0.3%
Achromobacter xylo ss dentrificans 1 1 0.2%
Aeromonas caviae 1 1 0.2%
Bordetella bronchiseptica 1 1 0.2%
Citrobacter amalonaticus 1 1 0.2%
Citrobacter species 1 1 0.2%
Corynebacterium pseudotuberculosis 1 1 0.2%
Delftia acidovorans 1 1 0.2%
Enterococcus faecium 1 1 0.2%
Flavimonas oryzihabitans 1 1 0.2%
Flavobacterium species 1 1 0.2%
Kluyvera ascorbata 1 1 0.2%
Kocuria rosea 1 1 0.2%
Micrococcus luteus 1 1 0.2%
P. pseudo. ss pseudoalcaligenes 1 1 0.2%
Pantoea agglomerans 1 1 0.2%
Pasteurella aerogenes 1 1 0.2%
Pasteurella aerogenes atypical 1 1 0.2%
Providencia rettgeri 1 1 0.2%
Pseudomonas aeruginosa/putida 1 1 0.2%
Raoultella planticola 1 1 0.2%
Salmonella choleraesuis ss arizonae 1 1 0.2%
Salmonella group D 1 1 0.2%
Salmonella sp. group C2 1 1 0.2%
Serratia plymuthica 1 1 0.2%
Staphylococcus hominis ss hominis 1 1 0.2%
Staphylococcus saprophyticus ss saprophyticus 1 1 0.2%
Staphylococcus warneri 1 1 0.2%
Streptococcus beta group ‐ C 1 1 0.2%
Streptococcus bovis 1 1 0.2%
Streptococcus uberis 1 1 0.2%





Organism 2005 2006 2007 Total % Total
Streptococcus equi ss zooepidemicus 1 6 3 10 21.3%
E. coli 2 6 8 17.0%
Klebsiella pneumoniae ss pneumoniae 3 3 6.4%
Actinobacillus species 1 1 2 4.3%
Enterococcus faecalis 1 1 2 4.3%
Enterococcus species 2 2 4.3%
Streptococcus dysgalactiae ss equisimilis 1 1 2 4.3%
Streptococcus species 1 1 2 4.3%
Acinetobacter lwoffi 1 1 2.1%
Actinobacillus equuli ss equuli 1 1 2.1%
Chryseobacterium indologenes 1 1 2.1%
Corynebacterium species 1 1 2.1%
Enterobacter aerogenes 1 1 2.1%
Enterococcus faecium 1 1 2.1%
Escherichia fergusonii 1 1 2.1%
Gram negative non fermenter 1 1 2.1%
P. pseudo. ss pseudoalcaligenes 1 1 2.1%
Pasteurella pneumotropica 1 1 2.1%
Pseudomonas aeruginosa 1 1 2.1%
Pseudomonas fluorescens 1 1 2.1%
Pseudomonas species 1 1 2.1%
Salmonella group ‐ B 1 1 2.1%
Salmonella species 1 1 2.1%
Streptococcus beta 1 1 2.1%




Source 2005 2006 2007 Total
Reproductive System 229 232 202 663
Uterus 190 191 176 557
Vagina 9 4 3 16
Cervix 4 1 5
Clitoris 1 1
Placenta 2 1 3 6
Milk 1 3 5 9
Urethra 9 2 3 14
Penis 2 1 3
Semen 6 26 10 42
Sheath 8 2 10
Gastrointestinal System 99 118 92 309
Feces 89 87 78 254
Intestinal Contents 4 19 9 32
Abdominal Fluid 6 7 13
Liver 5 3 8
Stomach Contents 2 2
Respiratory System 89 101 116 306
Trachea/Bronchi/Lung 51 83 66 200
Guttural Pouch 10 6 16
Sinus/Nasal Passages 25 17 11 53
Thorax/Pleura 3 1 33 37
Soft Tissue 73 94 85 252
Abscess 26 24 36 86
Incisions 6 25 17 48
Wounds/Skin Lesions 41 45 32 118
Hemolymphatic 21 36 57 114
Blood 16 22 22 60
IV Catheter 1 11 27 39
Lymph Node 4 3 8 15
Urinary 32 23 30 85
Urine 18 14 22 54
Urolith/Calculus 2 2
Umbilicus 12 9 7 28
Kidney 1 1
Ocular 18 15 6 39
Eye 17 14 6 37
Conjunctiva 1 1 2
Musculoskeletal 18 5 8 31
Joint 12 3 8 23
Bone 3 1 4
Tendon/Sheath 3 3
Cartilage 1 1
Other 33 31 22 86




Miscellaneous Swabs/Fluids 31 29 19 79





Source 2005 2006 2007 Total
Reproductive System 1 12 9 22
Uterus 1 9 4 14




Gastrointestinal System 6 54 45 105
Feces 3 45 41 89
Abdominal Fluid 3 6 9
Liver 3 3 6
Stomach Contents 1 1
Respiratory System 10 41 62 113
Trachea/Bronchi/Lung 7 37 38 82
Guttural Pouch 2 2
Sinus/Nasal Passages 2 4 5 11
Thorax/Pleura 1 17 18
Soft Tissue 15 37 43 95
Abscess 7 20 27
Incisions 2 13 12 27
Wound/Skin Lesion 13 17 11 41
Hemolymphatic 0 30 44 74
Blood 20 20 40
IV Catheter 10 24 34
Urinary 2 10 10 22
Urine 2 3 10 15
Umbilicus 7 7
Ocular 7 15 4 26
Eye 7 14 4 25
Conjunctiva 1 1
Musculoskeletal 1 4 0 5
Joint 2 2
Bone 1 1 2
Cartilage 1 1
Other 5 18 12 35
Ear Swab 2 2
Miscellaneous Swabs/Fluid 5 16 12 33





Source 2005 2006 2007 Total
Reproductive System 23 170 162 355
Uterus 16 146 150 312
Vagina 2 2 4
Cervix 1 1
Placenta 2 1 3
Milk 3 3
Urethra 2 3 5
Semen 2 14 8 24
Sheath 1 2 3
Gastrointestinal System 2 36 15 53
Feces 1 19 6 26
Intestinal Contents 1 17 8 26
Stomach Contents 1 1
Respiratory System 10 51 22 83
Trachea/Bronchi/Lung 7 40 14 61
Guttural Pouch 3 3
Sinus/Nasal Passages 3 10 5 18
Thorax/Pleura 1 1
Soft Tissue 11 42 27 80
Abscess 6 15 10 31
Incisions 5 5
Wounds/Skin Lesions 5 22 17 44
Hemolymphatic 0 3 8 11
Lymph Node 3 8 11
Urinary 0 2 6 8
Urine 1 1
Kidney 1 1
Umbilicus 1 5 6
Ocular 2 0 1 3
Eye 2 1 3
Musculoskeletal 0 1 8 9
Joint 1 8 9
Other 13 15 9 37
Hair 2 2
Miscellaneous Swabs/Fluids 13 15 7 35





Source 2005 2006 2007 Total





Other 1 3 4





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15 PT 16 PT 17 PT 18 PT 19 PT 20 PT 21 PT 22
Amikacin S S S S S S S S S S S S S S S S S S S S S S
Amoxicillin/CA S S S S S S S S S S S S S S S S S R R R S R
Ampicillin S S S S S S S S R R R R R S R R R R R R R R
Cefazolin S S S S S S S S S S I S I S S R S R S R S R
Cefoxitin S S S S S S S S S S S S S S S S S R I R S R
Cefpodoxime S NT NT S NT NT S NT S S S I S I S NT NT R S R
Ceftiofur S S S S S S S S S S S S S S S R S R S R S R
Cephalothin S S S I I S S S S I R S R S R R R R R R I R
Chloramphenicol S S S S S S S S S S R R R R R R S R S S S R
Enrofloxacin S S S S S S S S S S S S S S S R S R R S S R
Clindamycin NT NT NT NT NT NT NT NT NT R NT NT R R R NT NT NT NT NT NT R
Erythromycin NT R R NT R R NT R NT NT R NT NT R NT R NT R R NT NT NT
Gentamicin S S S S S S S S R R R R R S R R R R R S S R
Imipenem S S S S S S S S S S S S S S S S S S S S S S
Marbofloxacin S NT NT S NT NT S NT S S NT S S S S NT S NT NT S S R
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin NT R R NT R R NT R NT NT R NT NT R NT R NT R R NT NT NT
Penicillin NT R R NT R R NT R NT NT R NT NT R NT R NT R R NT NT NT
Rifampin R R R R R I R R R R R R R R R R R R R R R R
Sulphadimethoxime NT S R NT S S NT S NT NT R NT NT NT NT R NT R S NT NT NT
Spectinomycin NT I I NT I I NT R NT NT R NT NT NT NT R NT R R NT NT NT
Tetracycline S S S S S S R S R S R R R R R R S R S R R R
Ticarcillin S S S S S S S S R R R R R S R R R R R I R R
Ticarcillin/CA S S S S S S S S S S S S S S S I S R S R S I
TMS S S R S S S S S R R R R R S S R R R S S S S
N 65 13 11 10 8 8 7 5 5 5 4 3 3 3 2 2 2 2 2 2 2 2
2005 8 13 3 3 8 3 3 5 1 4 1 1 1 1 1 1 1 1
2006 34 4 3 5 1 2 4 2 3 1 1 1 1 2
2007 23 4 4 3 2 1 3 1 1 1
UN 6 13 3 2 8 3 5 1 3 1 1 1 1 1 1
RVC 38 5 6 2 5 3 4 2 1 1 1 1 1 1 2
BVMTH 17 2 1 3 2 1 1 3 2 1 1 1 1







































PT 23 PT 24 PT 25 PT 26 PT 27 PT 28 PT 29 PT 30 PT 31 PT 32 PT 33 PT 34 PT 35 PT 36 PT 37 PT 38 PT 39 PT 40 PT 41 PT 42
S S S S S S S S S S S S S S S S S S S S
S S S S R I S R S S R S R S S S S S S S
R S R R R R R R R S R R R R R S R R S R
S S R S R R R R S S I S R S S S S S S S
S S S S R S S R S S R S R S S S S S S S
S S R S R R R NT NT NT NT NT NT NT NT NT NT NT NT NT
S S R S R R I R S S R S R S S S S S S S
S I R S R R R R S S R S R I S I S I S R
S S R R R S R S R S I S R R S S S S S R
S S R R R R S I I S I S S R S S S S S S
R R R R R R R NT NT NT NT NT NT NT NT NT NT NT NT NT
NT NT NT NT R R R R R R R R R R R R R R R R
S S R R R R R S R S S R R R S S I R S R
S S S S S S S I S S S S S S S S S S S S
S S R R R R S NT NT NT NT NT NT NT NT NT NT NT NT NT
NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
NT NT NT NT R R R R R R R R R R R R R R R R
NT NT NT NT R R R R R R R R R R R R R R R R
R I R R R R R R R R R R R R R R R R R R
NT NT NT NT NT NT NT R R R R R R R R R R R R R
NT NT NT NT NT NT NT I I R R R R R I I R R R R
S S R R R R R S R R S S R R S S R S S R
R S R R R R R R R I I R R R R S R R S R
S S S S I R S R S S R S R S S S S S S I
R S R R R R R NM R R S R R R R R R R R R
2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1
2 2 2 1
1 2 2 2
1 1 1 1 1 1 1 1 1 1 1 1 1
1 2 2 1 1 1 1







































PT 43 PT 44 PT 45 PT 46 PT 47 PT 48 PT 49 PT 50 PT 51 PT 52 PT 53 PT 54 PT 55 PT 56 PT 57 PT 58 PT 59 PT 60 PT 61 PT 62
S S S S S S S S S S S S S S S S S S S S
S S S S I S R S I S S S S S S S S S S S
R S R S R S R R R S R R R R R R R R S R
S S S S S S R R R S S S S S S S S S I I
S S S S I S R I R S S S S S S S S S S S
NT NT NT NT NT NT NT R R S S S S S S S S S I I
S S S S S S R S R S S S S S S S S S S S
I S I I R S R R R S I S I I I I S I S R
S S R S R S R R R R R S S R R S R R NM S
S S S S I S S R R R R I S S S S S S S S
NT NT NT NT NT NT NT NT NT NT NT NT R R R R R R R R
R R R R R R R NT NT NT NT NT NT NT NT NT NT NT NT NT
R S R S R S R R R R R R S R R R S S R R
S S S S S S S S S S S S S S S S S S S S
NT NT NT NT NT NT NT R R R R S S S S S S S S S
NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
R R R R R R R NT NT NT NT NT NT NT NT NT NT NT NT NT
R R R R R R R NT NT NT NT NT NT NT NT NT NT NT NT NT
R R R R R I R R R R R R R I R R R R R R
R S R R R R R NT NT NT NT NT NT NT NT NT NT NT NT NT
R I R R R S R NT NT NT NT NT NT NT NT NT NT NT NT NT
R I R R R R R R R R R S S R S S R R S R
R S R S R S I R R S R R R R R R R R S R
S S S S I S R S I S S S S S I I S S S S
R S R S R S S S R R R S S R R S R R S R
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1







































PT 63 PT 64 PT 65 PT 66 PT 67 PT 68 PT 69 PT 70 PT 71 PT 72 PT 73 PT 74 PT 75 PT 76 PT 77 PT 78 PT 79 PT 80 PT 81 PT 82
S S S R S R S R S S R R S S S S S S S S
R S R R S R R R S S R R S S S S S S I I
R R R R S R R R R I R R R R R R R S R R
R S R R S R R R S S R R S S S S S S R S
R S R R S R R R S S R R I S S S S S S I
R S R R S R R R S S R R S S S S S S R S
R S R R S R R R S S R R S S S S S S S S
R S R R R R R R I S R R I S I S I S R I
R S R R S R R R S S R R R S S S R S S S
R S R R S S S R S S S R R S S R S S S S
R R R R R R R R R R R R R R R R R R R R
NT NT NT NT NT NT NT NT NT NT NT NT NT NT R R R R R R
R S S R S R R R R S R R R R R R R S R R
S S S S S S S S S S S S S S S S S S S S
R S R R S S S R S S S R R S S R S S S S
NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
NT NT NT NT NT NT NT NT NT NT NT NT NT NT R R R R R R
NT NT NT NT NT NT NT NT NT NT NT NT NT NT R R R R R R
R R R R R R R R R R R R R R R R R R R R
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
I S R R S R R R R S R R S S R R R I R S
R R R R S R R R R R R I R R R R R I R R
I S R R S I I I S S R I S S I S I S I S
R S R R S R R R S S R R R R R R R S R R
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1








































PT 83 PT 84 PT 85 PT 86 PT 87 PT 88 PT 89 PT 90 PT 91 PT 92 PT 93 PT 94
S S S I S S R S S S S S
R S S R S S R R R S S S
I R S R S R R R R R R R
R R S R S S R R R S S S
R R S R S S R R S S S I
S I S S S S R R S S S S
S R S S S S R R S S S S
R R S R S S R R R I S S
S R S R S S R R S S R S
S S I S S S S S S S S I
R R R R R R R R R R R R
R R R R R R R R R R R R
S S S R S S R R S R R R
S S S S S S S S S S S S
S S S S S S S S S S S R
NI NI NI NI NI NI NI NI NI NI NI NI
R R R R R R R R R R R R
R R R R R R R R R R R R
R R R R I R R R R R I R
NT NT NT NT NT NT NT NT NT NT NT NT
NT NT NT NT NT NT NT NT NT NT NT NT
S S S R S R R R S R R R
S S S R S R R S S R R R
S S S R S S I I S I S S
S R S S R S R R S S S R
1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1
1 1







Antibiotic 2005 2006 2007
Amikacin 100% 100% 97%
Amoxicillin/CA 100% 94% 78%
Ampicillin 17% 58% 50%
Cefazolin 83% 81% 72%
Cefoxitin 100% 90% 78%
Cefpodoxime 100% 81% 78%
Ceftiofur 100% 94% 78%
Cephalothin 33% 65% 63%
Chloramphenicol 67% 77% 72%
Enrofloxacin 67% 90% 88%
Clindamycin ‐‐ 0% 0%
Erythromycin ‐‐ ‐‐ 0%
Gentamicin 33% 74% 66%
Imipenem 100% 100% 100%
Marbofloxacin 83% 90% 88%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ ‐‐ 0%
Penicillin ‐‐ ‐‐ 0%
Rifampin 0% 0% 0%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 33% 74% 53%
Ticarcillin 17% 58% 59%
Ticarcillin/CA 100% 94% 81%
TMS 50% 65% 59%
N 6               31             32            








Antibiotic 2005 2006 2007
Amikacin 100% 92% 97%
Amoxicillin/CA 100% 85% 83%
Ampicillin 100% 52% 69%
Cefazolin 100% 79% 86%
Cefoxitin 100% 85% 89%
Cefpodoxime 100% 77% 86%
Ceftiofur 100% 81% 91%
Cephalothin 86% 56% 66%
Chloramphenicol 86% 69% 86%
Enrofloxacin 86% 84% 86%
Clindamycin ‐‐ 0% 0%
Erythromycin ‐‐ 0% 0%
Gentamicin 86% 55% 71%
Imipenem 100% 100% 100%
Marbofloxacin 86% 84% 89%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ 0% 0%
Penicillin ‐‐ 0% 0%
Rifampin 0% 0% 0%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 57% 65% 66%
Ticarcillin 100% 52% 69%
Ticarcillin/CA 100% 79% 83%
TMS 86% 55% 71%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15 PT 16 PT 17 PT 18 PT 19 PT 20 PT 21 PT 22
Amikacin S S S S I S S S I I I S I I I I I S I I S S
Amoxicillin/CA S S S S S S S S S S S S S S S S S S S S S S
Ampicillin S S S S S S S S S S S S S S S S S S S S S S
Cefazolin S S S S S S S S S S S S S S S S S S S S S S
Cefoxitin S S S S S S S S S S S S S S S S S S S S S S
Cefpodoxime S S S I S NT S NT NT S S I NT NT S I I S NT NT NT NT
Ceftiofur S S S S S S S S S S S S S S S S S S S S S S
Cephalothin S S S S S S S S S S S S S S S S S S S S S S
Chloramphenicol S S S S S S S S S S S S S S S S S S S S S S
Enrofloxacin S S I S S I I S I I I S I I I S S S R I S S
Clindamycin S S S S S NT NT NT NT NT S S NT NT S S S S NT NT NT NT
Erythromycin I I I R I S S S S I I I S S I R I I S S S S
Gentamicin S S S S S S S S S S S S A S S S S S S S S S
Imipenem S S S S S S S S S S S S S S S S S S S S S S
Marbofloxacin S S S S S NT NT NT NT S S S NT NT S S S S NT NT NT NT
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin S S S S S S S S S S S S S S S S S S S S S S
Penicillin S S S S S S S S S S S S S S S S S S S S S S
Rifampin S S S S S S S S S S S S S S S S S S S S S S
Sulphadimethoxime NT NT NT NT NT R R R R NT NT NT R R NT NT NT NT R R S R
Spectinomycin NT NT NT NT NT R I I R NT NT NT R I NT NT NT NT R I I R
Tetracycline S R S S S S S S S S S S S S R S S I S R S S
Ticarcillin S S S S S S S S S S S S S S S S S S S S S S
Ticarcillin/CA S S S S S S S S S S S S S S S S S S S S S S
TMS S S S S S S S S S S S S S S S S S S S S S S
N 32 11 10 8 6 7 6 4 4 4 4 4 3 3 3 3 3 3 2 2 2 2
2005 8 2 7 6 4 4 4 3 3 1 2 2 2 2
2006 17 7 2 6 5 2 1 2 2 1 2
2007 7 4 6 2 1 2 3 1 1 1 1
UN 4 7 6 4 4 3 3 3
RVC 20 6 6 3 4 2 2 2 3 3 3 2 2 1 2
BVMTH 7 4 4 4 2 1 1 2 1







































PT 23 PT 24 PT 25 PT 26 PT 27 PT 28 PT 29 PT 30 PT 31 PT 32 PT 33 PT 34 PT 35 PT 36 PT 37 PT 38 PT 39 PT 40 PT 41 PT 42 PT 43
S S R R S S S I I S R R R I I S I I I S I
S S S S S S S S S S S S I S S S S S S S S
S S S S S S S S S S S R R S S S S S S S I
S S S S S S S S S S S R R S S S S S S S S
S S S S S S R S S S S R R S S S S S S S S
S I S S I I NT NT NT NT NT NT NT NT S NT S S I S I
S S S S S S S S S S S R R S S S S S S S S
S S S S S S S S S S S R R S S S S S S S S
S S S S S S I S S S S S S S S S S S S S S
I I I I I S S S I I R R R S S S S I I S I
NT S S S S S NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
I I I I R I R S S S S I R S I S I I I R R
S S I I S S S S S S I R S I I S S S I S S
S S S S S S R S S S S R R S S S S S S S S
I S S S S S NT NT NT NT NT NT NT NT S NT S I S S I
NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
S S S S S S S S S S S S NM S S S S S S S S
S S S S S S S S S S S R R S S S S S S S S
S S S S S S R S S S S NM I S S S S S S S S
NT NT NT NT NT NT R R S S R R R R NT R NT NT NT NT NT
NT NT NT NT NT NT S I I R I R R I NT S NT NT NT NT NT
S S S R S R R I S S S S S S S R S R S R R
S S S S S S S S S S S S R S S S S S S S S
S S S S S S I S S S S I I S S R S S S S S
S S S S S S S S NM S S S S S S S S S S S S
2 2 1 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1
2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1
1 1 1
1 1 2
1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 2 2








































PT 44 PT 45 PT 46 PT 47 PT 48 PT 49 PT 50 PT 51 PT 52 PT 53 PT 54 PT 55 PT 56 PT 57 PT 58 PT 59 PT 60 PT 61 PT 62 PT 63 PT 64
S S S R R S S R I R I I S R I S R I I I R
S S S S S R S R S S R S S S S S S S S S S
I S S S S R R R S S R S S S I I S S S S I
S S S S S R S R S S R S S S S S S S S S S
S S S S S R S R S S R S S S S S S S S S S
S S I I I R S R S I R S S I I S S S S S S
S R S S S R S R S S R S S S S S S S S S S
S S S S S R R I S S R S S S S S S S S S S
S NM I S S R S R I I I S S S I S S S I S S
S S S I S I S R I I S S I S S S S S I I I
S R S S S R R R R I R S S S R S S S S R S
R I I R I R R R I R R I I R R I I R I I I
S S S I I S S R S I I I S I I S I S S S I
S S S S S S S S S S R S S S S S S S S S S
S S S I S S S R S S S S S S S S S S I S S
NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
NM S S S S R R R S S S S S S S S S S S S S
R S S S S R R R S S R S S S S I S S S S S
NM S S S S R I R S S R S S S S S S S S S S
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
S R S S S R S R R R R S R S R S S S R R R
S S S S S R S R S S R S S S S I S S S S S
S S S S S I S R S S S S S S S S S S S S S
S S S S S R S S NM S S S S S S S S S S S S
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1
1 1 1 1 1 1 1 1 1 1 1








































PT 65 PT 66 PT 67 PT 68 PT 69 PT 70 PT 71 PT 72 PT 73 PT 74 PT 75 PT 76 PT 77 PT 78 PT 79 PT 80 PT 81 PT 82 PT 83 PT 84 PT 85
S I I I I I R S I S I I S I I S I S I I S
R S S S S S S S S S S S S S S R S S S S S
R I S R S S S I S S I S S S S R S S S S I
S S S R S S S R S S S S S S S R S S S S S
R S S S S S S S S S S S S S S R S S S S S
R S S R I I S S S S S S S S I R I S S S S
S S S R S S R S S S S S R S S R S S S R S
S S S S S S S I S S S S S S S R S S S S S
S S S I S S I S S S S S I S S I S S I I S
S S I R I I S S S I S S S S I I S R I S S
R S S R S S R NM S S S I R S S R S S I R R
R I I R R R R R I I R I R I R R R I I I R
S S I I S S S S S S S S S S I S S S S S S
S S S S S S S S S S S S S S S S S S S S S
S S S R S S S S S S S S S S I S S I S S S
NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
S S S S S S S S S S NM S S S S S S S S S R
S S S S S S S R S S I S S S S R S S S S R
NM S S R R S S R S S S S S S S R S S S S I
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
S S I R S S R I I I S R R R S I R S R R S
S S S S S S S S S S S S S S S S S S S S S
S S S S S S S S S S S S S S S S S S S S S
S S S S S S S S S S S S S S S S S S S S S
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1








































PT 86 PT 87 PT 88 PT 89 PT 90 PT 91 PT 92 PT 93 PT 94 PT 95
S S R S R S S I S S
S S S S I S S S S R
S S S S S S I I I R
S S S S S S S S S R
S S S S S S S S S R
S I S S S S S S S I
S S S S S S S R R R
S S S S S S S S S R
I S S S S S S S S S
S S R S I S S S S S
S S S S S I NM R R R
I R I I I I R R R R
S S I I I S S S S S
S S S S S S S S S S
S S S S S S S S S R
NI NI NI NI NI NI NI NI NI NI
S S S S S S NM R R R
S S S S S S S R R R
S S S S S S NM R R R
NT NT NT NT NT NT NT NT NT NT
NT NT NT NT NT NT NT NT NT NT
S R R S S S R R S S
S S S S S S S S S S
S S S S S S S S S S
S S S S S S S S S S
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1







Antibiotic 2005 2006 2007
Amikacin 50% 50% 84%
Amoxicillin/CA 100% 96% 88%
Ampicillin 83% 82% 92%
Cefazolin 100% 100% 92%
Cefoxitin 100% 96% 92%
Cefpodoxime 60% 71% 60%
Ceftiofur 100% 96% 88%
Cephalothin 100% 96% 92%
Chloramphenicol 100% 93% 88%
Enrofloxacin 33% 68% 60%
Clindamycin ‐‐ 79% 88%
Erythromycin 17% 0% 0%
Gentamicin 83% 79% 92%
Imipenem 100% 100% 100%
Marbofloxacin 60% 100% 88%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin 100% 96% 96%
Penicillin 100% 96% 92%
Rifampin 100% 96% 92%
Sulphadimethoxime 100% ‐‐ ‐‐
Spectinomycin 0% ‐‐ ‐‐
Tetracycline 83% 61% 72%
Ticarcillin 100% 100% 100%
Ticarcillin/CA 100% 100% 100%
TMS 100% 100% 100%
N 6                28              25             
BVMTH 5               22             22            







Antibiotic 2005 2006 2007
Amikacin 100% 62% 59%
Amoxicillin/CA 100% 94% 100%
Ampicillin 100% 87% 83%
Cefazolin 100% 90% 100%
Cefoxitin 100% 94% 100%
Cefpodoxime 88% 71% 79%
Ceftiofur 100% 90% 90%
Cephalothin 100% 92% 100%
Chloramphenicol 100% 85% 93%
Enrofloxacin 63% 75% 76%
Clindamycin ‐‐ 88% 75%
Erythromycin 0% 0% 0%
Gentamicin 100% 87% 93%
Imipenem 100% 98% 100%
Marbofloxacin 100% 94% 100%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin 100% 96% 89%
Penicillin 100% 88% 86%
Rifampin 100% 88% 89%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 75% 65% 59%
Ticarcillin 100% 92% 100%
Ticarcillin/CA 100% 96% 100%
TMS 100% 98% 100%





Organism 2005 % 2005 2006 % 2006 2007 % 2007 Total % Total
Salmonella group ‐ B
Community 1 2% 7 11% 3 6% 11 6%
Ranch 1 2% 1 1%
Unknown 16 27% 1 2% 17 10%
VTH 1 2% 9 15% 3 6% 13 7%
Salmonella group ‐ B Total 18 30% 17 27% 7 13% 42 24%
Salmonella species group C1
Community 1 2% 2 4% 3 2%
Unknown 8 13% 8 5%
VTH 1 2% 4 6% 6 11% 11 6%
Salmonella species group C1 Total 9 15% 5 8% 8 15% 22 13%
Salmonella sp. group C2
Community 1 2% 1 1%
Unknown 23 38% 23 13%
VTH 4 6% 2 4% 6 3%
Salmonella sp. group C2 Total 23 38% 5 8% 2 4% 30 17%
Salmonella group D
Community 1 2% 1 1%
Salmonella group D Total 1 2% 1 1%
Salmonella group ‐ E
Unknown 4 7% 4 2%
VTH 1 2% 2 3% 3 2%
Salmonella group ‐ E Total 5 8% 2 3% 7 4%
Salmonella choleraesuis ss arizonae
Community 1 2% 1 1%
Salmonella choleraesuis ss arizonae Total 1 2% 1 1%
Salmonella subgenus 1
VTH 1 2% 1 1%
Salmonella subgenus 1 Total 1 2% 1 1%
Salmonella species
Community 1 2% 13 21% 11 21% 25 14%
Ranch 1 2% 1 1%
Unknown 4 7% 4 2%
VTH 19 31% 22 42% 41 23%
Salmonella species Total 5 8% 32 52% 34 64% 71 41%
Subtotal
Community 2 3% 23 37% 17 32% 42 24%
Ranch 2 4% 2 1%
Unknown 55 92% 1 2% 56 32%
VTH 3 5% 38 61% 34 64% 75 43%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14
Amikacin S S S S S S S I S S S S S S
Amoxicillin/CA S R R R R R S S R R R I S S
Ampicillin S R R R R R R R R R R R S R
Cefazolin S R R R R R R R R R R R S S
Cefoxitin S R R R R R S S R R R S S S
Cefpodoxime S NT R NT NT NT R R R R R S S S
Ceftiofur S R R R R R I R R R R S S S
Cephalothin S R R R R R R R R R R R S S
Chloramphenicol S R R R R R R R R S S R R S
Enrofloxacin S S S R S S S S S S S S S S
Clindamycin R NT R NT NT NT R R R R R R R R
Erythromycin R R NT R R R NT NT NT NT R R R R
Gentamicin S R S S S R R R S R R R R S
Imipenem S S S I S S S S S S S S S S
Marbofloxacin S NT S NT NT NT S S S S S S S S
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin R R NT R R R NT NT NT NT R R R R
Penicillin R R NT R R R NT NT NT NT R R R R
Rifampin R R R R R R R R R R R R R R
Sulphadimethoxime S R NT R R R NT NT NT NT NT NT NT NT
Spectinomycin R R NT R R R NT NT NT NT NT NT NT NT
Tetracycline S R R R R R R R R R R R S S
Ticarcillin S R I R I R R R R R I R S R
Ticarcillin/CA S R I R R R S I I I I R S S
TMS S R S R R S R R R S S R S S
N 23 5 3 1 1 1 1 1 1 1 1 1 1 1
2005 10 5 1 1 1
2006 10 3 1 1 1 1
2007 2 1 1 1 1
UN 9 5 1 1 1
RVC 8 1 1 1






Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7
Amikacin S S S S S S S
Amoxicillin/CA S R R S R R S
Ampicillin S R R S R R S
Cefazolin S R R S R R S
Cefoxitin S R R S R R S
Cefpodoxime S R R NT R R S
Ceftiofur S R R S R R S
Cephalothin S R R S R R S
Chloramphenicol S R R S R R S
Enrofloxacin S R S I S S S
Clindamycin R NT R NT NT R R
Erythromycin R R NT R NT NT R
Gentamicin S S S S S R S
Imipenem S S S S S S S
Marbofloxacin S S S NT S S S
Orbifloxacin NI NI NI NI NI NI NI
Oxacillin R R NT R NT NT R
Penicillin R R NT R NT NT R
Rifampin R R R R R R R
Sulphadimethoxime S R NT S NT NT NT
Spectinomycin S R NT R NT NT NT
Tetracycline S R R S R R R
Ticarcillin S I R S R R S
Ticarcillin/CA S I R S I R S
TMS S S S S S R S
N 14 2 2 1 1 1 1
2005 4 2 1 1 1
2006 3 1 1
2007 7 1
UN 4 2 1 1
RVC 2 1






Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15
Amikacin S S S S S S S S S S S S S S S
Amoxicillin/CA S R R R R R R R R R R R S S S
Ampicillin S R R R R R R R R R R I R S S
Cefazolin S R R R R R R R R R R R R S S
Cefoxitin S R R R R R R R R R R R S S S
Cefpodoxime S R NT NT NT NT NT NT NT NT NT R S I S
Ceftiofur S R R R R R R R R R R R S S S
Cephalothin S R R R R R R R R R R R R S S
Chloramphenicol S R R R R R R R R R R R S S S
Enrofloxacin S S S S I I I R S S S S S S S
Clindamycin R NT NT NT NT NT NT NT NT NT NT NT NT NT R
Erythromycin R R R R R R R R R R R NT NT NT NT
Gentamicin S S S S S S S S S S S S S S S
Imipenem S S S S S S I I I S S S S S S
Marbofloxacin S S NT NT NT NT NT NT NT NT NT S S S S
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin R R R R R R R R R R R NT NT NT NT
Penicillin R R R R R R R R R R R NT NT NT NT
Rifampin R R R R R R R R R R R R R R R
Sulphadimethoxime S R R R R R R R R R R NT NT NT NT
Spectinomycin S R R R R R R R R I I NT NT NT NT
Tetracycline S R R R R R R R R R R R S S R
Ticarcillin S R R I R I R R R I R I R S S
Ticarcillin/CA S R I R R R R R R R R I S S S
TMS S S S S R S R R R S S S S S S
N 9 6 2 2 1 1 1 1 1 1 1 1 1 1 1
2005 3 6 2 2 1 1 1 1 1 1 1 1 1 1
2006 4 1
2007 2








Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15 PT 16 PT 17 PT 18 PT 19 PT 20
Amikacin S S S S S S S S S S S S S S S S S S S S
Amoxicillin/CA S R S R R R R S R S R I R R S S S R R R
Ampicillin S R S R R R R S R R R R R I R R R R R R
Cefazolin S R S R R R R S R R R R R R R R R R R R
Cefoxitin S R S R R R R S R S R S R I S S S R S R
Cefpodoxime S R S R R R R S R S R S R S R R S R R R
Ceftiofur S R S R R R R S R S R S R S R R S R R R
Cephalothin S R S R R R R S R R R R R R R R R R R S
Chloramphenicol S R S R R R R NM R S R R R S R R S R NM S
Enrofloxacin S I S S S I S S S I S S S R S S S S I S
Clindamycin R R R R R R R R R R R R R R R R R R R R
Erythromycin R R R NT NT NT NT NT NT NT NT R R R R R R R R R
Gentamicin S S S S R S R S R S R R S R R R S S S S
Imipenem S S S S S S S S S S S S S S S S S S S S
Marbofloxacin S S S S S S S S S S S S S S S S S S R S
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin R R R NT NT NT NT NT NT NT NT R R R R R R R R R
Penicillin R R R NT NT NT NT NT NT NT NT R R R R R R R R R
Rifampin R R R R R R R R R R R R R R R R R R R R
Sulphadimethoxime S NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Spectinomycin R NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Tetracycline S R R R R R R S R S R R R R S R S R S R
Ticarcillin S R S I I R R S R R R R I S R R R R I S
Ticarcillin/CA S R S I I R I I R S R I I S I I S I I S
TMS S R S R S S R S R S S R S S R R S S NM S
N 45 4 3 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2005 5
2006 17 3 2 2 2 1 1 1 1 1 1
2007 23 1 1 1 1 1 1 1 1 1 1 1
UN 4
RVC 14 4 1 1 1 1 1 1 1








Antibiotic 2005 2006 2007
Amikacin 100% 97% 100%
Amoxicillin/CA 67% 74% 81%
Ampicillin 67% 66% 72%
Cefazolin 67% 66% 75%
Cefoxitin 67% 74% 89%
Cefpodoxime 67% 68% 83%
Ceftiofur 67% 68% 83%
Cephalothin 67% 66% 78%
Chloramphenicol 50% 71% 86%
Enrofloxacin 100% 97% 94%
Clindamycin ‐‐ 0% 0%
Erythromycin ‐‐ ‐‐ 0%
Gentamicin 100% 79% 83%
Imipenem 100% 100% 100%
Marbofloxacin 100% 100% 97%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ ‐‐ 0%
Penicillin ‐‐ ‐‐ 0%
Rifampin 0% 0% 0%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 67% 58% 81%
Ticarcillin 67% 66% 78%
Ticarcillin/CA 67% 71% 81%
TMS 100% 84% 89%
N 3               38             36            








Antibiotic 2005 2006 2007
Amikacin 100% 100% 100%
Amoxicillin/CA 100% 61% 88%
Ampicillin 100% 61% 76%
Cefazolin 100% 61% 76%
Cefoxitin 100% 61% 88%
Cefpodoxime 100% 61% 88%
Ceftiofur 100% 61% 88%
Cephalothin 100% 61% 76%
Chloramphenicol 100% 59% 82%
Enrofloxacin 100% 83% 94%
Clindamycin ‐‐ 0% 0%
Erythromycin ‐‐ 0% 0%
Gentamicin 100% 96% 88%
Imipenem 100% 100% 100%
Marbofloxacin 100% 100% 100%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ 0% 0%
Penicillin ‐‐ 0% 0%
Rifampin 0% 0% 0%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 100% 61% 76%
Ticarcillin 100% 61% 76%
Ticarcillin/CA 100% 57% ‐‐
TMS 100% 78% 94%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15 PT16 PT17 PT18 PT19 PT20 PT21 PT22 PT23 PT24
Amikacin R S S R S S S S S R R S R S S S R R S S S S S S
Amoxicillin/CA R S S R S S S S S R R S S R S S S R S R S S S S
Ampicillin R NI NI R NI R NI S NI R R R NI R NI NI R R R R NI R NI R
Cefazolin R S S R S S S S S R R S S R S S S R S R S S S S
Cefoxitin R S S R S S S S S R R S S R S S I R S R S S S S
Cefpodoxime NT S S S S I NT R R R S R S S R R S R S S S S
Ceftiofur R S S R S S S S S R R I S R S S I R S R S S S S
Cephalothin R S S R S S S S S R R S S R S S S R S R S S S S
Chloramphenicol S S S S S S S S S S S S R S S S S S R S S S R S
Enrofloxacin S S S S S S S S S S S S S R R S S S S S I S S S
Clindamycin NT S NT NT R NT R NT NT NT NT NT S R S S R R R NM R R S S
Erythromycin R S S R R S R S S S S R S R S S R R R I R R S S
Gentamicin R S S R S S S S S R R S R R S S R R I R S S S S
Imipenem R S S R S R S R S R R R S R S S R R R R S R S R
Marbofloxacin NT S S S S S NT NT S S S S R R S S S S S S S S S
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin R S S R S S S S S R R S S R S S S R S R S S S S
Penicillin R NI NI R NI R NI R NI R R R NI R NI NI R R R R NI R NI R
Rifampin S S S S S S S S S S S S S S S S S R S S S S S S
Sulphadimethoxime R NT NT R NT NT NT R R NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Spectinomycin R NT NT R NT NT NT R R NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Tetracycline S S S S S S S S S R R S S S R R S R S S S S S S
Ticarcillin R NI NI R NI S NI S NI R R S NI R NI NI I R S R NI S NI S
Ticarcillin/CA R S S R S S S S S R R S S R S S S R S R S S S S
TMS R S S S S S S S S R S S S S NM S R R S S S S S S
N 11 11 5 4 4 3 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2005 2 5 1 3 1 1 1 1 1
2006 2 6 2 1 1 1 1 1 1 1
2007 7 5 1 4 1 1 1 1 1 1 1
UN 2 2 1 1 1 1 1
RVC 7 3 1 3 2 1 1 1 1 1 1 1 1











































Antibiotic 2005 2006 2007
Amikacin 86% 67% 100%
Amoxicillin/CA 86% 83% 91%
Ampicillin 0% 0% 0%
Cefazolin 86% 83% 91%
Cefoxitin 86% 83% 91%
Cefpodoxime 71% 83% 91%
Ceftiofur 71% 83% 91%
Cephalothin 86% 83% 91%
Chloramphenicol 100% 83% 82%
Enrofloxacin 100% 83% 100%
Clindamycin ‐‐ 83% 50%
Erythromycin 86% 83% 45%
Gentamicin 86% 67% 82%
Imipenem 43% 83% 73%
Marbofloxacin 100% 83% 100%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin 86% 83% 91%
Penicillin 0% 0% 0%
Rifampin 100% 100% 100%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 86% 83% 100%
Ticarcillin 75% 0% 67%
Ticarcillin/CA 86% 83% 91%
TMS 100% 100% 100%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15 PT16 PT17 PT18 PT19 PT20
Amikacin S S S S S S S S S S S S S S S S S I S S
Amoxicillin/CA R R R R R R R R R R R R R R R R R R R R
Ampicillin R R R R R R R R R R R R R R R R R R R R
Cefazolin R R R R R R R R R R R R R R R R R R R R
Cefoxitin R R R R R R R R R R R R R R R R R R R R
Cefpodoxime R R NT NT NT R NT R NT NT NT NT R R R R R R R R
Ceftiofur R R R R R R R R R R R R R R R R R R R R
Cephalothin R R R R R R R R R R R R R R R R R R R R
Chloramphenicol I I R R R S I R R R R S R R R S S R I I
Enrofloxacin S S S S I S S I I R S S I S S S S I I I
Clindamycin NT NT NT NT NT R NT NT NT NT NT NT R R R R R R R R
Erythromycin NT NT R R R NT R R R R R NT NT NT NT R R R R
Gentamicin S S S S S R R S S S R S S S R S S I S I
Imipenem S S S S S S S S S R S S S S S S S S S S
Marbofloxacin NI NI NT NT NT NI NT NI NT NT NT NT NI NI NI NI NI NI NI NI
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin NT NT R R R NT R NT R R R R NT NT NT NT S R R R
Penicillin NT NT R R R NT R NT R R R R NT NT NT NT R R R R
Rifampin R R R R R R R R R R R R R R R R R R R R
Sulphadimethoxime NT NT R R R NT R NT R R R R NT NT NT NT NT NT NT NT
Spectinomycin NT NT R R R NT R NT R R R R NT NT NT NT NT NT NT NT
Tetracycline R R R R R R R R R R R R R R R R R R R R
Ticarcillin S S S S S S S R S R S S R R R R R R S R
Ticarcillin/CA S S S S S S S R S R S S R R S R R R S R
TMS R S R S S R R S R R R S R S R S S R S R
N 11 10 5 5 3 3 2 2 1 1 1 1 1 1 1 1 1 1 1 1
2005 2 2 2 1 3 1 1 1 1 1 1
2006 5 4 2 1 1 1 1 1 1
2007 4 4 3 2 2 1 1 1 1 1
UN 1 2 1 1 3 1 1 1 1 1
RVC 7 5 3 3 3 2 1 1 1 1 1








Antibiotic 2005 2006 2007
Amikacin 100% 100% 83%
Amoxicillin/CA 0% 0% 0%
Ampicillin 0% 0% 0%
Cefazolin 0% 0% 0%
Cefoxitin 0% 0% 0%
Cefpodoxime 0% 0% 0%
Ceftiofur 0% 0% 0%
Cephalothin 0% 0% 0%
Chloramphenicol 0% 0% 0%
Enrofloxacin 100% 100% 67%
Clindamycin ‐‐ 0% 0%
Erythromycin ‐‐ ‐‐ 0%
Gentamicin 100% 80% 83%
Imipenem 100% 100% 100%
Marbofloxacin ‐‐ ‐‐ ‐‐
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ ‐‐ 0%
Penicillin ‐‐ ‐‐ 0%
Rifampin 0% 0% 0%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 0% 0% 0%
Ticarcillin 100% 80% 83%
Ticarcillin/CA 100% 80% 83%
TMS 100% 60% 33%









Antibiotic 2005 2006 2007
Amikacin 100% 100% 100%
Amoxicillin/CA 0% 0% 0%
Ampicillin 0% 0% 0%
Cefazolin 0% 0% 0%
Cefoxitin 0% 0% 0%
Cefpodoxime 0% 0% 0%
Ceftiofur 0% 0% 0%
Cephalothin 0% 0% 0%
Chloramphenicol 0% 17% 23%
Enrofloxacin 67% 92% 85%
Clindamycin ‐‐ 0% 0%
Erythromycin ‐‐ ‐‐ 0%
Gentamicin 100% 83% 77%
Imipenem 100% 100% 100%
Marbofloxacin ‐‐ ‐‐ ‐‐
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ ‐‐ 8%
Penicillin ‐‐ ‐‐ 0%
Rifampin 0% 0% 0%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 0% 0% 0%
Ticarcillin 67% 75% 77%
Ticarcillin/CA 67% 83% 77%
TMS 33% 42% 46%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15 PT16 PT17 PT18 PT19 PT20 PT21 PT22
Amikacin S S S S S S S S S S S R S S S S S S S I S S
Amoxicillin/CA S S S S S I S S S R S R S R R S S R I I S S
Ampicillin R R R R R R R R R R R R R R R R R R R R R R
Cefazolin S S S R S S S S S I S R S S R R S S S S R S
Cefoxitin S S S S S S S S S S S R S R R S S S S S S S
Cefpodoxime S NT S S S NT NT S S S S R S S R R S S S S R S
Ceftiofur S S S S S S S S S S S R S S I R S S S S R S
Cephalothin S S S S S I S S S R R R S R R R S R R R R S
Chloramphenicol S S S S S S R R R R R R S S R S S R S S R R
Enrofloxacin S S S S S S S R S S S S S S S I R S S S R S
Clindamycin R NT R R R NT NT NT NT R R R R R R R R R R R R R
Erythromycin R R NT NT NT R R NT NT NT NT NT NT NT NT NT NT R R R R R
Gentamicin S S S S S R S R R R R R S S R R I R R R R S
Imipenem S S S S S S S S S S S S S S S S S S S S S S
Marbofloxacin S NT S S S NT NT S S S S S S S S S S S S S S S
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin R R NT NT NT R R NT NT NT NT NT NT NT NT NT NT R R R R R
Penicillin R R NT NT NT R R NT NT NT NT NT NT NT NT NT NT R R R R R
Rifampin R R R R R R R R R R R R R R R R R R R R R R
Sulphadimethoxime NT S NT NT NT R S NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Spectinomycin NT I NT NT NT R I NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Tetracycline S S S S S R S S R S R R S S R S R R S S R R
Ticarcillin R R R R R R R R R R R R S R R R R R R R R R
Ticarcillin/CA S S S S S I S S S R S R S S I S S R R R S S
TMS S S R R R R S S R S R R S S R S R R NM R R R
N 25 4 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2005 2 4 1 1 1 1
2006 8 1 1 1 1 1 1 1 1 1 1 1 1
2007 15 1 1 1 1 1
UN 2 4 1 1
RVC 12 1 1 1 1 1 1 1 1 1 1











































Antibiotic 2005 2006 2007
Amikacin 100% 100% 92%
Amoxicillin/CA 100% 71% 83%
Ampicillin 0% 0% 0%
Cefazolin 100% 71% 100%
Cefoxitin 100% 86% 100%
Cefpodoxime 100% 86% 100%
Ceftiofur 100% 100% 100%
Cephalothin 100% 43% 83%
Chloramphenicol 33% 57% 100%
Enrofloxacin 67% 86% 100%
Clindamycin -- 0% 0%
Erythromycin -- -- 0%
Gentamicin 33% 43% 83%
Imipenem 100% 100% 100%
Marbofloxacin 100% 100% 100%
Orbifloxacin -- -- --
Oxacillin -- -- 0%
Penicillin -- -- 0%
Rifampin 0% 0% 0%
Sulphadimethoxime -- -- --
Spectinomycin -- -- --
Tetracycline 67% 57% 100%
Ticarcillin 0% 14% 0%
Ticarcillin/CA 100% 86% 83%
TMS 67% 57% 91%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15 PT16 PT17 PT18 PT19 PT20 PT21 PT22
Amikacin S S I I R I S S S I S R I I S S R S S I I I
Amoxicillin/CA S S S S S S S S S S S S S S S S S S S S S S
Ampicillin S S S S S S S S I S S I S S I S S S S S S S
Cefazolin S S S S S S S S S S S S S S S S S S S S S S
Cefoxitin S S S S S S S S S S S S S S S S S S S S S S
Cefpodoxime S NT NT I S I I I NT NT NT NT NT NT NT S I S I S S
Ceftiofur S S S S S S S S S S S S S S S S S S S S S S
Cephalothin S S S S S S S S S S S S S S S S S S S S S S
Chloramphenicol S S S S S S S S S S S S S S S S S I S I S I
Enrofloxacin S S I S S S I S R I S I I R I S S S I I S S
Clindamycin S NT NT NT NT NT S S NT NT NT NT NT NT NT NT NT NT NT NT S I
Erythromycin I S S R I I R R I S S I S S S I R R S R I I
Gentamicin S S S S R S S S S S S I S S S S R S S I S S
Imipenem S S S S S S S S R S S S S S S S S S S S S S
Marbofloxacin S NT NT S S S S S NT NT NT NT NT NT NT S S S NT S S S
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin S S S S S S S S S S S S S S S S S S S S S S
Penicillin S S S S S S S S S S S S S S S S S S S S S S
Rifampin S S S S S S S S NM S S S S S S S S S S S S S
Sulphadimethoxime NT S R NT NT NT NT NT R R R R R R R NT NT NT R NT NT NT
Spectinomycin NT S R NT NT NT NT NT I S S I S R R NT NT NT I NT NT NT
Tetracycline S S S S R S S S R R R S S R S R R R S R S R
Ticarcillin S S S S S S S S S S S S S S S S S S S S S S
Ticarcillin/CA S S S S S S S S S S S S S S S S S S S S S S
TMS S S S S S S S S S S S S S S S S S S S S S S
N 5 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2005 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2006 3 1 1 1 1 1 1
2007 2 1 1 1
UN 2 2 1 1 1 1 1 1 1 1 1 1 1 1
RVC 4 1 2 2 1 1 1 1








































PT23 PT24 PT25 PT26 PT27 PT28 PT29 PT30 PT31 PT32 PT33 PT34 PT35 PT36 PT37
I S S S S S S S R S I S I S I
S S S S S I S S I S S S I S S
R S S I I R R S I S S S R S I
S S S S I R S S S S S S R S S
S S S S S S S S S S S S R S S
S S S S I R I I I I S S R S S
R S S S R R R S S S S S R S S
S S S S S S S S S S S S S S S
I S S S I I I I S S S S R S S
S S S S S R I S S I I S R I I
R S NM S R R R R R S S S R S S
R I I R R R I R R I I R R I I
S S S S S I S S R S S S I S S
S S S S S S S S S S S S S S S
S S S S S R S S S S S S R S I
NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
S S S S S S S S S S S S S S S
S S S I S S S S S S S S S S S
S S S S S R S S S S S S S S S
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
R R R S R R R R R S S R R S R
S S S S S S S S S S S S S S S
S S S S S S S S S S S S S S S
S S S S S S S S S S S S S S S
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1











































Antibiotic 2005 2006 2007
Amikacin 0% 67% 67%
Amoxicillin/CA 100% 100% 89%
Ampicillin 100% 78% 78%
Cefazolin 100% 100% 89%
Cefoxitin 100% 100% 89%
Cefpodoxime 25% 100% 44%
Ceftiofur 100% 89% 89%
Cephalothin 100% 100% 100%
Chloramphenicol 75% 78% 89%
Enrofloxacin 75% 100% 44%
Clindamycin ‐‐ 75% 89%
Erythromycin 0% 0% 0%
Gentamicin 50% 89% 89%
Imipenem 100% 100% 100%
Marbofloxacin 100% 100% 78%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin 100% 100% 100%
Penicillin 100% 89% 100%
Rifampin 100% 100% 100%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 50% 44% 67%
Ticarcillin 100% 100% 100%
Ticarcillin/CA 100% 100% 100%
TMS 100% 100% 100%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15 PT 16 PT 17 PT 18 PT 19
Amikacin R I S R S I R R R I R I R R S R S R R
Amoxicillin/CA S S S S S S S S R S S S S S S S S I I
Ampicillin R S S I S I I S R S S S R R S I I R R
Cefazolin S S S S S S R S R S S S R R S S S R R
Cefoxitin S S S S S S S S R S S S S S S S S R R
Cefpodoxime I NT NT NT NT NT NT S R NT NT S R S I I I R R
Ceftiofur R S S S S S R S R S S S R S S I S R R
Cephalothin S S S S S S S S S S S S S S S S S S R
Chloramphenicol I S S S S S S I R S S S I I S I S I R
Enrofloxacin R R I R R R R I R I I I R R I R S R R
Clindamycin NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT R R
Erythromycin R S S I S R R I R R I I R I I R R R R
Gentamicin I S S S S S S I R S S S I I S I R R I
Imipenem S S S S S I I S S S S S S S S S S S S
Marbofloxacin I NT NT NT NT NT NT S R NT NT I I I I R S R R
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin S S S S S S S S S S S S S S S S R S R
Penicillin S S S S S S R S I S S S S S S S R S R
Rifampin S S S S S S R S R NM S S S R S S R R R
Sulphadimethoxime NT R R R S R R NT NT R R NT NT NT NT NT NT NT NT
Spectinomycin NT I S I I I I NT NT S I NT NT NT NT NT NT NT NT
Tetracycline R S S S S S S R R R S S R R S R R R R
Ticarcillin S S S S S S S S R S S S S S S S S S R
Ticarcillin/CA S S S S S S S S R S S S S S S S S S R
TMS S S S S S S S S S S S S S S S S R S R
N 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2005 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2006 1 1
2007 1
UN 1 1 1 1 1 1 1 1 1 1 1 1









































PT 20 PT21 PT22 PT23 PT24 PT25 PT26 PT27 PT28 PT29 PT30 PT31 PT32 PT33 PT34 PT35 PT36 PT37
I R R R R I I R R S I R R I R S I I
S S S S S S S S I S S S S S R S S S
I R I S S S S S R S S S R S R S S R
S S S S S S S S R S S S R S R S S S
S S S S S S S S R S S S R S R S S S
I I I I I S S S R I S I R S R NM S S
R R S R S S S S R S S S R S R I S I
S S S S S S S S S S S S S S S S S S
I I I I I S I I R S S I I S R S I I
R R I I I I I I R S I R R S R S I R
R R R R S S NM R R S S NM R S R S R R
R R R I I I I R R R I R R I R NM I R
I I I I I S I I R S S I R S R S S I
S S S S S S S S S S S S S S S S S S
I R I I I S I I R S I R R S R S I I
NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
S S S S S S S S S S NM S S S R S S S
S S S S S S S S S S S S S S R I S S
S S S S S S S S R S S S R S R S S S
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
R R R R R S R R R R I R R S R S R R
S S S S S S S S S S S S S S R S S S
S S S S S S S S S S S S S S S S S S
S S S S S S S S NM S S S S S S S S S
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1










































Antibiotic 2005 2006 2007
Amikacin 50% 0% 20%
Amoxicillin/CA 100% 75% 80%
Ampicillin 50% 38% 80%
Cefazolin 75% 75% 80%
Cefoxitin 100% 75% 80%
Cefpodoxime 50% 13% 40%
Ceftiofur 100% 38% 80%
Cephalothin 100% 88% 100%
Chloramphenicol 75% 13% 20%
Enrofloxacin 25% 0% 20%
Clindamycin ‐‐ 25% 25%
Erythromycin 0% 0% 0%
Gentamicin 50% 13% 40%
Imipenem 100% 100% 100%
Marbofloxacin 25% 13% 20%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin 75% 88% 100%
Penicillin 75% 88% 100%
Rifampin 50% 75% 80%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 50% 13% 0%
Ticarcillin 100% 88% 100%
Ticarcillin/CA 100% 88% 100%
TMS 75% 88% 100%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12 PT 13 PT 14 PT 15 PT16 PT17 PT18 PT19 PT20 PT21 PT22
Amikacin S S I R I S I I S S S R I S R I R I R I R S
Amoxicillin/CA S S S S S S S S S S S S S S I S I S R S S S
Ampicillin S S S S S S S I S S S R R S R R R R R I R R
Cefazolin S S S S S S S S S S S R S S R R R R R S R R
Cefoxitin S S S S S S S S S S S S S S R S R S R S R S
Cefpodoxime S NT NT NT NT NT NT NT NT NT NT R S S R I R I R I R R
Ceftiofur S S S S S S S S S S S R R S R R R R R R R R
Cephalothin S S S S S S S S S S S I S S S S S S S S S S
Chloramphenicol S S S S S S S S S S S I I I I I R I I I I I
Enrofloxacin S S I S S S I R S S S R S I R R R R R I R I
Clindamycin NT NT NT NT NT NT NT NT NT NT NT NT NT R R R R R R R R R
Erythromycin I S S R R S S I S S S R R R R R R I R R R R
Gentamicin S S S R R S S S S S S I S S R I R S I S I S
Imipenem S S S S S S S R S S S S S S S S S S S S S S
Marbofloxacin S NT NT NT NT NT NT NT NT NT NT R I S R I R R R S R R
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin S S S S S S S S S S S S S S S S S S S S S S
Penicillin S S S S S S S S S S S S S S S S I S S S S S
Rifampin S S S R S S S S S S S R S S R S R S R S R I
Sulphadimethoxime NT S R R S S R R R R S NT NT NT NT NT NT NT NT NT NT NT
Spectinomycin NT S I S S S S I S S S NT NT NT NT NT NT NT NT NT NT NT
Tetracycline S S S S S R R S R S R R R R R R R R R R R R
Ticarcillin S S S S S S S S S S S S S S S S I S R S S S
Ticarcillin/CA S S S S S S S S S S S S S S S S S S S S S S
TMS S S S S S S S S S S S S S S S S S S S S S S
N 10 2 1 1 1 1 1 1 1 1 1
2005 2 2 1 1 1 1 1 1 1 1 1 1 1
2006 3 1 1 1 1 1 1 1 1 1
2007 5
UN 1 2 1 1 1 1 1 1 1 1 1









































PT23 PT24 PT25 PT26 PT27
I R I S S
S R S S S
I R S S S
S R S S S
S R S S S
I R S S S
I R S S S
S R S S S
I R S S S
S R S S S
R R S S S
R R I R I
S R S S S
S S S S S
S R S S S
NI NI NI NI NI
S R S S S
S R S S S
S R S S S
NT NT NT NT NT
NT NT NT NT NT
R R S S R
S R S S S
S R S S S
S R S S S
1 1
1 1 1









































Antibiotic 2005 2006 2007
Amikacin 33% 40% 100%
Amoxicillin/CA 100% 70% 100%
Ampicillin 33% 30% 100%
Cefazolin 67% 40% 100%
Cefoxitin 100% 60% 100%
Cefpodoxime 67% 30% 100%
Ceftiofur 33% 30% 100%
Cephalothin 67% 100% 100%
Chloramphenicol 33% 20% 100%
Enrofloxacin 67% 20% 100%
Clindamycin -- 20% 100%
Erythromycin 0% 0% 0%
Gentamicin 67% 60% 100%
Imipenem 100% 100% 100%
Marbofloxacin 33% 40% 100%
Orbifloxacin -- -- --
Oxacillin 100% 100% 100%
Penicillin 100% 90% 100%
Rifampin 67% 50% 100%
Sulphadimethoxime -- -- --
Spectinomycin -- -- --
Tetracycline 33% 20% 100%
Ticarcillin 100% 80% 100%
Ticarcillin/CA 100% 100% 100%
TMS 100% 100% 100%





Antibiotic PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8 PT9 PT10 PT11 PT12 PT13 PT14 PT15 PT16 PT17 PT18 PT19 PT20 PT21 PT22 PT23 PT24
Amikacin S S S S S S S S S R S S S S S S S S S S S S I NT
Amoxicillin/CA S R S R R S S S S R S S R R S S R S S S R R S NT
Ampicillin S R S R R S S S S R S S R R S R R S S S R R S NT
Cefazolin S R S R R S S S S R S S R R S S R S S S S R S NT
Cefoxitin S S S R R S S S S R S S S R S S R S S S S S S NT
Cefpodoxime S R S NT NT NT NT NT S R I S R R S R R S S S R R S NT
Ceftiofur S R S R R S S S S R S S R R S S R S S S S R S NT
Cephalothin S S S R R S S S S R S S S R S S S S S S S S S NT
Chloramphenicol S I R S I S S S R R S R I I S R R S S S I R S NT
Enrofloxacin S S S I S S S S S R S S R S S S R S S S S R I NT
Clindamycin R NT S NT NT NT NT NT NT R R R R R I R R R R S R R S NT
Erythromycin R R S R R S R R R R R R R R R I R I R S I R S NT
Gentamicin S S S R R S S S S R S S S R S S S S S S S S S NT
Imipenem S R S R R S S S S R S S R R S R R S S S R R S NT
Marbofloxacin S S S NT NT NT NT NT S R S S R S S S R S S S R R I NT
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NT
Oxacillin S S S R R S S S S R S S S R S S S S S S S S S NT
Penicillin S R S R R S R S S R S S R R S R R S S S R R S NT
Rifampin S S S S S S S S S R S S S R S S S S S S S S S NT
Sulphadimethoxime NT NT NT S R S R S NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Spectinomycin NT NT NT R R R R I NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Tetracycline S R S R S R S S S R S S R R R R R S R S R R S NT
Ticarcillin S S S R R S S S S R S S S R S S S S S S S S S NT
Ticarcillin/CA S S S R R S S S S R S S S R S S S S S S S S S NT
TMS S S S S R S S S S R S S NM S S S R S S S S S S NT
N 8 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2005 2 1 1 1 1 1 1
2006 3 2 1 1
2007 5 1 1 1 1 1 1 1 1 1 1 1 1 1
UN 2 1 1 1 1 1 1
RVC 4 2 1 1 1 1 1 1 1 1 1 1 1 1










































































Antibiotic PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8 PT9 PT10 PT11 PT12 PT13 PT14 PT15 PT16 PT17 PT18 PT19 PT20 PT21 PT22 PT23 PT24
Amikacin S S S S S S S S S S S S S R S S S S S S S S R NM
Amoxicillin/CA S S S R R S S S S S S S S R S S S S S S R S S NM
Ampicillin S S S R R S S S R S R R R R R R R R R S R R R NM
Cefazolin S S S R S S S S S S R S S R S R R S S S R S S NM
Cefoxitin S S S S S S S S S S S S S R S S S S S S R S S NM
Cefpodoxime S S S NT NT NT NT NT I I R S S R S R R I S I R S R NM
Ceftiofur S S S S S S S S S S R S S R S R R R S S R S I NM
Cephalothin S S S S S S S S S S S S S R S S S S S S R S S NM
Chloramphenicol S S S S S S S S S S S R S R S S S S S S S S R NM
Enrofloxacin S S S I I S S S S S S S S R S S S S S S S I R NM
Clindamycin R S R NT NT NT NT NT NT NT NT R R R S R R R R R S I R NM
Erythromycin S S R R S R S S R S R R R R S R R R I R S I R NM
Gentamicin S S S S S S S S S S I S S R S S I S S S I S R NM
Imipenem S S S I S S S S S S S S S R S S S S S S R S S NM
Marbofloxacin S S S NT NT NT NT NT S S S S S R S S S S S S S S R NM
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NM
Oxacillin S S S S S S S S S S S S S R S S S S S S R S S NM
Penicillin S S S R R S S R R S S R R R R S R S S R R R R NM
Rifampin S S S R S S S S S S R S S R S I I S S S S S S NM
Sulphadimethoxime NT NT NT S S S S S NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Spectinomycin NT NT NT R R I R I NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Tetracycline S S S S S S S S S S S S S R S S I S S S S S S NM
Ticarcillin S S S S S S S S S S S S S R S S S S S S R S S NM
Ticarcillin/CA S S S S S S S S S S S S S R S S S S S S R S S NM
TMS S S S S S S S S S S S S S R S S S S S S S S S NM
N 4 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2005 2 1 1 1 1 1 1 1 1
2006 3 1 1 1 1 1
2007 2 3 1 1 1 1 1 1 1 1
UN 2 1 1 1 1 1 1 1
RVC 2 2 3 1 1 1 1 1 1 1 1








Antibiotic 2005 2006 2007
Amikacin 100% 100% 100%
Amoxicillin/CA 100% 100% 67%
Ampicillin 50% 100% 0%
Cefazolin 50% 100% 67%
Cefoxitin 100% 100% 67%
Cefpodoxime 0% 100% 67%
Ceftiofur 50% 100% 67%
Cephalothin 100% 100% 67%
Chloramphenicol 100% 100% 100%
Enrofloxacin 100% 100% 67%
Clindamycin ‐‐ 100% 33%
Erythromycin 50% 100% 33%
Gentamicin 50% 100% 67%
Imipenem 100% 100% 67%
Marbofloxacin 100% 100% 100%
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin 100% 100% 67%
Penicillin 100% 100% 33%
Rifampin 50% 100% 100%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 100% 100% 100%
Ticarcillin 100% 100% 67%
Ticarcillin/CA 100% 100% 67%
TMS 100% 100% 100%
N 2 1 4







































Antibiotic PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8 PT9 PT10 PT11 PT12 PT13 PT14 PT15 PT16 PT17 PT18 PT19 PT20 PT21 PT22 PT23 PT24 PT25 PT26 PT27
Amikacin S I S S S S S R I I R S R R S R I R R R S I R R R I R
Amoxicillin/CA S S S S S S S S S S S R S S S S S S S R I S S S I S S
Ampicillin S S S S S S S S R S S R S S S S R S S R R S S S R S R
Cefazolin S R S S S R S R R S R R R R S S R S R R R S R R R I R
Cefoxitin S S R S S R R R R S I R R I S R R R R R R I R S R I R
Cefpodoxime NT NT I S R R R R R R R R R R R R R R R R R R R R R R
Ceftiofur S I S S S R R R R S R R R R S R R R R R R R R R R R R
Cephalothin S S S S S R S R R R S R R I S I R I R R R S I S R S S
Chloramphenicol S R S I S S S S R S S R R S R S S S R I R S R S NM R I
Enrofloxacin S R S R S R I R R R S R R S R R R I R R S I S R R R R
Clindamycin NT NT NT NT NT NT NT R R R R R R R R R R R R S R I R NM R R R
Erythromycin S R S R S I I R R S S R I S R I R I R R R I I R R R R
Gentamicin S R S S S S S R R R I R R R S R I S R R S S R R R R R
Imipenem S I S S S I S I I R S R I S S S R S R R S S S S R I R
Marbofloxacin NT NT NT NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NM
Oxacillin S S S R S R R R R S S R R R R R R R R R R R R R R R R
Penicillin S S S R S R S R R S S S R S S S S S R R R S S S R S S
Rifampin S R R R S S I R R S S R R S R S R R I R R I S R R S R
Sulphadimethoxime S R R NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Spectinomycin S R R NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Tetracycline S R S S S R S R R R S R R S I S R S S R R S R S R R R
Ticarcillin S S S S S R S R R S S R R S S S I S R R I S S S R S R
Ticarcillin/CA S S I S S R S R R R S R R S S S I S R R I S S S R S R
TMS S S S R S S S R S S S R R S S S S S R R R S R R R S NM
N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2005 1 1 1 1 1 1 1
2006 1 1 1 1 1 1
2007 1 1 1 1 1 1 1 1 1 1 1 1 1 1
UN 1 1 1 1 1
RVC 1 1 1 1 1 1 1








Antibiotic 2005 2006 2007
Amikacin 100% 33% 0%
Amoxicillin/CA 100% 67% 80%
Ampicillin 100% 67% 60%
Cefazolin 50% 0% 20%
Cefoxitin 0% 0% 10%
Cefpodoxime 0% 0% 0%
Ceftiofur 0% 0% 0%
Cephalothin 50% 33% 30%
Chloramphenicol 100% 33% 56%
Enrofloxacin 0% 33% 20%
Clindamycin ‐‐ 0% 11%
Erythromycin 0% 33% 10%
Gentamicin 100% 0% 10%
Imipenem 50% 33% 50%
Marbofloxacin ‐‐ ‐‐ ‐‐
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin 0% 33% 0%
Penicillin 50% 67% 80%
Rifampin 50% 33% 40%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 50% 33% 40%
Ticarcillin 50% 33% 60%
Ticarcillin/CA 50% 33% 60%
TMS 100% 33% 56%
N 2 3 10







































Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5
Amikacin S S S S S
Amoxicillin/CA S S S S S
Ampicillin S S S S S
Cefazolin S S S S S
Cefoxitin S S S S S
Cefpodoxime S S S S
Ceftiofur S S S S S
Cephalothin S S S S S
Chloramphenicol S S S S S
Enrofloxacin S S S S S
Clindamycin NT NT I I I
Erythromycin NT I I S I
Gentamicin S S S S S
Imipenem S S S S S
Marbofloxacin NI NT NI NI NI
Orbifloxacin NI NI NI NI NI
Oxacillin NT S S S NM
Penicillin NT R R R R
Rifampin S S S S S
Sulphadimethoxime NT S NT NT NT
Spectinomycin NT R NT NT NT
Tetracycline S S I S S
Ticarcillin S S S S S
Ticarcillin/CA S S S S S
TMS S S S S S
N 9 4 2 2 1
2005 4 4 1
2006 3 1
2007 2 1 2
UN 4 1
RVC 3








Antibiotic 2005 2006 2007
Amikacin 100% 100% 100%
Amoxicillin/CA 100% 100% 100%
Ampicillin 100% 100% 100%
Cefazolin 100% 100% 100%
Cefoxitin 100% 100% 100%
Cefpodoxime 100% 100% 100%
Ceftiofur 100% 100% 100%
Cephalothin 100% 100% 100%
Chloramphenicol 100% 100% 100%
Enrofloxacin 100% 100% 100%
Clindamycin ‐‐ 0% 0%
Erythromycin ‐‐ 0% 50%
Gentamicin 100% 100% 100%
Imipenem 100% 100% 100%
Marbofloxacin ‐‐ ‐‐ ‐‐
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ ‐‐ 100%
Penicillin ‐‐ 0% 0%
Rifampin 100% 100% 100%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 100% 100% 75%
Ticarcillin 100% 100% 100%
Ticarcillin/CA 100% 100% 100%
TMS 100% 100% 100%
N 3 3 4








Antibiotic 2005 2006 2007
Amikacin 100% 100% 100%
Amoxicillin/CA 100% 100% 100%
Ampicillin 100% 100% 100%
Cefazolin 100% 100% 100%
Cefoxitin 100% 100% 100%
Cefpodoxime 100% 100% 100%
Ceftiofur 100% 100% 100%
Cephalothin 100% 100% 100%
Chloramphenicol 100% 100% 100%
Enrofloxacin 100% 100% 100%
Clindamycin ‐‐ 0% 0%
Erythromycin ‐‐ ‐‐ 0%
Gentamicin 100% 100% 100%
Imipenem 100% 100% 100%
Marbofloxacin ‐‐ ‐‐ ‐‐
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ ‐‐ 100%
Penicillin ‐‐ ‐‐ 0%
Rifampin 100% 100% 100%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 100% 100% 100%
Ticarcillin 100% 100% 100%
Ticarcillin/CA 100% 100% 100%
TMS 100% 100% 100%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT7
Amikacin S S S S S S S
Amoxicillin/CA S S S S S S S
Ampicillin S S S S S S S
Cefazolin S S S S S S S
Cefoxitin S S S S S S S
Cefpodoxime S S S S S S
Ceftiofur S S S S S S S
Cephalothin S S S S S S S
Chloramphenicol S S S S S S S
Enrofloxacin S S S S S S S
Clindamycin I NT R NT R R I
Erythromycin NT NT NT I R I I
Gentamicin S S S S S S S
Imipenem S S S S S S S
Marbofloxacin NI NI NI NT NI NI NI
Orbifloxacin NI NI NI NI NI NI NI
Oxacillin NT NT NT S R S S
Penicillin NT NT NT R R R R
Rifampin S S S S S S S
Sulphadimethoxime NT NT NT S NT NT NT
Spectinomycin NT NT NT R NT NT NT
Tetracycline S S S S S S S
Ticarcillin S S S S S S S
Ticarcillin/CA S S S S S S S
TMS S S S S NM S S
N 8 4 3 2 1 1 1
2005 4 2
2006 8 3
2007 1 1 1
UN 2 2
RVC 4 2 1 1











































Antibiotic 2005 2006 2007
Amikacin 100% 100% 100%
Amoxicillin/CA 100% 100% 100%
Ampicillin 100% 100% 100%
Cefazolin 100% 100% 100%
Cefoxitin 100% 100% 100%
Cefpodoxime 100% 100% 100%
Ceftiofur 100% 100% 100%
Cephalothin 100% 100% 100%
Chloramphenicol 100% 100% 100%
Enrofloxacin 100% 100% 100%
Clindamycin ‐‐ 0% 0%
Erythromycin ‐‐ ‐‐ 0%
Gentamicin 100% 100% 100%
Imipenem 100% 100% 100%
Marbofloxacin ‐‐ ‐‐ ‐‐
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ ‐‐ 100%
Penicillin ‐‐ ‐‐ 0%
Rifampin 100% 100% 100%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 100% 100% 100%
Ticarcillin 100% 100% 100%
Ticarcillin/CA 100% 100% 100%
TMS 100% 100% 100%





Antibiotic PT 1 PT 2 PT 3 PT 4 PT 5 PT 6 PT 7 PT  8 PT 9 PT 10 PT 11 PT 12
Amikacin S S S S S S S R S S S S
Amoxicillin/CA S S S S S S S S S S S R
Ampicillin S S S S S S S R S S R R
Cefazolin S S S S S S S I S S S R
Cefoxitin S S S S S S S R S S I R
Cefpodoxime S S S S S NT S I S S S R
Ceftiofur S S S S S S S R S S S I
Cephalothin S S S S S S S R S S S S
Chloramphenicol S S S S S S S R S S S R
Enrofloxacin S S S S S S S S S S S S
Clindamycin S NT S R I NT I I R I R R
Erythromycin S NT NT NT I I NT NT S R I I
Gentamicin S S S S S S S R S S S S
Imipenem S S S S S S S S S S S S
Marbofloxacin NI NI NI NI NI NI NI NI NI NI NI
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin S NT NT NT S S NT NT S R S R
Penicillin R NT NT NT R R NT NT R R R R
Rifampin S S S S S S S S S S NM S
Sulphadimethoxime NT NT NT NT NT S NT NT NT NT NT NT
Spectinomycin NT NT NT NT NT R NT NT NT NT NT NT
Tetracycline S S S S S S S S S S S R
Ticarcillin S S S S S S S I S S S R
Ticarcillin/CA S S S S S S S S S S S R
TMS S S S S S S S S S S S R
N 3 2 2 2 2 1 1 1 1 1 1 1
2005 2 1
2006 2 2 1 1
2007 3 2 1 1 1 1
UN 1 1
RVC 2 1 1 1 1 1








Antibiotic 2005 2006 2007
Amikacin 100% 67% 100%
Amoxicillin/CA 100% 100% 80%
Ampicillin 100% 67% 80%
Cefazolin 100% 67% 80%
Cefoxitin 100% 67% 80%
Cefpodoxime 100% 67% 80%
Ceftiofur 100% 67% 80%
Cephalothin 100% 67% 100%
Chloramphenicol 100% 67% 80%
Enrofloxacin 100% 100% 100%
Clindamycin ‐‐ 33% 20%
Erythromycin ‐‐ ‐‐ 40%
Gentamicin 100% 67% 100%
Imipenem 100% 100% 100%
Marbofloxacin ‐‐ ‐‐ ‐‐
Orbifloxacin ‐‐ ‐‐ ‐‐
Oxacillin ‐‐ ‐‐ 60%
Penicillin ‐‐ ‐‐ 0%
Rifampin 100% 100% 100%
Sulphadimethoxime ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐
Tetracycline 100% 100% 80%
Ticarcillin 100% 67% 80%
Ticarcillin/CA 100% 100% 80%
TMS 100% 100% 80%








































Antibiotic PT1 PT2 PT3 PT4 PT5 PT6 PT7 PT8 PT9 PT10 PT11 PT12 PT13 PT14
Amikacin S S S S S S S S S S S S S S
Amoxicillin/CA S S S S S S S S S S S S S S
Ampicillin I R R I R I I I I S I R R I
Cefazolin I R R S R S I S R S S R R R
Cefoxitin S R S S S S S S S S S S S S
Cefpodoxime NT R I NT R R S S R S R R R S
Ceftiofur S NT NT S NT NT NT NT NT NT NT I S S
Cephalothin R R S I R S S S S S S R R S
Chloramphenicol S S S S S S S S S S S S S S
Enrofloxacin R I S R I S S S S S S S I S
Clindamycin NT NT NT NT NT NT NT NT R I I R I I
Erythromycin S R I S I I S I R S S I I S
Gentamicin S R S S S S S S S S S S S S
Imipenem S S S S S S S S S S S S S S
Marbofloxacin NT NT NT NT NT NT NT NT NT NT NT NI NI NI
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin S R S S S S S S S S S S S S
Penicillin R R R R R R R R R NI R R R R
Rifampin S R R S S S S S S S S S S S
Sulphadimethoxime S NT NT S NT NT NT NT NT NT NT NT NT NT
Spectinomycin R NT NT R NT NT NT NT NT NT NT NT NT NT
Tetracycline S R R S R R R R R S I R S S
Ticarcillin S R S S S S S S S S S R I S
Ticarcillin/CA S S S S S S S S S S S R I S
TMS S S S S S S S S S S S S S S
N 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2005 1 1 1 1 1 1 1 1
2006 1 1 1
2007 1 1 1
UN 1 1 1 1 1 1 1 1












































CVHSR/BVMTH RVC CVHSR/BVMTH RVC
E. coli E. coli Strep. equi zoo. Strep. equi zoo.
Amikacin 100% 91% 40% 59%
Amoxicillin/CA 89% 85% 100% 97%
Ampicillin 56% 66% 100% 89%
Cefazolin 89% 84% 100% 97%
Cefoxitin 89% 87% 100% 97%
Cefpodoxime 89% 85% 40% 78%
Ceftiofur 89% 87% 100% 92%
Cephalothin 67% 66% 100% 97%
Chloramphenicol 100% 79% 90% 86%
Enrofloxacin 100% 90% 40% 76%
Clindamycin 0% 0% 78% 83%
Erythromycin 0% 0% 0% 0%
Gentamicin 78% 71% 60% 89%
Imipenem 100% 100% 100% 100%
Marbofloxacin 100% 91% 90% 97%
Orbifloxacin ‐‐ ‐‐ ‐‐ ‐‐
Oxacillin 0% 0% 100% 94%
Penicillin 0% 0% 100% 89%
Rifampin 0% 0% 100% 94%
Sulphadimethoxime ‐‐ ‐‐ ‐‐ ‐‐
Spectinomycin ‐‐ ‐‐ ‐‐ ‐‐
Tetracycline 67% 69% 70% 73%
Ticarcillin 56% 66% 100% 97%
Ticarcillin/CA 78% 84% 100% 97%
TMS 100% 72% 100% 100%







Year LOHS Problem MRSA E. Faecalis A. baumannii S. marcescens
Horse 1 2006 12 Uterine Torsion Surgery X X
Horse 2 2006 30 Draining Tract on Withers X
Horse 3 2006 22 Colic Surgery X
Horse 4 2006 34 Colic Surgery X X
Horse 5 2006 16 Opthalmologic Surgery X
Horse 6 2006 52 Sporothrix, Surgery X
Horse 7 2007 13 Colic Surgery X
Horse 8 2007 45 HIE, Bladder Surgery X X
Horse 9 2007 15 Opthalmologic Surgery X
Horse 10 2007 86 Pleuropneumonia, Thoracotomy X X X
Horse 11 2007 115 Pleuropneumonia, Thoracotomy X X X X
Horse 12 2007 30 Colic Surgery X
Horse 13 2007 91 Orphan, Umbilical Resection X
Horse 14 2007 32 Colic Surgery X X
Horse 15 2007 31 Sepsis, Laryngeal Dysfunction X
Horse 16 2007 28 Rhabdomyolysis, Renal Failure X
Horse 17 2007 9 Opthalmology X
Horse 18 2007 22 Thrombocytopenia X
Horse 19 2007 7 Abscess X
Horse 20 2007 OP Hock Infection X
Horse 21 2006 92 Abdominal Hernia Surgery X
Horse 22 2006 9 Surgery X






Patient Horse 1 Horse 2 Horse 2 Horse 3 Horse 3 Horse 4 Horse 5 Horse 6 Horse 7 Horse 8 Horse 9 Horse 10 Horse 9 Horse 11 Horse 12
Specimen uterus tissue tissue other other incision unspecified incision incision catheter eye thorax eye thorax incision
Date 4/13/06 10/6/06 10/6/06 11/4/06 11/4/06 11/9/06 11/21/06 12/18/06 3/8/07 4/23/07 4/28/07 4/30/07 5/21/07 5/27/07 6/2/07
Phenotype PT1 PT3 PT3 PT2 PT3 PT3 PT4 PT3 PT3 PT3 PT3 PT3 PT4 PT3 PT3
Amikacin S R R R R R R R R R R R R R R
Amoxicillin/CA R R R R R R R R R R R R R R R
Ampicillin R R R R R R R R R R R R R R R
Cefazolin R R R R R R R R R R R R R R R
Cefoxitin R R R R R R R R R R R R R R R
Cefpodoxime R R R R R R R R R R R R R R R
Ceftiofur R R R R R R R R R R R R R R R
Cephalothin R R R R R R R R R R R R R R R
Chloramphenicol S S S S S S S S S S S S S S S
Enrofloxacin R S S S S S S S S S S S S S S
Clindamycin R R R R R R R R R R R R R R R
Erythromycin R R R R R R R R R R R R R R R
Gentamicin R R R R R R R R R R R R R R R
Imipenem R R R R R R R R R R R R R R R
Marbofloxacin R S S S S S S S S S S S S S S
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin R R R R R R R R R R R R R R R
Penicillin R R R R R R R R R R R R R R R
Rifampin S S S R S S S S S S S S S S S
Sulphadimethoxime NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Spectinomycin NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
Tetracycline S S S R S S S S S S S S S S S
Ticarcillin R R R R R R R R R R R R R R R
Ticarcillin/CA R R R R R R R R R R R R R R R


































Horse 11 Horse 11 Horse 11 Horse 13 Horse 14 Horse 12 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11
TTW TTW TTW abscess incision incision fluid fluid thorax thorax fluid fluid TTW TTW
6/2/07 6/2/07 6/2/07 6/15/07 6/16/07 6/23/07 6/28/07 6/29/07 7/18/07 7/18/07 10/20/07 10/20/07 12/3/07 12/3/07
PT3 PT3 PT3 PT3 PT4 PT3 PT3 PT3 PT3 PT3 PT3 PT3 PT3 PT5
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R
S S S S S S S S S S S S S S
S S S S S S S S S S S S S S
R R R R R R R R R R R R R S
R R R R R R R R R R R R R S
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R
S S S S S S S S S S S S S S
NI NI NI NI NI NI NI NI NI NI NI NI NI NI
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R
S S S S S S S S S S S S S S
NT NT NT NT NT NT NT NT NT NT NT NT NT NT
NT NT NT NT NT NT NT NT NT NT NT NT NT NT
S S S S S S S S S S S S S S
R R R R R R R R R R R R R R
R R R R R R R R R R R R R R





Patient Horse 1 Horse 2 Horse 2 Horse 3 Horse 3 Horse 4 Horse 5 Horse 6 Horse 7 Horse 8 Horse 9 Horse 9 Horse 10
Specimen uterus tissue tissue other other incision unspecified incision incision catheter eye eye thorax
Date 4/13/06 10/6/06 10/6/06 11/4/06 11/4/06 11/9/06 11/21/06 12/18/06 3/8/07 4/23/07 4/28/07 5/21/07 4/30/07
Phenotype PT1 PT3 PT3 PT2 PT3 PT3 PT4 PT3 PT3 PT3 PT3 PT4 PT3
Amikacin S R R R R R R R R R R R R
Amoxicillin/CA R R R R R R R R R R R R R
Ampicillin R R R R R R R R R R R R R
Cefazolin R R R R R R R R R R R R R
Cefoxitin R R R R R R R R R R R R R
Cefpodoxime R R R R R R R R R R R R R
Ceftiofur R R R R R R R R R R R R R
Cephalothin R R R R R R R R R R R R R
Chloramphenicol S S S S S S S S S S S S S
Enrofloxacin R S S S S S S S S S S S S
Clindamycin R R R R R R R R R R R R R
Erythromycin R R R R R R R R R R R R R
Gentamicin R R R R R R R R R R R R R
Imipenem R R R R R R R R R R R R R
Marbofloxacin R S S S S S S S S S S S S
Orbifloxacin NI NI NI NI NI NI NI NI NI NI NI NI NI
Oxacillin R R R R R R R R R R R R R
Penicillin R R R R R R R R R R R R R
Rifampin S S S R S S S S S S S S S
Sulphadimethoxime NT NT NT NT NT NT NT NT NT NT NT NT NT
Spectinomycin NT NT NT NT NT NT NT NT NT NT NT NT NT
Tetracycline S S S R S S S S S S S S S
Ticarcillin R R R R R R R R R R R R R
Ticarcillin/CA R R R R R R R R R R R R R


































Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 11 Horse 12 Horse 12 Horse 13 Horse 14
thorax TTW TTW TTW fluid fluid thorax thorax fluid fluid TTW TTW incision incision abscess incision
5/27/07 6/2/07 6/2/07 6/2/07 6/28/07 6/29/07 7/18/07 7/18/07 10/20/07 10/20/07 12/3/07 12/3/07 6/2/07 6/23/07 6/15/07 6/16/07
PT3 PT3 PT3 PT3 PT3 PT3 PT3 PT3 PT3 PT3 PT3 PT5 PT3 PT3 PT3 PT4
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R
S S S S S S S S S S S S S S S S
S S S S S S S S S S S S S S S S
R R R R R R R R R R R S R R R R
R R R R R R R R R R R S R R R R
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R
S S S S S S S S S S S S S S S S
NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R
S S S S S S S S S S S S S S S S
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT NT
S S S S S S S S S S S S S S S S
R R R R R R R R R R R R R R R R
R R R R R R R R R R R R R R R R





Patient Horse 22 Horse 1 Horse 23 Horse 4 Horse 21 Horse 21 Horse 21 Horse 11 Horse 14 Horse 11
Specimen Catheter Uterus Umbilicus Incision Incision Incision Incision Catheter Incision Catheter
Date 2/9/06 4/14/06 5/9/06 11/9/06 11/30/06 12/23/06 12/27/06 5/31/07 6/16/2007 7/7/2007
Phenotype PT1 PT2 PT3 PT4 PT4 PT4 PT4 PT5 PT6 PT7
Amikacin R R R R R R R R R R
Amoxicillin/CA I S S S S S S S S S
Ampicillin R S S S S S S S S S
Cefazolin R R R R R R R R R R
Cefoxitin R R R R R R R R R R
Cefpodoxime R R R R R R R R R R
Ceftiofur R R R R R R R I R R
Cephalothin R R R R R R R R R R
Chloramphenicol I S S R R R R R S R
Enrofloxacin R I S S S S S S S R
Clindamycin R R R R R R R R R R
Erythromycin R I R R R R R R I R
Gentamicin R I R R R R R R I R
Imipenem R S S S S S S S S S
Marbofloxacin NI NI NI NI NI NI NI NI NI NI
Orbifloxacin NI NI NI NI NI NI NI NI NI NI
Oxacillin R R R R R R R R R R
Penicillin R S S S S S S S S S
Rifampin R I I I I I I I S S
Sulphadimethoxime NT NT NT NT NT NT NT NT NT NT
Spectinomycin NT NT NT NT NT NT NT NT NT NT
Tetracycline R S R R R R R R S R
Ticarcillin R I I I I I I I I I
Ticarcillin/CA R I I I I I I I I I





Patient Horse 8 Horse 10 Horse 10 Horse 11 Horse 15 Horse 16 Horse 17 Horse 18
Specimen Catheter Thorax Thorax Catheter Blood Blood Ear Catheter
Date 4/27/07 4/30/07 5/25/07 5/31/07 5/17/07 6/6/07 10/28/06 7/31/07
Phenotype PT1 PT1 PT2 PT2 PT3 PT4 PT5 PT6
Amikacin S S S S S S S S
Amoxicillin/CA R R I I I I I R
Ampicillin R R R R I I R R
Cefazolin R R R R R R R R
Cefoxitin R R R R R R R R
Cefpodoxime R R R R R R S R
Ceftiofur R R R R R R R R
Cephalothin R R R R R R R R
Chloramphenicol R R R R R R I R
Enrofloxacin R R R R S S S S
Clindamycin R R R R R R R R
Erythromycin R R R R R R NT R
Gentamicin R R R R S S S R
Imipenem S S S S S S S S
Marbofloxacin NI NI NI NI NI NI NI NI
Orbifloxacin NI NI NI NI NI NI NI NI
Oxacillin R R R R R R NT R
Penicillin R R R R R R NT R
Rifampin R R R R R I R R
Sulphadimethoxime NT NT NT NT NT NT NT NT
Spectinomycin NT NT NT NT NT NT NT NT
Tetracycline R R R R S S S R
Ticarcillin I I I I S I S R
Ticarcillin/CA I I I I S S S R





Patient Horse 10 Horse 11 Horse 11 Horse 19 Horse 20
Specimen Thorax Catheter Catheter Abscess Skin
Date 4/30/07 7/5/07 7/5/07 4/30/07 8/13/07
Phenotype PT1 PT2 PT3 PT4 PT5
Amikacin R I S R R
Amoxicillin/CA R R R R R
Ampicillin R R R R R
Cefazolin R R R R R
Cefoxitin R I I R R
Cefpodoxime S R R I S
Ceftiofur S R R S I
Cephalothin R R R R R
Chloramphenicol R R R R R
Enrofloxacin S S S S S
Clindamycin R R R R R
Erythromycin R R R R R
Gentamicin R R R R R
Imipenem S S S S S
Marbofloxacin S S S S S
Orbifloxacin NI NI NI NI NI
Oxacillin R R R R R
Penicillin R R R R R
Rifampin R R R R R
Sulphadimethoxime NT NT NT NT NT
Spectinomycin NT NT NT NT NT
Tetracycline R R R R I
Ticarcillin R R R R R
Ticarcillin/CA R I I R R























































































































































E. coli 97% 78% 50% 72% 78% 78% 78% 63% 72% 88% 0% 0% 66% 100% 88% ‐‐ 0% 0% 0% ‐‐ ‐‐ 53% 59% 81% 59%
E. coli (foal) 100% 94% 75% 88% 94% 89% 94% 63% 81% 88% 0% 0% 81% 100% 89% ‐‐ 0% 0% 0% ### 0% 69% 75% 94% 81%
S. equi zoo 84% 88% 92% 92% 92% 60% 88% 92% 88% 60% 88% 0% 92% 100% 88% ‐‐ 96% 92% 92% ‐‐ ‐‐ 72% 100% 100% 100%
Salmonella 100% 81% 72% 75% 89% 83% 83% 78% 86% 94% 0% 0% 83% 100% 97% ‐‐ 0% 0% 0% ‐‐ ‐‐ 81% 78% 81% 89%
S. aureus 38% 38% 0% 38% 38% 31% 38% 38% 100% 92% 15% 15% 38% 31% 100% ‐‐ 38% 0% 100% ‐‐ ‐‐ 100% 11% 38% 46%
P. aeruginosa 83% 0% 0% 0% 0% 0% 0% 0% 0% 67% 0% 0% 83% 100% ‐‐ ‐‐ 0% 0% 0% ‐‐ ‐‐ 0% 83% 83% 33%
K. pneumoniae 100% 100% 0% 88% 100% 88% 88% 88% 75% 88% 0% 0% 88% 100% 100% ‐‐ 0% 0% 0% ‐‐ ‐‐ 75% 0% 100% 63%
Strep. beta 33% 67% 67% 100% 100% 67% 100% 100% 100% 67% 67% 0% 67% 100% 100% ‐‐ 100% 100% 100% ‐‐ ‐‐ 67% 100% 100% 100%
S.equi equi 13% 88% 50% 75% 75% 57% 38% 100% 38% 25% 50% 0% 38% 100% 25% ‐‐ 86% 75% 75% ‐‐ ‐‐ 25% 88% 100% 100%
Strep. dysgalactiae 75% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 100% 100% 100% ‐‐ 100% 100% 100% ‐‐ ‐‐ 75% 100% 100% 100%
S. xylosus 80% 80% 80% 80% 100% 80% 80% 100% 80% 60% 40% 40% 100% 80% 60% ‐‐ 100% 80% 100% ‐‐ ‐‐ 80% 100% 100% 100%
Staph. species 100% 67% 0% 67% 67% 67% 67% 67% 100% 67% 33% 33% 67% 67% 100% ‐‐ 67% 33% 100% ‐‐ ‐‐ 100% 67% 67% 100%
Enterococcus species 0% 80% 60% 20% 10% 0% 0% 30% 56% 20% 11% 10% 10% 50% ‐‐ ‐‐ 0% 80% 40% ‐‐ ‐‐ 40% 60% 60% 56%
Actinobacillus equuli 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 50% 100% 100% ‐‐ ‐‐ 100% 0% 100% ‐‐ ‐‐ 75% 100% 100% 100%
Actinobacillus suis 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 0% 100% 100% ‐‐ ‐‐ 50% 0% 100% ‐‐ ‐‐ 100% 100% 100% 100%
























































































































































E. coli 97% 83% 69% 86% 89% 86% 91% 66% 86% 86% 0% 0% 71% 100% 89% ‐‐ 0% 0% 0% ‐‐ ‐‐ 66% 69% 83% 71%
S. equi zoo 59% 100% 83% 100% 100% 79% 90% 100% 93% 76% 75% 0% 93% 100% 100% ‐‐ 89% 86% 89% ‐‐ ‐‐ 59% 100% 100% 100%
Salmonella 100% 88% 76% 76% 88% 88% 88% 76% 82% 94% 0% 0% 88% 100% 100% ‐‐ 0% 0% 0% ‐‐ ‐‐ 76% 76% ‐‐ 94%
S. aureus 100% 91% 0% 91% 91% 91% 91% 91% 82% 100% 50% 45% 82% 73% 100% ‐‐ 91% 0% 100% ‐‐ ‐‐ 100% 67% 91% 100%
P. aeruginosa 100% 0% 0% 0% 0% 0% 0% 0% 23% 85% 0% 0% 77% 100% ‐‐ ‐‐ 8% 0% 0% ‐‐ ‐‐ 0% 77% 77% 46%
K. pneumoniae 92% 83% 0% 100% 100% 100% 100% 83% 100% 100% 0% 0% 83% 100% 100% ‐‐ 0% 0% 0% ‐‐ ‐‐ 100% 0% 83% 91%
Strep. beta 67% 89% 78% 89% 89% 44% 89% 100% 89% 44% 89% 0% 89% 100% 78% ‐‐ 100% 100% 100% ‐‐ ‐‐ 67% 100% 100% 100%
S.equi equi 20% 80% 80% 80% 80% 40% 80% 100% 20% 20% 25% 0% 40% 100% 20% ‐‐ 100% 100% 80% ‐‐ ‐‐ 0% 100% 100% 100%
Strep. dysgalactiae 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 100% 100% 100% ‐‐ 100% 100% 100% ‐‐ ‐‐ 100% 100% 100% 100%
S. xylosus 100% 67% 58% 75% 83% 58% 75% 92% 50% 83% 0% 0% 92% 58% 75% ‐‐ 92% 58% 92% ‐‐ ‐‐ 42% 92% 92% 91%
Staph. species 89% 100% 67% 89% 100% 56% 67% 100% 89% 89% 0% 22% 78% 100% 89% ‐‐ 100% 67% 89% ‐‐ ‐‐ 89% 100% 100% 100%
Enterococcus species 50% 75% 75% 50% 25% 0% 25% 50% 25% 25% 0% 0% 75% 75% ‐‐ ‐‐ 0% 50% 0% ‐‐ ‐‐ 50% 50% 50% 50%
Actinobacillus equuli 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 0% 100% 100% ‐‐ ‐‐ 100% 0% 100% ‐‐ ‐‐ 100% 100% 100% 100%
Actinobacillus suis 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 0% 0% 100% 100% ‐‐ ‐‐ 100% 0% 100% ‐‐ ‐‐ 100% 100% 100% 100%





N Resistant to 0 Antibiotics Resistant to 1 Antibiotic Resistant to 2 to 4 Antibiotics Resistant to 5 or More Antibiotics
E. coli 245 0% 31% 18% 50%
S. equi zoo 205 42% 30% 21% 7%
Salmonella Group B 42 0% 0% 0% 100%
Salmonella Group C1 22 0% 0% 5% 95%
Salmonella Group C2 30 0% 3% 3% 93%
Salmonella species 71 0% 0% 1% 99%
S. aureus 57 28% 4% 28% 40%
P. aeruginosa 53 0% 0% 0% 100%
K. pneumoniae 50 0% 0% 2% 98%
Strep. beta 48 27% 27% 38% 8%
S.equi equi 38 16% 5% 39% 39%
Strep. dysgalactiae 37 35% 16% 24% 24%
S. xylosus 32 9% 9% 47% 34%
Staph. species 30 13% 23% 37% 27%
Enterococcus species 27 7% 0% 11% 81%
Actinobacillus equuli 18 50% 28% 22% 0%
Actinobacillus species 18 28% 44% 17% 11%
Actinobacillus suis 16 60% 20% 20% 0%
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Scope and Method of Study:  
Antimicrobial resistance is a topic of pervasive importance in both human and 
veterinary medicine.  Increasingly, the zoonotic transfer of pathogens such as 
multi-drug resistance strains of Salmonella, methicillin-resistant Staphylococcus 
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Analysis was performed on pathogens identified, susceptibility phenotypes, and 
overall susceptibility patterns. 
 
Findings and Conclusions:   
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particularly Staphylococcus aureus, have occurred at the BVMTH.  These 
findings are supportive of real-time surveillance of major equine pathogens. 
 
 
 
 
 
 
